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Dysfunction of dopaminergic (DA) neurons in the midbrain is responsible for 
diseases such as schizophrenia and Parkinson’s disease. In this study, we employ an 
immature dopaminergic cell line, MN9D to identify genes that are up-regulated when the 
cells are induced to differentiate with 1 mM n-butyric acid. One of the genes identified is 
neuronal PAS domain protein 1 (NPAS1). Expression studies showed that NPAS1 is 
found in the mouse ventral midbrain from E11.5 onwards. Domains analysis revealed that 
a NES within NPAS1 excludes it from the nucleus and nuclear localization of NPAS1 
requires ARNT. Further analysis identified two non-overlapping repression domains 
within NPAS1. Furthermore, over-expression and siRNA experiments revealed that 
NPAS1 is able to down-regulate the expression of tyrosine hydroxylase, the rate-limiting 
enzyme required for synthesis of catecholamines. This down-regulation is due to a direct 
binding of NPAS1 to the TH promoter. These findings provide new insight into role of 
NPAS1 during the developmental process of ventral midbrain DA neurons, the 
significance of which is discussed. 
 





1.1) Introduction to Dopaminergic Neurons 
  
 Dopaminergic neuron is one of the most intensively studied neuronal groups due 
to its involvement in several mental and neurological diseases. Historically, dopaminergic 
neurons of the adult mammal have been placed into nine distinct groups, residing in the 
ventral midbrain (these groups are referred to as A8, A9 and A10), diencephalon (groups 
A11-15) [Dahlstrom and Fuxe, 1964; Björklund and Lindvall, 1984] and in the 
telencephalon where they are restricted to the olfactory bulb (A16) and the retina (A17) 
[Cooper et al, 1977; Paxinos, 1995]. The most prominent dopaminergic cell group is 
found in the ventral part of the mesencephalon which accounts for 90% of the total 
number of brain dopaminergic cells.  
 The mesencephalic dopaminergic system is subdivided into several nominal 
systems (Figure 1.1). These include the nigrostriatal system (made up of the A9 cell 
group) which originates in the substantia nigra pars compacta (SNc) and extends its fibers 
into the caudate putamen (also known as the dorsal striatum). This pathway plays an 
important role in the control of voluntary motor movement. More medial to this pathway 
are the mesolimbic and mesocortical dopaminergic systems arising from the A10 
dopaminergic cells present in the ventral tegmental area (VTA). These cells project most 
prominently into the nucleus accumbens, olfactory tubercle but also innervate the septum, 
amygdale and hippocampus. This subset of projections is known as the mesolimbic 
dopaminergic system. Cells in the medial VTA project to the prefrontal, cingulated and 
perirhinal cortex. This pathway is known as the mesocortical dopaminergic system. There 
is considerable overlap between the VTA cells that project to these different targets. Due 
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to this overlapping between the mesocortical and mesolimbic dopaminergic neurons, the 
two systems are collectively known as the mesocorticolimbic system (Wise, 2004). 
 Considerable differences exist in the numbers of midbrain dopaminergic cell 
bodies in various mammals ranging from about 45,000 in the rat, 165,000 in the macaca 
monkey, to 590,000 in human beings (German and Manaye, 1993). This latter number 
applies to humans in their fourth decade of life but drops to an average of about 350,000 
during the sixth decade of life (Bogerts et al, 1983). Such an age-dependent decrease has  
also been reported for nonhuman primates but not for rodents such as mice or rats 
perhaps due to their shorter life span. 
                                        
        
Figure 1.1 Representation of dopaminergic pathway system in human brain. The 
nigrostriatal system originates from the substantia nigra pars compacta and extends its 
fibers into the caudate putamen. The mesolimbic and mesocortical systems originate from 
the ventral tegmental area and projects into different regions. (Adapted from Chinta and 
Andersen, 2005). 
 
1.2) Determination of Cell Fates in the Central Nervous System 
 The central nervous system (CNS) arises from the neural plate, a sheet of 
epithelial cells that forms the dorsal surface of the gastrula-stage embryo. During 
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neurulation, the neural plate folds up on its anterior-posterior (AP) axis to form a tube 
whose anterior end expanded to partition into several vesicles, representing the anlagen 
of the prosencephalon (forebrain), the mesencephalon (midbrain) and the 
rhombencephalon (hindbrain). The long and narrow tube at the posterior end forms the 
spinal cord. These early morphological compartmentalization along the neural axis, 
together with position-specific expression of developmental control genes, dictate the 
overall plan of the CNS and determine its regional specializations. Within each region, a 
large diversity of neuronal cell types, each with distinct identities in terms of 
morphology, axonal projections, synaptic connections and neurotransmitter phenotype, is 
generated (Lumsden and Krumlauf, 1996; Tanabe and Jesssell, 1996).  These various cell 
and neuron populations generate and differentiate into stereotypic defined positions along 
the main axes of the neural tube (the DV and AP axis). Patterning of cells types seems to 
be organized on a Cartesian grid of positional information, the coordinates of which 
correspond to the AP and DV axes of the neural tube. Neural progenitors develop 
according to their position in the Cartesian grid. Cell fate determination along the DV 
axis is controlled by the notochord, the floor plate and the roof plate. Patterning and 
compartmentalization into morphogenetic units along the AP axis is mediated by 
signaling centers, which include the anterior neural ridge and the isthmus organizer. 
Therefore, the development of neurons along the DV axis is thought to be controlled by 
epigenetic factors, represented by several families of secreted proteins. 
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1.3) Factors Important for Specification of Dopaminergic Neuron 
 Mesencephalic dopaminergic neurons can be first detected at about embryonic 
day (E) 11.5 in the mouse. Most of the midbrain dopaminergic neurons that lie in the 
substantia nigra and ventral tegmental area are positioned in the vicinity of two essential 
signaling centers for the DV and AP axis, that is, the floor plate and the isthmic 
organizer, respectively. Many studies on dopaminergic neuron development have shown 
that dopaminergic progenitors become committed to give rise to dopaminergic neurons 
by the action of two factors, Shh and FGF8, representing the inductive signal from the 
floor plate and isthmus respectively. More recently, members of the transforming growth 
factor-beta (TGF-β) have been implicated in the inductive process as well (Figure 1.2). 
                       
 
Figure 1.2 Signals involved in the induction and specification of mesencephalic (Ms) 
dopaminergic neurons. Sonic hedgehog (Shh; green) is produced in the notochord and 
floor plate and is involved in cell fate determination along the dorsoventral (DV) axis of 
the neural tube. Fibroblast growth factor (FGF8; yellow) is secreted by the isthmus and is 
involved in patterning along the AP axis. Transforming growth factor-beta (TGF-β; pink) 
is also expressed in the notochord and floor plate and is required for induction of 
midbrain dopaminergic neurons (Mt metencephalon, Di diencephalon). (Taken from 
Roussa and Krieglstein, 2004). 
 
  Introduction 
 5
1.3.1) Sonic Hedgehog 
 The Shh protein is initially synthesized as a 45-kDa precursor protein that 
undergoes autoproteolytic cleavage generating an amino-terminal cleavage product of 
approximately 20 kDa that has been implicated in mediating signaling activities in 
Drosophila (Lee et al, 1994; Porter et al, 1995) and in vertebrates. Shh is found to be both 
necessary and sufficient for the induction of the floor plate at the ventral midline of the 
neural tube (Echelard et al, 1993; Krauss et al, 1993; Riddle et al, 1993) and contributes 
to the establishment of a polarity at the DV axis of the vertebrate nervous system. In 
addition, this peptide is secreted by the notochord and floor plate which encodes a  
ventralizing signal, thereby inducing ventral cell types, of which is the dopaminergic 
phenotype. 
 In vitro experiments with midbrain explants lacking the floor plate have shown 
that dopaminergic neurons are generated in the presence of an exogenous floor plate 
(Hynes et al, 1995). These results were complemented by in vivo experiments which 
showed that dopaminergic neurons can be induced in the dorsal midbrain under the 
control of an ectopic floor plate. These data, together with the observation that 
mesencephalic dopaminergic neurons developed in a region nearest to the floor plate, 
promoted Sasaki and Hogan (1994) to formulate a model whereby the induction of 
dopaminergic neurons occurred by contact with the floor plate. Since the floor plate is 
known to produce Shh, a crucial link between Shh and dopaminergic neuron 
development was thus established. 
 Detailed immunohistochemical studies revealed that the Shh protein in the CNS is 
found at the 8-somite-stage in the notochord, node, and ventral midbrain.  At E9.5, Shh 
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expression is restricted to the ventral midline of most of the brain, with the exception of 
the presumptive hypothalamic area (Marti et al, 1995). Investigations carried out in 
rodents (Hynes et al, 1995a; 1995b) and chick (Wang et al, 1995) revealed that Shh alone 
was able to induce dopaminergic neurons in explants from which the endogenous floor 
plate had been removed.  Along this line, conditioned medium by cells expressing the 
amino-terminal autoproteolytic fragment of Shh and purified Shh-N were also enough to 
induce dopaminergic neurons in the absence of a floor plate. Moreover, Shh-N was 
capable of inducing HNF-3β (a ventral marker)-positive cells and floor plate cells in 
forebrain and midbrain explants. These findings firmly established the capability of Shh 
to mimic the activities of the notochord and floor plate, and to induce ventral neuronal 
phenotypes in the midbrain. Consistent with this notion, a distinct floor plate was found 
to be absent in Shh mutant mice. In addition, there is a degeneration of notochord 
accompanied by reduced expression of HNF-3β expression in the neural tube. In these 
mutants, the midbrain was reduced and the morphology was abnormal, especially in the 
anterior part. For a greater understanding of the mechanism of Shh in inducing a ventral 
phenotype, please refer to a review by Roussa and Krieglstein (2004). 
1.3.2) Fibroblast Growth Factor 8 
 
 FGF8 has a broad expression in the developing embryo and with regards to 
mesencephalic development, FGF8 is expressed in cardiac mesoderm underlying the 
mesencephalic/metencephalic region (Heikinheimo et al., 1994; Crossley and Martin, 
1995; Mahmood et al., 1995). FGF8 is expressed in the primitive streak, at the midbrain-
hindbrain border, in the forebrain, in limb ectoderm and in the apical ectodermal ridge. 
Expression of FGF8 in these regions which have been previously identified as signaling 
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centres crucial for patterning of the midbrain led to the assumption that FGF8 might be 
involved in this process. To determine if FGF8 has the same midbrain-inducing and 
polarizing effect as the isthmus, beads soaked in recombinant FGF8 were implanted into 
the caudal diencephalons of chick embryos. Results showed that there is an ectopic 
expression of En-2 and long-term observation of the embryos at later developmental 
stages revealed transformation of the dorsal thalamus to ectopic midbrain (Crossley et al., 
1996), suggesting that FGF8 does indeed play a role in the specification of midbrain 
neurons. 
 Like FGF8, members of the Wnt family are also secreted proteins which are 
expressed in the midbrain (Parr et al., 1993). Wnts regulate precursor proliferation 
(Taipale and Beachy, 2001; Chenn and Walsh, 2002; Megason and McMahon, 2002), 
date decisions (Dorsky et al., 1998; Wilson et al., 2001) and neuronal differentiation (for 
a review, see Danielian and Reichardt, 2000). These Wnt proteins have been suggested to 
play a role a role in development of the midbrain. In Wnt-1-/- embryos, the midbrain and 
anterior hindbrain failed to develop (Danielian and McMahon, 1996). More recently, the 
physiological role of Wnts during dopaminergic neuron differentiation was studied in 
depth (Castelo-Branco et al., 2003). It was found that Wnt-1, Wnt-5a and TH are highly 
expressed in the ventral mesencephalon at E11.5, the time at which dopaminergic 
neurons are born. In-vitro experiments further showed that treatment of ventral midbrain 
precursor cells with Wnt-1 or Wnt-5a resulted in the proliferation of precursor cells and a 
significant increase in the number of TH-positive cells, albeit using distinct mode of 
action. Therefore, the family of Wnts adds to a growing list of factors involved in the 
development of dopaminergic neurons in the ventral midbrain. 
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1.3.3) Transforming Growth Factor-β 
 
 Like Shh, TGF-β is expressed in early structures such as notochord and floor plate 
(Flanders et al., 1991; Unsicker et al., 1996), as well as in the area in which midbrain 
dopaminergic neurons develop (Farkas et al., 2003). Studies have identified members of 
the TGF-β superfamily as potent survival factors for midbrain dopaminergic neurons. It 
was reported that TGF-β2, TGF-β3 and GDNF exert survival-promoting effects in 
cultured rat midbrain dopaminergic neurons (Poulsen et al., 1994). These results have 
been reinforced by observations demonstrating that members of the TGF-β superfamily 
such as TGF-β2, TGF-β3, activin A, BMP2, BMP4, BMP6, growth differentiation factor 
(GDF) 5 and GDF15, but not GDNF are expressed in the mesencephalon floor at E14 
where postmitotic dopaminergic neurons differentiate and extend their exons to the 
striatum, whereas GDNF is expressed from E16 onwards (Krieglstein et al., 1995; Jordan 
et al., 1997; Krieglstein et al., 1998; Strelau et al., 2000). 
 Cell culture systems have proved to be a valuable tool for determining the signals 
require for dopaminergic neuron induction. When cells dissociated from the ventral 
midbrain floor of E12 rats were treated with TGF-β, there is an increase in the number of 
TH-positive cells within 24h while neutralization of TGF-β in vitro totally eliminates the 
induction of dopaminergic neurons. TGF-β affects the function of Shh since Shh can no 
longer induce TH-positive neurons, as shown by neutralization experiments of 
endogenous TGF-β in the presence of exogenous Shh. Vice versa, neutralizing 
endogenous Shh abolishes the ability of TGF-β to induce dopaminergic neurons in-vitro. 
Taken together, these results suggest that both TGF-β and Shh are required to induce 
dopaminergic neurons in vitro. 
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 The importance of TGF-β in dopaminergic neuron development has been further 
verified in vivo. Neutralization of endogenous TGF-β from E2-7, but not E4-7 of chick 
embryos shows a significant reduction of TH-positive neurons in the ventral midbrain 
floor but no effect in the locus coeruleus or diencephalon. This suggests that the critical 
period of dopaminergic neuron induction occurs on E2-3. When endogenous TGF-β is 
neutralized between E6 and E10, that is, after the critical period of phenotype induction 
and acquisition of the TH phenotype (occurring at E4-E7), a significant loss of TH-
positive neurons is again observed, suggesting that TGF-β acts as a survival-promoting 
molecule at later stages of development (Farkas et al., 2003). 
1.4) Transcription Factors in the Control of Dopaminergic Neuron Development 
  
 The first postmitotic differentiating dopamine neurons appear at approximately 
E10-10.5 in the mouse (Lauder and Bloom, 1974). The cessation of proliferation is 
ensued by upregulation of general and specific dopaminergic markers such as TH. Newly 
formed neurons migrate into medial and lateral positions to form the A8-A10 areas, and 
also begin to initiate target innervation. Several transcription factors controlling these 
developmental processes have been characterized. These factors include the nuclear 
receptor Nurr1 and the homeodomain transcription factors Lmx1b, Pitx3, and Engrailed 1 
and 2. Figure 1.3 shows the temporal sequence of expression of these factors in the 
mouse ventral midbrain. 
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Figure 1.3 Temporal expression of different transcription factors involved in the 
development of dopaminergic neurons in the mouse ventral midbrain. The 
expression of Lmx1b in the ventral midbrain starts at E7.5 but it is uncertain if the early 
expression is confined to DA progenitor cells. At later stages, Lmx1b is expressed in DA 




 Nurr1 is an orphan member of the nuclear hormone receptor superfamily of 
transcription factors (Law et al., 1992). Nurr1 is widely expressed in the embryonic 
midbrain and only a small proportion of Nurr1-expressing neurons overlap with the 
midbrain DA progenitor neurons. The expression of Nurr1 expression in midbrain DA 
neurons begins at E10.5 in the mouse, just before the induction of TH and Pitx3 at E 11.5 
(Smidt et al., 1997; Zetterstrom et al., 1996; Zetterstrom et al., 1997). The expression of 
Nurr1 is maintained in the adult stage, albeit in a more restricted pattern, but including 
the midbrain DA system (Saucedo-Cardenas and Conneely, 1996; Xiao et al., 1996; 
Backman et al., 1999). The expression pattern of Nurr1 suggests that it may be involved 
in developmental and regulatory role that are not restricted to DA neurons.  
 Creation of Nurr1 knockout mice has shed some light on the function of Nurr1 in 
the brain (Zetterstrom et al., 1997; Saucedo-Cardenas et al., 1998; Castillo et al., 1998), 
showing that Nurr1 is essential for the generation of midbrain DA neurons. Mice with a 
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targeted deletion of Nurr1 gene die soon after birth and analysis of these animals showed 
an absence of midbrain DA neurons in these newborn animals. In contrast, all other 
catecholaminergic cell groups are intact in the Nurr1 knockout mice; even 
nonmesencephalic DA neurons in the olfactory bulb and the hypothalamus, for example, 
develop normally in these knockout mice. These results suggest that Nurr1 is specifically 
promoting midbrain DA cell development. However, when E12.5 embryos from these 
Nurr1-null mutants were studied, it was found that they express other markers associated 
with midbrain DA neurons, such as HNF 3β, Pitx3 and Lmx1b, although TH was not 
detected (Wallen et al., 1999; Wallen et al., 2001, Smidt et al, 2000; Saucedo-Cardenas et 
al., 1998). In addition, the GDNF signal transducing receptor, c-Ret was absent in the 
ventral midbrain of Nurr1-null mutants (Saucedo-Cardenas et al., 1997), suggesting a link 
between Nurr1 and GDNF, which promotes survival of DA neurons (Wallen et al., 2001; 
Beck et al., 2001). 
 The importance of Nurr1 in the determination of the dopaminergic phenotype of 
midbrain DA neurons has been reinforced by two key findings. First, it was shown that 
Nurr1+/- mice displayed reduced DA levels, suggesting that TH activity is strictly 
regulated by Nurr1 (Zetterstrom et al., 1996). Second, in humans, a correlation between 
Nurr1 and TH has been found in the age-related decrease of Nurr1 in the SN (Chu et al., 
2002). In fact, Nurr1 has been found to binds and activates transcription from the TH 
promoter (Sakurada et al., 1999; Iwawaki et al., 1999).  
 However, the effect of knockout of the Nurr1 gene is neither attributed to the 
absence of TH (Smidt et al., 2003) nor to the absence of c-Ret (Marcos and Pachnis, 
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1996; Wallen et al., 2001). The exact role of Nurr1 in the early midbrain dopaminergic 
progenitors remains unclear, as does the mechanism underlying the maintenance defect. 
1.4.2) Homeobox transcription factors – Lmx1b, Pitx3 and Engrailed 1 and 2 
 
 Lmx1b is a member of the LIM homeodomain family and has been identified to 
be an essential regulator of dorsoventral patterning of the developing limbs (Dreyer et al., 
1998; Chen et al., 1998). Lmx1b is detected in the mouse CNS as early as E7.5, including 
the ventral mesencephalon (Smidt et al., 2000). Pitx3 is expressed in three different 
tissues in different temporal domains – in the eye lens, skeletal muscles and in the brain 
(Smidt et al., 1997). The most striking feature of the brain expression of Pitx3, which 
starts at around E11.5, is the strict association with midbrain DA neurons, where the 
expression of Pitx3 completely overlaps with that of TH in the ventral midbrain (Smidt et 
al., 1997; Smidt et al., 2000; Smidt et al., 2004). Deletion of Lmx1b gene results in loss 
of embryonic Pitx3 expression, although Nurr1 and TH were still detected at E12.5 (Chen 
et al., 1998). Conversely, as mentioned before, Pitx3 is initially expressed in Nurr1 
knock-out embryos, suggesting the existence of at least two independent pathways in 
developing DA neuron differentiation. From E16.5 onwards, no TH-positive midbrain 
DA neurons can be detected in the Lmx1b-null mice, indicating that Lmx1b is required to 
sustain the dopaminergic cell fate (Smidt et al., 2000). 
 Engrailed 1 (En1) and Engrailed 2 (En2) play an essential role in the development 
and maintenance of mesencephalic DA neurons. They are expressed between E11.5 and 
E12 in the mouse and the expression continues into adulthood (Alberi et al., 2004). 
Homozygous double null mutants for En1 and En2 die at birth and show a large deletion 
of midbrain and hindbrain structures (Simon et al., 2003). Although this deficiency is 
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evident as early as E9, neurons are still generated in the ventral midbrain, become 
postmitotic and express their dopaminergic phenotype. However, thereafter, they rapidly 
die by apoptosis (Alberi et al, 2004; Simon et al., 2001), suggesting that the Engrailed 
proteins are requires for the survival for these DA neurons. 
1.5) Dopamine and Associated Pathologies 
 Dopaminergic neurons are believed to be particularly susceptible to oxidative 
stress due to their high oxygen metabolism rate, low antioxidant levels and high iron 
content. The neurotransmitter, dopamine is thought to be capable of generating toxic 
reactive oxygen species (ROS) via both its enzymatic and non-enzymatic catabolism 
(Halliwell, 1992). 
 Dysfunction of the midbrain dopaminergic neurons have been implicated in 




Schizophrenia is a severe brain disease that interferes with normal brain and 
mental function—it can trigger hallucinations, delusions, paranoia, and significant lack of 
motivation. Without treatment, schizophrenia affects the ability to think clearly, manage 
emotions, and interact appropriately with other people. 
The hypothesis that abnormal regulation of ventral striatal, specifically nucleus 
accumbens (NAC), dopaminergic transmission represents a neuronal hallmark of 
schizophrenia has been substantiated in recent years. Most etiologic scenarios agree that 
the mesolimbic hyperdopaminergic state in schizophrenia is a result of developmental 
abnormalities in telencephalic circuits that cause a dysregulation of midbrain 
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dopaminergic neurons (Weinberger and Lipska, 1995; O'Donnell and Grace, 1998; 
Grace, 2000; Laruelle, 2000; Lewis and Levitt, 2002). 
1.5.2) Parkinson’s Disease 
 
 Parkinson’s disease (PD) is a common neurodegenerative disease that affects 
more than 2% of the population over 65 years of age. PD is characterized at a 
pathological level by a progressive degeneration and loss of: (1) nigrostriatal and 
mesolimbic dopaminergic neurons (Hassler, 1938; Hirsch et al, 1998) leading to tremor, 
rigidity and hypokinesia, the classical symptoms of the disease (Carlsson, 1993; 
Hornykiewicz, 1993); (2) noradrenergic neurons of the locus coeruleus (German et al, 
1992; Hassler, 1938), involved in the progression of the disease (German et al, 1992; 
Mavridis et al, 1991), dementia (Zweig et al, 1993), and depression (Chan-Palay and 
Asan, 1989); and (3) serotonergic neurons of the raphe obscurus and medial raphe 
(Halliday et al, 1990), also involved in the symptoms of depression (Jing et al, 1996), 
often associated with PD.  
1.6) Treatment for Parkinson’s Disease 
 
 Although the pathological changes and motor dysfunction that characterize PD 
are well documented, the mechanism(s) responsible for the death of dopaminergic 
neurons has yet to be clearly determined. Therefore, current approaches for the treatment 
of PD is largely symptomatic than preventive. The most common treatment is with 
combined L-DOPA and carbidopa, which increase the synthesis and release of dopamine 
and are particularly effective at alleviating the akinesia and rigidity during early stages of 
the disease. Unfortunately, these drugs are only able to control the symptoms of the 
disease but not on-going cell death. Therefore, as the disease progress, less dopaminergic 
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neurons are available to synthesize dopamine and the effectiveness of such treatment 
decreases. 
 Another approach often combined with L-DOPA and carbidopa is deep brain 
stimulation of the globus pallidus and the subthalamic nuclei, where electrodes are placed 
in the brain (Olanow et al., 2000; Pollak et al., 1997). Such method is believed to relieve 
the motor symptoms by inducing a depolarization blockage of neurons in the area.  
 Different methods have also been developed to deliver neurotrophic factors into 
the striatum to promote survival of the existing dopaminergic neurons. These strategies 
include infusion of protein (Beck et al., 1995; Bowenkamp et al., 1995; Gash et al., 1996; 
Kearns and Gash, 1995; Sauer et al., 1995; Tomac et al., 1995), the implantation of 
polymer-encapsulated cells releasing the neurotrophic factors (Lindner et al., 1996), 
direct gene transfer into the host brain by viruses (Bensadoun et al., 2000; Björklund and 
Lindvall, 2000; Bohn et al., 1999; Choi-Lundberg et al., 1997; Connor et al., 2001; Kirik 
et al., 2000; Kordower et al., 2000; Latchman and Coffin, 2001; Mandel et al., 1999; 
Mandel et al., 1997) or engineering cells to produce these neurotrophic factors (Levivier 
et al., 1995).  These methods have shown promising results in animal model and may 
prove to be powerful tool for the future treatment of PD.  
 Transplantation of neural stem cells from fetal tissue into the PD striatum seems 
to be the most promising approach, as the fetal tissue does not only survive in the host but 
also replaces the function of the damaged dopaminergic neurons (Storch et al., 2004). 
However, a recent clinical trial examining transplantation of fetal stem cell tissue into 
older Parkinsonian patients did not show any efficacy based on patient self-report (Freed 
et al., 2001). Moreover, this technique carries with it a host of ethical issues. It is hoped 
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that eventually techniques will be more refined to enable stem cells from the patient’s 
own body to be coaxed into dopaminergic SNc neurons, which can then be used for the 
replacement of DA neurons that were lost during the progression of the disease. 
1.7) Role of bHLH Transcription Factors During Development 
 
 The bHLH transcriptional regulators are essential for controlling gene expression 
circuitry in many fundamental biological processes. These include early cell 
determination and differentiation, cell cycle maintenance, and homeostasis or stress 
response pathway (Massari and Murre, 2000). This large family of proteins is 
characterized by a basic DNA binding region adjacent to a helix-loop-helix dimerization 
region, both of which are required for formation of functional DNA binding complexes.  
 There are three main sub-families of bHLH proteins - (a) those containing only 
the bHLH domain; and those where the bHLH domain is contiguous with a second 
dimerization domain which can either be (b) the leucine zipper or (c) the PER/aryl 
hydrocarbon receptor nuclear translocator (ARNT)/single minded (SIM) (PAS) 
homology domain (Figure 1.4). The first group includes mammalian proteins involved in 
myogenesis (MyoD, myogenin and their partner E47), neurogenesis (NeuroD and 
neurogenin) or haemopoiesis (SCL) (Massari and Murre, 2000). The presence of a 
leucine zipper is found in members of the Myc/Max/Mad network of transcription factors 
(Lüscher, 2001). Both the bHLH and bHLH/Zip proteins recognize the classic E-box core 
enhancer sequence (CANNTG) in their target genes and generally exhibit constitutive 
activity corresponding to restricted tissue or developmental expression patterns (Massari 
and Murre, 2000). In contrast, the bHLH/PAS proteins tend to be ubiquitous, latent 
transcription factors whose activity is signal regulated. Furthermore, bHLH/PAS 
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heterodimers are distinguished by recognizing DNA sequences which often diverge from 
the prototypical E-box (Crews, 1998; Crews and Fan, 1999; Taylor and Zhulin, 1999).  
 Many aspects of the functional control of bHLH/PAS proteins are analogous to 
the nuclear receptor signaling proteins such as the Vitamin D and retinoic acid receptors. 
Both systems combine a specific with a generic partner protein, and family members can 
be grouped into two classes (Figure 1.4). Class I bHLH/PAS factors neither 
homodimerize nor heterodimerize with other Class I factors, and include the circadian 
proteins (Period and Clock), aryl hydrocarbon receptor (AhR), the hypoxia inducible 
factors (HIF; HIF-1α, HIF-2α and HIF-3α), single minded proteins (SIM1 and SIM2), 
neuronal PAS domain proteins (NPAS1 and NPAS2), inhibitory PAS domain protein 
(IPAS) as well as Drosophila’s Trachealess (Ema et al, 1996; Lindebro et al, 1995; Wang 
et al, 1995). In order to form active transcription factor complexes, these proteins must 
dimerize with a Class II bHLH/PAS factor, which promiscuously homo- and 
heterodimerize. Class II proteins include the well characterized ubiquitous ARNT 
(Hoffman et al, 1995), the tissue restricted ARNT2, and the circadian rhythm proteins 
BMAL1 and BMAL2 (Hirose et al, 1996; Ikeda and Nomura, 1997; Okano et al, 2001). 






Figure 1.4 Schematic representations of the domain structures of different families 
of bHLH proteins. There are three main sub-families of bHLH proteins - (a) those 
containing only the bHLH domain; and those where the bHLH domain is contiguous with 
a second dimerization domain which can either be (b) the leucine zipper or (c) the 
PER/aryl hydrocarbon receptor nuclear translocator (ARNT)/single minded (SIM) (PAS) 
homology domain. The family of bHLH-PAS proteins can be further subdivided into two 
classes. Class I bHLH/PAS factors neither homodimerize nor heterodimerize with other 
Class I factors. In order to form active transcription factor complexes, these proteins must 
dimerize with a Class II bHLH/PAS factor, which promiscuously homo- and 
heterodimerize. (Adapted from Kewley et al., 2004) 
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1.7.1) Mechanism of bHLH/PAS protein signaling 
 
 The PAS domain is made up of two adjacent degenerate repeats of ~130 amino 
acids, PAS A and PAS B. The domain is an ancient signaling device conserved through 
evolution, having been identified in proteins throughout the animal kingdom, in bacteria, 
fungi and yeast in addition to mammals and flies, where the most commonly studies 
bHLH/PAS proteins originate. Signals mediated by PAS domains include redox state, 
hypoglycaemia, oxygen balance and xenobiotic metabolism, and many bacteria contain 
PAS-like domains that detect light (Crews, 1998; Crews and Fan, 1999; Taylor and 
Zhulin, 1999). 
 The AhR was one of the initial bHLH/PAS proteins to be cloned and its signaling 
mechanism has been closely studied. It is activated by dioxin and related environmental 
pollutants to regulate genes encoding xenobiotic metabolizing enzymes and mediates the 
severe toxicity associated with dioxin and polychlorinated biphenol poisoning (Shimizu 
et al., 2000). Other recently discovered bHLH/PAS proteins include the HIF-α proteins, 
which mediate transcriptional responses to low oxygen levels, and the SIM proteins, 
which are involved in control of neural development. HIF-α, SIM and ARNT proteins are 
biologically essential, since gene knockouts in mice are lethal in all cases (Compernolle 
et al., 2002; Goshu et al., 2002; Hosoya et al., 2001; Keith et al., 2001; Maltepe et al., 
1997; Michaud et al., 1998; Peng et al., 2000; Ryan et al., 1998; Tian et al., 1998). 
 Signaling involves the conversion of a bHLH/PAS protein into a form that is able 
to dimerize with a second bHLH/PAS partner protein within the nucleus, bind to DNA 
via the basic region of the bHLH domain and interact with the transcriptional machinery 
to modulate expression of target genes (Ema et al., 1996; Fukunaga et al., 1995; Jiang et 
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al., 1996; Kobayashi et al., 1997). The primary dimerization interface lies within the N-
terminal bHLH domain, with the PAS domain acting as a second dimerization interface 
which defines partner choice (Ema et al., 1996; Michaud et al., 2000; Pongratz et al., 
1998). Many competing bHLH/PAS proteins, such as ARNT and its variant forms, are 
co-expressed and show a variety of dimerization activities, suggesting complex 
mechanisms exist for the cross coupling of signaling pathways and specificity of gene 
expression networks. 
1.7.2) Members of the bHLH/PAS Protein Family 
1.7.2.1) Circadian rhythms proteins – Clock, NPAS2 and BMAL1 
 
 The rotation of the Earth causes predictable changes in light and temperature in 
our natural environment. Accordingly, natural selection has favored the evolution of 
circadian clocks or biological clocks – endogenous cellular mechanisms for keeping track 
of time. These clocks impart a survival advantage by enabling an organism to anticipate 
daily environmental changes and thus tailor its behavior and physiology according to 
appropriate time of the day. In organisms as diverse as the fruit flies and mammals, 
circadian rhythms are controlled by a transcriptional feedback system whose activity 
fluctuates as a function of the light-dark (LD) cycle (Konopka and Benzer, 1971; Dunlap, 
1999).  In fruit flies, two bHLH/PAS proteins, dClock (dCLK) and CYCLE (CYC) 
(Darlington et al., 1998; Rutila et al. 1998; Allada et al., 1998) are involved in 
maintaining the circadian rhythms, in concert with another PAS domain containing 
protein PERIOD (PER) (Konopka et al., 1971) and TIMELESS (TIM) (Sehgal et al., 
1994; Vosshall et al. 1994). The bHLH/PAS heterodimeric pair, dCLK and CYC reside 
in the nucleus and binds to E-box elements in the per and tim structural genes, positively 
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regulating their transcription (Hao et al., 1997; Darlington et al., 1998). PER and TIM 
protein levels continue to rise throughout the day to their peak levels in the early evening 
– a few hours after the peak level of per and tim mRNAs. PER and TIM then 
heterodimerize and translocate into the nucleus where they inhibit the transcriptional 
activity of the dCLK/CYC complex, thus repressing their own transcription (Darlington 
et al., 1998). As both PER and TIM proteins are degraded before dawn, this process is 
relieved, lifting repression of the dCLK/CYC complex, thereby starting another cycle of 
PER and TIM accumulation. Contrary to its name, CYC in the fly does not cycle with 
any detectable amplitude at the RNA or protein level (Bae et al., 1998). dCLK, however, 
does cycle with a phase almost opposite to that of PER and TIM (Lee et al., 1998). PER 
also has some role in promoting dCLK transcription, constituting another feedback loop 
(Glossop et al., 1999).  
 A combination of forward mutagenesis screening in mice and the use of sequence 
comparisons with known components of the fly clock have produced a picture of the 
functional clock in mammals that is highly similar to that in flies. The most similar 
components are CLOCK (circadian locomotor output cycle kaput) and BMALI/MOP3, 
which are mammalian orthologes of fly dCLK and CYC, respectively. In mammals, 
NPAS2 gene encodes a functional analog of Clock (Reick et al., 2001; Hogenesch et al., 
1998) but is expressed in a distinct pattern of tissues including the prefrontal cortex of the 
brain. 
 In mammals, the positive arm of the clock is specified by a heterodimeric 
transcription factor composed of Clock and BMAL1. The Clock/BMAL1 and 
NPAS2/BMAL1 heterodimers regulate the expression of genes encoding other 
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components of the molecular clock. Both complexes activate expression of the Per2 and 
Cry1 genes, which themselves encode negative components of the clock (Reick et al., 
2001; Griffin et al., 1999; Kume et al., 1999). In addition, the NPAS2/BMAL1 
heterodimer represses BMAL1 gene expression (Reick et al., 2001). Since BMAL1 is an 
obligate component of the activating arm of the clock and BMAL1 mRNA fluctuate 
rhythmically as a function of the LD cycle (Reick et al., 2001; Abe et al., 1998), the 
repressive action of NPAS2/BMAL1 on BMAL1 gene expression ensures that the clock 
oscillates in a faithful and robust manner. 
 The Clock mutant reduces mPer expression and lengthens the overt activity 
rhythm (Jin et al., 1999), whereas a loss-of-function Bmal1/MOP3 mutant abolishes mPer 
expression and eliminates activity rhythms altogether (Bunger et al., 2000).  
1.7.2.2) Aryl hydrocarbon receptor (AhR) 
 
 Dioxin (2,3,7,8-tetrachlorodibenzo-ρ-dioxin, TCDD) and structurally related 
halogenated aromatic hydrocarbons are members of a class of environmental pollutants. 
Exposure to TCDD and similar compounds results in a variety of biochemical and toxic 
responses in animal models including severe wasting syndrome, epidermal hyperplasia 
and metaplasia, tumor promotion and thymic involution (Poland and Knutson, 1982; 
Safe, 1986).  
 At the molecular level, responses to TCDD and related chemicals are mediated 
through the AhR. In its inactive (non-DNA binding) state, the AhR is found in the 
cytoplasm, stably associated with two molecules of the 90kDa molecular chaperone heat 
shock protein 90 (Hsp90), p23 and hepatitis B virus X-associated protein 
(XAP2/AIP/Ara9) (Carver and Bradfield, 1997; Kazlauskas et al., 1999; Meyer et al., 
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1998; Ma and Whitlock, 1997; Pollenz et al., 1994; Perdew, 1988). Hsp90 interacts with 
the AhR via both the bHLH region and PAS B, which contains the ligand binding 
domain, and this association is required for AhR signaling (Antonsson et al., 1995; 
Dolwick et al., 1993; Whitelaw et al., 1993; Whitelaw et al., 1995). Hsp90 seems to 
chaperone a high affinity ligand binding conformation of the AhR and is involved in 
retention of the AhR in the cytoplasm, perhaps by masking its nuclear localization signal 
(NLS) (Ikuta et al., 1998; Pongratz et al., 1992). 
 Upon ligand binding, a conformational change exposes the NLS and the 
AhR/Hsp90 complex translocates to the nucleus where Hsp90 is exchanged for ARNT 
partner protein (Lees and Whitelaw, 1999; Pollenz et al., 1994). The ligand-bound 
AhR/ARNT heterodimer recognizes and promotes transcription from xenobiotic response 
elements (XREs) found upstream of TCDD-responsive genes, that include the xenobiotic 
metabolizing enzyme cytochrome P4501A1 and the glutathione S-transferase Ya subunit 
(Poellinger, 1995). Another target gene activated by AhR/ARNT is another bHLH/PAS 
protein, the aryl hydrocarbon receptor repressor (AhRR) (Baba et al., 2001; Mimura et 
al., 1999). The AhRR shows high sequence similarity with the AhR in the N-terminal 
region up to end of the PAS A domain, but differs greatly towards the C-terminus and 
does not have ligand binding or transactivation domains. The AhRR is able to 
heterodimerize with ARNT and bind XRE sequences in vitro and overexpression of the 
AhRR ablates ligand induced AhR/ARNT-mediated reporter gene activity in tissue 
culture (Mimura et al., 1999). It is proposed that in vivo, the AhRR is expressed in 
response to AhR ligands and functions to down-regulate AhR target genes by 
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sequestering ARNT and competing for XRE sequences in the promoters of target genes 
(Baba et al., 2001; Mimura et al., 1999). 
 In the adult rat, the AhR is expressed predominantly in the lungs, thymus, kidney 
and liver, with lower levels found in the heart and spleen (Carver et al., 1994). The AhR 
exhibits spatial and temporal restricted expression in the developing embryo, suggesting a 
role for the AhR in development. Expression of the AhR protein and mRNA has been 
found within the mouse embryo neuroepithelium, branchial arches, heart, somites, liver, 
adrenal, ectoderm, bone and muscle, at different developmental stages of embryogenesis 
(Abbott and Probst, 1995). The result from gene knockout experiments in mice is 
consistent with a developmental role for AhR. AhR-/- mice generated by three research 
groups showed a common phenotype which includes smaller livers and decreased body 
weight (Fernandez-Salguero et al., 1995; Mimura et al., 1997; Schmidt et al., 1996). 
Evidence of a development function for the AhR suggests that an endogenous ligand or 
physiological activation mechanism exists, though none as yet have been identified. 
 The AhR homolog in Drosophila is the spineless gene (Ducan et al., 1998). 
Spineless is expressed in the precursors to antenna, sensory cells and tarsus, and forms a 
heterodimer with Tango (the Drosophila homolog of mammalian ARNT). Null mutants 
of spineless are viable and show a number of adult phenotypes. The distal region of the 
leg (tarsus) is deleted and sensory bristles are reduced in size. The most striking mutant 
phenotype is a transformation of distal antenna into distal leg. Till far, spineless has no 
known role in toxin metabolism, although mammalian AhR is important for toxin 
metabolism. 
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1.7.2.3) Hypoxia inducible factor (HIF)  
 
 The ability to maintain oxygen homeostasis is essential for survival of mammals. 
The hyperoxic state, or high O2 tension, can result in the generation of reactive oxygen 
intermediates and potentially lethal damage to membranes and DNA. The hypoxic state, 
or low O2 tension, can results in levels of ATP insufficient to maintain essential cellular 
functions. The hypoxic state occurs in a number of medical conditions, such as cancer 
and ischemias, inspiring research into understanding the cellular mechanisms for 
detecting and responding to low levels of oxygen. 
 Responses to hypoxia are mediated by three bHLH/PAS proteins, HIF-1α, HIF-
2α (also known as Endothelial PAS domain protein 1, HIF-like factor and member of 
PAS family 2), and HIF-3α (Ema et al., 1997; Gu et al., 1998; Hogenesch et al., 1997; 
Tian et al., 1997; Wang et al., 1995). HIF-1α and HIF-2α (collectively known as HIF-α 
subunits) shared 48% amino acid sequence identity and both contain an oxygen 
dependent degradation domain (ODD), N-terminal and C-terminal transactivation 
domains (N-TAD and C-TAD). As predicted from homology, both HIF-1α and HIF-2α 
show similar mechanisms of regulation (O’Rourke et al., 1999). Under normoxic 
condition (20% O2), HIF-α is continuously synthesized and rapidly degraded by the 
ubiquitin-proteasome system (Huang et al., 1998). The process of HIF-α degradation is 
dependent on oxygen and consists of several steps. Firstly, an oxygen and iron-dependent 
prolyl hydroxylase hydroxylates HIF-α at two proline residues (P564 and P402 in human 
HIF1-α and P530 and P405 in human HIF2-α) found within the ODD (Ivan et al., 2001; 
Jaakkola et al., 2001). These hydrox motifs serve as docking site for the von Hippel-
Lindau tumor suppressor protein (VHL), which forms part of a complex with elongins B 
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and C, Cullin 2 and RBX1 to constitute a functional E3 ubiquitin-protein ligase (Iwai et 
al., 1999). Subsequent ubiquitination of HIF-α targets it for degradation. 
 Another mechanism involving hydroxylation occurs to prevent the remaining low 
levels of HIF-α from activating transcription of target genes. This process is mediated by 
the asparaginyl hydroxylase factor inhibiting HIF-1 (FIH-1) which hydroxylates an 
asparagines residue located within the C-TAD, thereby preventing the recruitment of co-
activator CBP/p300 and subsequent transactivation of target genes (Lando et al., 2002a; 
Lando et al., 2002b). Under hypoxia, the prolyl hydroxylase and FIH-1 are inactivated by 
low O2 levels, enabling the accumulation of HIF-α protein which dimerizes wit partner 
protein ARNT in the nucleus, binds to hypoxia response elements (HREs) located in the 
enhancer regions of a variety of target genes, interacts with CBP and initiates 
transcription. The genes regulated by HIF are involved in glycolysis, erythropoiesis and 
angiogenesis and include erythropoietin and vascular endothelial growth factor (VEGF) 
(Bunn and Poyton, 1996; Guillemin and Krasnow, 1997). 
 Although there are many similarities between HIF-1α and HIF-2α, there are still 
some functional differences between the two proteins. Unlike HIF-1α, DNA binding by 
HIF-2α is increased by Ref-1, a protein with reducing activity, mediated via a Cys within 
the basic region (Lando et al., 2000). The expression patterns of HIF-1α and HIF-2α are 
also different (Ema et al., 1997; Tian et al., 1997). While most human tissues express 
both HIF-2α and HIF-1α mRNA, HIF-2α mRNA expression is selectively observed in 
endothelial cells of Days 11 and 13 mouse embryos, and is expressed at high levels in 
adult endothelial cells. The phenotypes of HIF-1α and HIF-2α knockout mice further 
support they have different roles in the cells. Mice deficient in HIF1-α die in utero by 
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embryonic Day 10, with embryos exhibiting poor vascularization (Ryan et al., 1998). 
Three independent HIF2-α knockout mice have been generated. One demonstrates the 
need for HIF2-α in the regulation of catecholamine homeostasis (Tian et al., 1998). 
These mice show bradycardia and decreased levels of catecholamines, consistent with an 
observed decrease in HIF2-α expression in the organ of Zuckerkandl, the principal source 
of catecholamine synthesis in mammalian embryos. A second HIF-2α knockout mouse 
displayed varying degrees of vascular disorganization and haemorrhaging, indicating 
HIF-2α is required for the control of vascular remodeling, while a third HIF-2α deficient 
mouse was found to die neonatally of respiratory distress syndrome due to impaired lung 
maturation (Compernolle et al., 2002; Peng et al., 2000). 
  A third HIF protein, HIF-3α was first identified in the mouse (Gu et al., 1998). 
Same as the other HIFs, HIF-3α can dimerize with ARNT and bind to the HRE sequence 
in vitro. HIF-3α is able to activate HRE-driven reporter expression under hypoxia in 
transient transfection studies (Gu et al., 1998). While numerous splice variants of the 
HIF-3α gene locus have been identified in both human and mouse, the best characterized 
is the Inhibitory PAS domain protein (IPAS) in which the HIF-3α protein is truncated at 
the end of PAS B, removing the C-terminal region containing the transactivation domain 
(Maynard et al., 2003; Makino et al., 2001). HIF-3α is found to be expressed in the adult 
thymus, lung, brain, heart and kidney, while IPAS shows differential expression in 
hypoxia and normoxia (Gu et al., 1998; Makino et al., 2001; Makino et al., 2002). Under 
normoxia, IPAS is expressed at low level in most tissues and under hypoxic conditions, 
IPAS expression was induced in corneal epithelium, cerebrum, cerebellum, heart and 
skeletal muscle. 
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1.7.2.4) Single minded proteins 
 
The first SIM protein identified came from Drosophila melanogaster. dSIM has 
been proposed to act as a master regulator of midline cell development in Drosophila and 
is required for all known developmental stages of the central nervous system midline cell 
lineage (Nambu et al., 1991). dSIM possesses a transactivation domain in the C-terminus, 
and forms a heterodimer with dARNT (also known as Tango) to give rise to a 
transcriptional activator complex (Sonnenfeld et al., 1997). 
 The murine homologues, mSIM1 and mSIM2 show considerable sequence 
divergence from dSIM over the C-terminal region and do not contain any transactivation 
domains but instead act as repressor proteins when heterodimerized with ARNT (Ema et 
al., 1996; Moffett et al., 1997). Repression mediated by mSIM1 seems to be indirect and 
occurs through competition for the partner protein ARNT, sequestering it away from 
other transactivating partner proteins. However, mSIM1/ARNT heterodimer has also 
been found to activate transcription from the erythropoietin hypoxic enhancer via the 
ARNT TAD (Woods and Whitelaw, 2002). On the other hand, repression mediated by 
mSIM2 occurs in two ways, through sequestration of ARNT from other partner proteins 
as well as active trans-repression (Ema et al., 1996). Two separate autonomous repression 
domains have been ampped in mSIM2 (Moffett et al., 1997). To date, it is still not clear if 
the SIMs are signal-responsive or exhibit their effect through their spatially and 
temporally restricted expression patterns. 
 Till far, no target genes have been identified for mSIM1 and SIM2. However, 
expression and knockout studies have provided some clue of their possible roles. Whole-
mount in situ hybridizations of embryos from Days 7.5 to 10.5 showed that mSIM1 and 
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mSIM2 expression was restricted and distinct (Ema et al., 1996). mSIM1 is expressed in 
the somites, the mesencephalon and neural tube, while mSIM2 is expressed in the 
diencephalons, branchial arches and rib primordia. Northern blot of adult tissues revealed 
that both mSIM1 and mSIM2 are expressed in the kidney and skeletal muscle, with 
mSIM2 also expressed in the lung (Ema et al., 1996). 
 Results from SIM1 knockout mice further indicate a likely role for SIM1 in the 
nervous system, specifically in the development of the hypothalamus-pituitary axis 
(Michaud et al., 1998). These mutant mice die perinatally, and exhibit defects in the 
terminal differentiation of certain endocrine lineages within the supraoptic nucleus, 
paraventricular nucleus and anterior periventricular nucleus. With both mSIM1 and 
ARNT2 expressed within the paraventricular and supraoptic nuclei, it has been postulated 
that ARNT2 may be the in vivo dimerization partner for mSIM1 (Michaud et al., 2000). 
More recently, it has been shown that SIM1 is involved in the prevention of obesity. 
mSIM1 heterozygous mice developed early-onset obesity and hyperphagia, while a 
balanced translocation resulting in the disruption of a single SIM1 allele in a human 
patient also led to profound early onset obesity (Holder et al., 2000; Michaud et al., 
2001). 
 The gene for human SIM2 is mapped to a region of chromosome 21 termed the 
Down syndrome critical region, implicating hSIM2 as a candidate gene in the etiology of 
the Down’s phenotype (Muenke et al., 1995). This is reinforced by the observation that 
transgenic mice trisomic for SIM2 have some aspects of Down’s phenotype (Chrast et al., 
2000). Based on sequence similarity and chromosomal localization, mSim2 is thought to 
be the murine orthologue of hSIM2 (Ema et al., 1996). mSIM2-/- mice die within postnatal 
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day 3 due to breathing failure (Goshu et al., 2002), showing reduced efficacy of lung 
inflation and numerous abnormalities within the structural components surrounding the 
pleural cavity.  
1.7.2.5) NXF (LE-PAS) 
 
 NXF was identified when a search on the human genome for hypothetical subtype 
or the relative of SIM2 was carried out. However, NXF is neither a subtype nor relative 
of SIM2 and showed only 24% similarity in amino acid sequence when compared to 
SIM2. Homology searches with the bHLH, PAS A and PAS B domains of NXF also 
showed comparable low degrees of similarity, suggesting that NXF could have a unique 
function distinct from those of already-known bHLH/PAS proteins. 
 Further characterization of NXF revealed that it contains a transactivation domain 
in its C-terminus whose activity is enhanced by the overexpression of the general 
transcriptional coactivator p300. NXF is able to interact with the ARNT subclass 
bHLH/PAS factors (ARNT, ARNT2 and BMALI). The heterodimer complex of 
NXF/ARNT is found to bind and activate SIM2-repressive CME element. Moreover, 
over-expression studies and chromatin immunoprecipitation experiments show NXF 
regulates the expression of Drebrin gene. Drebrin is reported to be abundant in the 
hippocampus of the human brain in immunocytochemical studies (Harigaya et al., 1996) 
and the expression of NXF overlaps with that of Drebrin, further supporting that NXF 
regulates Drebrin gene in vivo (Norihisa et al., 2004). 
Northern blot analysis and in-situ hybridization experiments revealed that LE-
PAS is exclusively expressed in the brain tissues – it is expressed in the hippocampus, 
olfactory bulb, entorhinal cortex and frontal cortex. These findings indicate that LE-PAS 
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expression is enhanced in the limbic system of the brain. LE-PAS is localized in the 
nucleus when over-expressed in COS-7 cells. Reporter gene assays showed that co-
expression of ARNT and LE-PAS transactivate a CME element but has no effect on the 
XRE motif (Moser et al., 2004). 
1.7.2.6) Trachealess and Dysfunction 
 
 The trachealess (trh) gene encodes a bHLH/PAS protein that is specifically 
expressed in the developing trachea and posterior spiracle, salivary gland placode and 
salivary ducts (Isaac and Andrew, 1996; Wilk et al., 1996). Genetic analysis indicates 
that trh is required for the formation of trachea and regulates the transcription of genes 
involved in this process (Younossi-Hartenstein and Hartenstein, 1993; Isaac and Andrew, 
1996; Wilk et al., 1996), as well as for the formation of the posterior spiracle and salivary 
duct (Isaac and Andrew, 1996).  
 Two-hybrid analysis and co-immunoprecipitation result indicate that Tango is a 
dimerization partner for Trh (Sonnenfeld et al., 1997). It was found that the Trh/Tgo 
heterodimer binds to CME-containing DNA in vitro (Ohshiro and Saigo, 1997) and that 
the heterodimer can activate transcription from CME-bearing promoters in Drosophila 
cell culture (Sonnenfeld et al., 1997). In addition, Trh also interacts with Drifter (Dfr), a 
POU-domain protein; ectopic expression of both Trh and Dfr (but not each one alone) 
was found to trigger trh autoregulation in several embryonic tissues (Zelzer and Shilo, 
2000).  More recently, it was found that Trh is a substrate for Protein kinase B (PKB) and 
using a combination of biochemical and transgenic approaches, direct phosphorylation of 
Trh by PKB at serine 665 is found to be essential for nuclear localization and functional 
activation of this regulator of branching morphogenesis (Jin et al, 2001). 
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Another bHLH-PAS protein, Dysfunction (Dys) is found to be involved in control 
of tracheal fusion and level of Trh protein (Jiang and Crews, 2003). Phylogenetic analysis 
revealed that Dys cluster as a discrete branch of the phylogenetic tree which includes 
human NXF. The dysfunction gene is expressed in a variety of embryonic cells, including 
tracheal-fusion, leading-edge, foregut atrium cells, nervous system, hindgut and anal pad 
cells. RNAi experiments indicate that dysfunction is required for dorsal branch, lateral 
trunk and ganglionic branch fusion. The Dys function is localized in the nucleus and 
heterodimerize with Tango to form a putative DNA-binding complex. However, the 
target genes of Dys remain to be investigated. 
1.7.2.7) ARNT 
 
 ARNT is the general partner protein for members of the bHLH/PAS family of 
proteins. mARNT is localized to the nucleus (Eguchi et al., 1997) through an N-terminal 
NLS, comprising amino acid residues 39-61. The NLS is a novel bipartite type, differing 
from the classical bipartite type NLSs and mediates ARNT nuclear localization through 
interactions with components of the nuclear pore targeting complex. ARNT also contains 
a strong autonomous transactivation domain in its C-terminus, which is functionally 
distinct from the DNA binding and heterodimerization domains (Whitelaw et al., 1994). 
This transactivation function is likely to be mediated through recruitment of the 
coactivator CBP/p300 since the transactivation domain of ARNT was shown to interact 
with CBP/p300 in a yeast-2-hybrid screen (Kobayashi et al., 1997). 
 The generation of ARNT-/- embryonic stem cells and mice shows the importance 
of interaction between ARNT and HIF-1α in response to hypoxia, as well as the 
importance of ARNT during development (Kozak et al., 1997; Maltepe et al., 1997). 
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ARNT-/- embryonic stem cells fail to activate genes that normally respond to hypoxia or 
reduced glucose concentration. Moreover, mouse embryos generated from these cells die 
before embryonic Day 10.5. The primary cause of death is due to defects in 
vascularization of the placenta and/or developing yolk sac and solid tissue, a phenotype 
similar to that reported for mice deficient in VEGF, a target gene of ARNT/HIF-1α 
(Carmeliet et al., 1996; Ferrara et al., 1996).  
 While the role ARNT as a general heterodimerizing partner for bHLH/PAS 
proteins such as AhR, HIF-1α and SIM proteins are well characterized, the physiological 
role of ARNT homodimer is still not known. ARNT is a constitutively nuclear localized 
protein, is ubiquitously expressed in mammalian tissues (Carver et al., 1994; Abbott and 
Probst, 1995; Sojka et al., 2000) and shows a promiscuous tendency to form homodimers 
and heterodimers with other bHLH/PAS proteins (Hirose et al., 1996). An 
oligonucleotide selection-amplification protocol and other electrophoretic mobility shift 
assays have shown that bacuolovirus-expressed ARNT is able to bind to the classical E-
box sequence (Huffman et al., 2001; Swanson et al., 1995). Moreover, there is evidence 
that ARNT can activate transcription from promoters driven by the E-box element in 
transient transfection experiments (Antonsson et al., 1995; Sogawa et al., 1995). 
 ARNT also exists as an alternatively spliced form in both mouse and human, 
containing an additional 15 amino acids just N-terminal of the basic region encoded by 
exon 5 (Hoffman et al., 1991; Reisz-Porszasz et al., 1994). The contribution of the 
different splice variants of ARNT has yet to be investigated. 
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1.7.2.8) Neuronal PAS domain protein 1 
 
 Neuronal PAS domain protein 1 (NPAS1) was identified during a search for novel 
bHLH-PAS domain proteins expressed in the brain (Zhou et al., 1997). Northern blot 
analysis revealed that NPAS1 begins expression in E16.5 mouse embryos and can only 
be detected in adult brain and spinal cord. Within the identification of NPAS3 (Pickard et 
al., 2005), it was found that NPAS1 is highly homologous to NPAS3, which has been 
implicated in schizophrenia. NPAS1 is found to be expressed in inter-neurons in the 
forebrain (Erbel-Sieler et al., 2004), where degeneration of these neurons are thought to 
be involved in schizophrenia, thereby strengthening the link between NPAS1 and the 
disease. NPAS1 knockout mice revealed a decrease in the protein Reelin, which is highly 
expressed in the inter-neurons. In the same study, it was also shown that NPAS1 and 
NPAS3 are functionally redundant. 
 Further characterization of NPAS1 revealed that it is localized to the nucleus of 
cortical neurons (Ohsawa et al, 2005). Moreover, NPAS1 was to be a repressor that is 
able to down-regulate the expression of erythropoietin in vivo, suggesting that it may 
play a role during neuronal differentiation. 
1.8) Overview of Experiment 
  
 The aim of this work is to identify new proteins that play a role during the 
development of dopaminergic neurons. An immature dopaminergic cell line, MN9D 
derived from the fusion between a primary neuronal cell from early mouse 
mesencephalon and the mouse (Choi et al, 1999) was induced to differentiate with 1 mM 
n-butyrate acid. Upon differentiation, MN9D cells exhibited a mature neuronal 
morphology, characterized by flattened cell body, extension of neurites and expression of 
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GAP-43. A cDNA subtractive library was then constructed to screen for genes that are 
up-regulated upon differentiation of these MN9D cells. 
 One of the genes identified from the subtractive library codes for a transcription 
factor, neuronal PAS domain protein 1 (NPAS1), that belongs to the family of basic 
helix-loop-helix PAS domain protein. To determine its role during development, an 
expression profile of NPAS1 during mouse development was conducted. It was found 
that NPAS1 is expressed in all the different regions analyzed (forebrain, midbrain, 
hindbrain, spinal cord, tail, liver and limb) throughout embryonic stage E12.5 to E18.5. 
However, in the adult stage, NPAS1 is restricted to expression in the brain, spinal cord 
and liver. In addition, NPAS1 is found to be expressed in the ventral midbrain from 
E12.5 onwards. This suggests that NPAS1 mat play a role during development of the 
ventral midbrain. 
 As relatively little has been done on characterizing the NPAS1 protein, we set out 
to uncover the different functional domains of NPAS1. Being a transcription factor, 
NPAS1 needs to be localized to the nucleus in order to exert its effect. We found that 
NPAS1 is not constitutively localized to the nucleus. In fact, NPAS1 is excluded from the 
nucleus and requires the presence of ARNT in order to enter the nucleus. Furthermore, 
we found that a nuclear export signal (NES) present within the N-terminus of NPAS1 is 
responsible for the nuclear exclusion of NPAS1. Similar to most of the other bHLH-PAS 
proteins, NPAS1 is able to interact with ARNT via its N-terminus. From the results 
mentioned, a mechanism of nuclear localization of NPAS1 was proposed in which 
interaction between NPAS1 and ARNT result in NPAS1 being guided into the nucleus 
via the nuclear localization signal of ARNT. We failed to identify any transactivation 
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domain within NPAS1; instead, two repression domains were identified. Upon further 
investigations, it was found that NPAS1 is able to repress the transactivation function of 
ARNT, thereby serving as a repressor to down-regulate gene expression, which is 
consistent with its role as a repressor as reporter by Ohsawa et al. (2005). 
 Next, we studied the role of NPAS1 during MN9D differentiation. It was found 
that during MN9D differentiation, there was an initial increase followed by a decrease in 
tyrosine hydroxylase level. Upon over-expression of NPAS1, TH level in MN9D cells 
decreased and this effect by NPAS1 was confirmed with siRNA experiments. When 
NPAS1 expression was knocked down with siRNA, the level of TH increased, suggesting 
that NPAS1 negatively regulates the expression of TH. We further showed that this effect 
is due to a negative regulation on the TH promoter by NPAS1. To gain an insight into the 
physiological relevance of this function of NPAS1, real-time PCR was carried out to 
trace the expression of TH in the ventral midbrain during mouse development. It was 
found that TH level peaks at E12.5 and subsequently decreased till E18.5. Since NPAS1 
expression increased in the VM from E12.5 to E18.5, we propose that NPAS1 may play a 
role in regulating TH level of dopaminergic neurons in the VM during development. 
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CHAPTER TWO 
- GENERAL MATERIALS AND METHODS 
 
2.1) Cell Culture 
 
 The murine clonal cell line MN9D was a kind gift from Dr. Jun Chen 
(Department of Neurology, University of Pittsburgh, with subsequent approval from the 
originator Dr Alfred Heller, University of Chicago). Cells were grown in DMEM media 
with 10% fetal bovine serum, streptomycin (100 μg/ml), and penicillin (100 U/ml) and 
maintained at 37ºC in a humidified atmosphere of 5% CO2. 
2.2) Transfection of Mammalian Cells 
 Cells were grown to the required confluency and transfected using Lipofectamine 
2000 (Invitrogen, USA) with a ratio of 1:2 of DNA (μg): Lipofectamine 2000 (μl). The 
amount of DNA used were followed as recommended by the manufacturer’s protocol. 
2.3) Quantification of Nucleic Acids 
 
 After purification, DNA or RNA was quantified using Nanodrop at a wavelength 
of 260nm. The factor of 50 for DNA and 30 for RNA was taken into account by the 
machine. 
2.4) Gel Electrophoresis and Purification of DNA 
 
2.4.1) Agarose Gel Electrophoresis 
 
 Agarose gels were used to analyze DNA fragments generated by restriction 
endonuclease digestion, or by PCR. The composition of gels used depended on the MW 
of the DNA fragment and dissolved in 1 X TAE (0.04M Tris-acetate, 0.001M EDTA) 
with 0.4 μg/ml EtBr. The voltage applied was normally 100 V. After electrophoresis, 
DNA bands were visualized with an UV illuminator. 
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2.4.2) Isolation and Purification of DNA Fragment by Agarose Gel 
 
 The DNA band required was excised out with a sterile bade when the gel was 
under the UV illuminator. The DNA fragment was purified using QIAquick Gel 
Extraction Kit from QIAGEN (QIAquick Spin Handbook, pg 24). 
2.5) Conventional Polymerase Chain Reaction (PCR) 
 
 PCR was carried out using AmpliTaq DNA polymerase (Promega, USA). 
Usually, a 20 μl reaction mixture was used, comprising 1 X PCR buffer, 10 mM  of each 
NTPs, 20 ng of DNA template, 5 pmol of each primer, 1U of AmpliTaq DNA 
polymerase and distilled water to make up the volume. PCR was done in a Peltier-Effect 
Cycling PTC-1000 Programmable thermal cycler (MJ Research, USA) as follows: 2 min 
at 94ºC;, 30 cycles of 30 sec at 94ºC, 30 sec at 55ºC, 1 min at 72ºC;, final extension of 7 
min at 72ºC. 
2.6) Purification of PCR Product 
 PCR product was purified using QIAquick Gel Extraction Kit from QIAGEN 
(USA) according to the manual. 
2.7) Enzymatic Manipulations of DNA 
 
2.7.1)  Endonuclease Restriction Digestion 
 
 All restriction endonuclease digestions of DNA were carried out in conditions and 
buffers recommended by the manufacturers (New England BioLabs or Promega, USA). 
For double restriction digestion, an optimal buffer in which the activity of each of the 
enzyme was more than 50% was used 
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2.7.2) Dephosphorylation of DNA Ends 
 Dephosphorylation was carried out for all vectors. Shrimp alkaline phosphatase 
was used in conditions and buffer recommended by the manufacturer (Promega, USA). 
2.7.3) A-tailing of DNA 
 Adenine tailing was required for cloning of PCR product into pGEM-T vector. 
Essentially, 1-2 μ of purified PCR product was added to a reaction mixture made up of 1 
μl of Taq DNA polymerase reaction 10x buffer, 1 μl of 25 mM MgCl2, 1 μl of 2mM 
dATP and 5 units of Taq DNA polymerase and deionized water to a final volume of 10 
μl. The reaction was incubated at 70ºC for 30 min.  
2.7.4) Ligation 
 
 Ligation was carried using Promega T4 DNA ligase at a vector : insert molar ratio 
of 1:3 in a 10-μl reaction. The ligation mix was incubated overnight at 4ºC. 
2.8) Growth, Preparation and Transformation of Competent E.coli Cells 
 
2.8.1) Growth of Bacteria in Liquid and Solid Media 
 
 The liquid medium used for culturing bacteria was Luria Broth (LB; 10 g 
tryptone, 5 g yeast extract, 5 g NaCl per litre; pH 7.2). Both small- and large-scale liquid 
cultures were initiated by inoculation with a single bacterial colony from an agar plate. 
They were grown in flasks having a volume at least 5 times that of the culture medium, 
and incubated at 37ºC with vigorous shaking (~280 rpm). 
 To isolate single bacterial colony arising from a single bacterium, or from 
transformation, bacteria were plated on LB agar plates (LB + 1.5% agar) and incubated 
overnight at 37ºC. To select for antibiotic resistant colonies, either ampicillin or 
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kanamycin (final concentration of 50 μg/ml) was added to the LB agar. For pGEM-T 
based construct, blue-white selection was carried out with X-gal and IPTG. 
2.8.2) Preparation of Competent E. coli Cells 
 Aliquots of competent E. coli cells were prepared according to the method 
described by Tang et al (1994). One hundred millitres of LB were inoculated with an 
appropriate volume of an overnight DH5α culture to reach an OD600 of 0.3. The fresh 
bacterial culture was grown for 2 hr at 37ºC with shaking until the OD600 was 
approximately 0.9. The bacterial culture was then chilled on ice for 15 min and the cells 
were harvested by a 10 min centrifugation at 2000 rpm and 4ºC. The bacterial pellet was 
resuspended in 15 ml of an ice-cold solution of 80 mM CaCl2 and 50 mM MgCl2 and 
stored on ice for 10 min. The cells were then re-harvested. This treatment was repeated 
twice. Finally, the cell pellet was resuspended in 4 ml ice-cold 0.1 M CaCl2 before 
mixing the suspension with an equal volume of ice-cold 50% glycerol and 50% 0.1 M 
CaCl2 solution. The competent cells were aliquoted into smaller volumes and were 
immediately frozen and stored at -80ºC. 
2.8.3) Transformation of Bacterial Competent Cells 
 
 For each transformation, 100 μl of thawed competent bacteria was added into a 
centrifuge tube containing 30 ng of plasmid DNA or 10 μl of ligation mix and left on ice 
for 20 min. Heat shock treatment was then performed for 5 min at 37ºC after which 400 
μl of LB was added. The bacterial culture was incubated at 37ºC for 45 min with shaking. 
The bacteria were then plated out onto the appropriate selective agar plates. 
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2.9) Pure Plasmid Isolation Using Affinity Matrix 
 
 When doing screening for correct transformed clones, plasmids were purified 
using QIAGEN Miniprep kit according to manufacturer’s instructions. For plasmids that 
are to be used for transfection, they were purified using QIAGEN MidiPrep kit. 
2.10) DNA Sequencing 
 
 Plasmids and DNA fragments were sequenced using ABI PRISM BigDye 
Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, USA) in 
accordance with the manufacturer’s instructions. The cycle sequencing profile includes 
30 cycles of 10 sec at 96ºC, 5 sec at 50ºC and 4 min at 60ºC. The extension products 
were purified using ethanol and sodium acetate precipitation. Precipitated products were 
run on ABI Sequencer 355. 
2.11) Isolation of Proteins from Mammalian Cells 
 Treated of transfected cells were washed twice with PBS and lysed with the lysis 
buffer (100mM HEPES, 150mM NaCl, 5mM MgCl2, 1mM EDTA and 1% Triton X-
100). Total cell lysates were collected and incubated overnight at -20°C. Cell debris were 
removed by centrifugation at 12000 x g for 5 min at 4°C. Protein concentration was 
determined by Bio-Rad Bradford assay kit. 
2.12) Western Blot Analysis 
 Proteins were separated by SDS-PAGE in 1 X running buffer (192mM glycine, 
25 mM Tris and 0.1%SDS) at 80V for approximately 2 hr. Next, transfer was carried out 
in a buffer consisting of 12mM Tris and 96mM glycine, onto a nitrocellulose membrane 
(Bio-Rad Laboratories, USA) at 80V for 1.5 hr. Membrane were then blocked in either 
5% skim milk or 5% BSA in TBST (10.8mM Tris, 150mM NaCl and 0.1% Tween-20) 
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for an appropriate amount of time. Membranes were probed incubated with primary 
antibody diluted in either 2% skim milk or 2% BSA in TBST. Next, the blot was washed 
with TBST for 5 min for a total of 5 times. The blot was then incubated with secondary 
antibody diluted with the same buffer as the primary antibody. Next, the blot was washed 
5 times with TBST for 5 min each time and a final wash with TBS (10.8mM Tris and 
150mM NaCl). Proteins were visualized with an ECL detection kit (Pierce Biotechnology 
Inc, USA). 
2.13) Flow Cytometry 
 Cells in 6-well plate format were used for flow cytometry. The medium from each 
well was discarded and the cells washed twice with 1 x PBS. Next, 200 μl of trypsin-
EDTA was added and incubated at 5 min to dissociate the cells from well. The trypsin 
was then neutralized with 1 ml of culture media. The cells were harvested and 
centrifuged at 2000 rpm for 10 min at 4ºC. The supernatant was discarded and the cells 
washed with 1 ml of 1 x PBS. The cells were then spun at 2000 rpm for 10 min at 4ºC 
and the supernatant discarded. The cells were then fixed in 0.5% paraformaldehyde in 
PBS for 5 min to prevent GFP leakage. Next, the cells were collected by centrifugation at 
2000 rpm for 5 min at 4ºC followed by one wash with 1 x PBS. The cells were then 
resuspended in 500 μl of 1 x PBS and 4.5 ml of ice cold 70% ethanol. The cells were 
stored at -20ºC until Propidium Iodide staining. 
 For PI staining, the fixed cells were centrifuged at 5000 rpm for 10 min at 4ºC. 
The ethanol was discarded and the tube dried by inverting it on c-fold towel. Next, 515 μl 
of PI stain [500 μl sample buffer (1 g glucose in 1 L 1 x PBS), 10 μl of 1000U/ml RNase 
A and 5 μl of 1 mg/ml Propidium Iodide] was added followed by an incubation for 30 
  Materials and Methods 
 43
min at room temperature. The cell samples were then passed through 41 nm nylon and 
subjected to flow cytometric analysis on 20,000 cells using EPICS Elite ESP cytometer 
(Beckman Coulter, USA). 
2.14) Dual Luciferase Assay 
 Dual Luciferase Assay was carried out using the Promega kit. Transfected cells in 
24-wells format were washed twice with ice-cold PBS and lysed in 100 μl of 1 X Passive 
Lysis Buffer. The cell lysate was then centrifuged at 15,000g at 4ºC for 5 min to remove 
the cell debris. A luminometer was programmed to perform a reading every 5 seconds. In 
a luminomoeter tube, 100 μl of LAR II was added followed by 20 μl of cell lysate. 
Mixing was carried out by shaking the tube several times. The tube was then placed in 
the luminometer and reading was initiated. Several readings (for firefly luciferase 
activity) were taken until the readings start to decrease before the tube was removed and 
100 μl of Stop & Glo Reagent added and mixed by shaking. The tube was then placed 
back into the luminometer and reading initiated. Several readings for Renilla luciferase 
activity were taken until the readings start to decrease. 









Stem cell therapy is currently being investigated as a cure for Parkinson’s disease. 
A major drawback to this approach is that the success rate is not high due to the poor 
survival of dopaminergic cells and the low efficiency to differentiate stem cells into the 
dopaminergic phenotype. Hence a greater understanding of how a progenitor cell matures 
into dopaminergic neuron is required. Our study employed suppressive subtractive 
hybridization as a tool to identify genes that are up-regulated during differentiation of a 
dopaminergic cell line, MN9D when treated with 1mM n-butyric acid. The efficiency of 
this approach was further confirmed by microarray profiling. Twenty-three percent of the 
library clones comprise of ribosomal proteins, indicating active translational activities 
during differentiation. The genes identified are known to be involved in neuritogenesis, 
cell cycle arrest and synaptogenesis. Seven genes - Rac1, Hsc70, SOD1, PARP, casein 
kinase 2β, Syndecan I and Prion protein exhibited a parallel increase in protein level 
during the course of MN9D differentiation. 






 Suppressive subtractive hybridization method provides a powerful tool for 
studying differential gene expression profile. Previously, this approach has been utilized 
to identify genes that are crucial for ES cell neural differentiation (Bain et al, 2000). 
Beside subtractive hybridization, other methods such as microarray and targeted display 
have also been used for large scale identification of genes that are up-regulated upon 
neuronal differentiation (Wen et al., 2002; Brown et al., 1999; Ahn et al., 2004; Yu et al, 
2004). However, in all of these studies, a mixed population of neurons and even glial 
cells are present, making it difficult to identify factors that are intrinsic to neurons. 
 In the present study, we used a suppressive subtraction approach to identify genes 
that are up-regulated during neuronal differentiation in a dopaminergic MN9D cell line. 
Our results have identified a number of genes that are known to play important role 
during neuritogenesis, cell cycle arrest and synaptic formation. The efficiency of the 
library was further verified with cDNA microarray, with more than 95% of the clones 
from the subtractive library showing up-regulation. Western blots for six proteins (Casein 
kinase 2β, SOD1, Hsc70, Syndecan I, Prion protein and PARP) identified from the 
library showed a parallel increase at the protein level. Based on the identification of many 
genes up-regulated during MN9D neuronal differentiation, we suggest that some of the 
genes identified in this screen may be playing previously unidentified roles in neuronal 
differentiation. 




3.2) Materials and Methods 
 
3.2.1) Cell Culture 
 
 After treatment with n-butyrate to induce maturation, MN9D cells were split after 
every 3 days over a period of 12 days. This sequential splitting is necessary to prevent 
over-crowding of the cells. RNA or protein sample collected at each time-point was thus 
referred to as 1st, 2nd, 3rd or 4th split. This annotation was used instead of 3, 6, 9 and 12 
days so as not to be mistaken that MN9D cells were treated with n-butyrate for a total of 
12 days without any splitting of cells throughout the 12 days. However, for subsequent 
chapters, the annotation of 3, 6, 9 and 12 days were used although sequential splits were 
still carried out. 
3.2.2) Differentiating Agent 
 n-butyric acid (sodium salt) (Sigma, St. Louis, MO) was dissolved in phosphate 
buffered saline (8 g/l NaCl, 0.2 g/l KCl, 1.44 g/l Na2HPO4 and 0.24 g/l KH2PO4) and 
stored at room temperature. Stock solution of n-butyric acid was added to the media to a 
working concentration of 1 mM prior to use. Maximal differentiation is achieved 12 days 
after treatment as determined by the formation of a flattened cell body and neurites. 
Control cultures were left untreated. 
3.2.3) Construction of cDNA PCR Subtractive Library  
 The library was prepared using CLONTECH PCR-SelectTM cDNA Subtraction kit 
(Clontech Laboratories, Palo Alto, CA) according to the manufacturer’s instructions. For 
first-strand cDNA synthesis, 2 μg of mRNA was used. Three microlitres of the final PCR 
mixture, which is enriched in differentially expressed cDNAs, was ligated to pGEMT-
Easy vector (Promega Corporation, WI) and the ligation mix was transformed into 




DH10B E.coli cells. The cells were then plated on bacterial agar plates supplemented 
with ampicillin (50 μg/ml), X-gal (0.006% w/v) and IPTG (0.2 mM) and incubated at 
37ºC overnight. 
3.2.4) Colony PCR Screening 
 White colonies were picked from the bacterial plates and subjected to PCR using 
vector-specific T7 and SP6 primers. Reactions were done in the presence of dNTPs (0.2 
mM final concentration), MgCl2 (1.875 mM final concentration), T7 and SP6 primer pair  
(4 pmol of each), and Taq DNA polymerase (1 U) in a 20 μl reaction. PCR was done in a 
Peltier-Effect Cycling PTC-1000 Programmable thermal cycler (MJ Research, USA) as 
follows: 2 min at 94ºC;, 30 cycles of 30 sec at 94ºC, 30 sec at 55ºC, 1 min at 72ºC;, final 
extension of 7 min at 72ºC. PCR products were resolved by gel electrophoresis and 
visualized by ethidium bromide staining.  
3.2.5) Identification of Subtractive Library Genes 
 Bacterial clones containing an insert were cultured overnight and the plasmid was 
isolated using Wizard® Plus SV Minipreps DNA Purification System kit (Promega 
Corporation, WI) following manufacturer’s specifications. The plasmid DNA 
concentration was determined by UV spectroscopy. The insert was then sequenced and 
the results sent for BLAST analysis (http://www.ncbi.nlm.nih.gov/BLAST/). 




3.2.6) Construction of cDNA Expression Array and Analysis 
Spotting of cDNAs 
 A 100-μl PCR reaction was carried out using primers specific to the adaptors 
linked to the SSH cDNAs during library construction. The PCR products were purified 
using the QIAquick PCR Purification kit (Qiagen, Chatsworth, CA). The purified cDNAs 
were precipitated with ethanol and dissolved in 1 X Micro Spotting Solution (ArrayItTM, 
USA). The dissolved cDNAs were subjected to spotting by the microarray spotting 
machine (Cartesian Technologies, USA) on FMB cDNA slides (Full Moon Biosystems, 
Inc.). The printed slides were then rehydrated by holding the slide over a 55ºC water bath 
and then snap-dried over an 80ºC heat block for 4 sec. Next, the cDNAs on the slides 
were immobilized by UV cross-linking. 
Labeling of total cDNA targets 
 CyScribe First Strand cDNA Labelling kit (Amersham Biosciences, UK) was 
used to prepare Cy3 or Cy5 labeled cDNA targets from purified total RNA.  
Blocking of microarray 
 The microarray slides were quickly immersed into a mixture of succinic 
anhydrous (SA) and 1-methyl-2-pyrrolidinone (NMP) solution for five times and left 
immersed in SA/NMP solution with slight agitation for 15 minutes. The slides were then 
quickly plunged five times into 98oC deionized water, followed by 2 minutes static soak. 
Next, the slides were plunged five times into absolute ethanol and spin dry in centrifuge 
at 500 x g for 5 minutes. The slides were ready for immediate hybridization. 




Hybridization to cDNA expression array 
 The Cy3-labeled and Cy5-labeled cDNAs were centrifuged in a SpeedVacTM 
concentrator for about 1- 2 hours to reduce the volume to about 15 µl each tube. The two 
tubes were then placed in a 95oC heat block for 2 minutes and immediately transferred 
into ice for 1 minute. To each tube, 15 µl of hybridization buffer and 30 µl of formamide 
were added. The spotted array slides were placed into Genomic Solution GeneTAC 
HybStation (Genomic Solutions, USA). Reaction mixtures from both tubes were then 
pooled together and injected into the hybridization chamber at steady temperature of 
50oC in the GeneTAC HybStation and incubated overnight at 42oC for about 16 hours. 
Microarray washing 
 Washing procedure was carried out in the GeneTAC HybStation with 2X SSC 
(standard saline citrate) solution, 0.1% SDS (sodium dedocyl sulfate) washing solution at 
50oC holding temperature for 3 cycles of 30 seconds flowthrough and 10 minutes of 
holding time, followed by washing with 2X SSC, 0.1% SDS washing solution at 27oC  
holding temperature for 6 cycles of 30 seconds flowthrough and 10 minutes of holding 
time. After which, the washing solution was drained off the hybridization chamber for 1 
minute. The array slide was then taken out from the hybridization chamber and rinsed 
briefly with 2X SSC washing solution. After brief rinsing, the array slide was dried by 
spinning at 500 rpm for 5 minutes in a tabletop centrifuge.  
Microarray scanning and data analysis 
The hybridized microarray slide was inserted into ScanArray 5000 scanning machine 
(GSI Lumonics, Packard BioScience, USA). The laser wavelength used for detecting 
fluorescence signals emitted from the cyanine-based dyes, Cy3-dye and Cy5-dye were 




543 nm and 633 nm respectively. The scanned images of the microarray were saved as 
Bitmap files and were analyzed by QuantArray Microarray Analysis Software version 3.0 
(Packard BioScience, USA). 






3.3.1) Comparison of Efficiency of Differentiation of MN9D Cells by BDNF, GDNF 
and n-butyric acid 
 
 As a first step towards identifying genes that are up-regulated during 
dopaminergic neuronal differentiation, an efficient method to induce differentiation in 
MN9D cells is essential. Glial cell line-derived neurotrophic factor (GDNF) is known to 
induce neuronal differentiation in MN9D cells (Heller et al., 1996). In addition, BDNF 
(Studer et al., 1996; Beck et al, 1993) and n-butyric acid (Goya and Timiras, 1991; Byrd 
and Alho, 1987; Liang et al., 2004) have also been used for differentiation of 
mesencephalic cells. MN9D cells were treated with these three different chemicals to 
determine which method is most efficient in inducing differentiation of MN9D cells. 
 The efficiency of neuronal differentiation was scored by the most direct 
morphological change, that is, neurite extensions. MN9D cells were treated with 50 
ng/ml BDNF, 10 ng/ml GDNF and 1 mM n-butyric acid respectively over a period of 21 
days. As shown in Figure 3.1A, extension of neurites was observed in the cells after 5 
days of treatment with 1 mM n-butyric acid.  Such observation was not found in cells 
treated with BDNF, GDNF or PBS (negative control) (Figure 3.1B, C and D). After 13 
days of treatment, the cell bodies of cells treated with 1 mM b-butyric acid started to 
flatten and the neurites are more prominent (Figure 3.1A). However, no comparable 
effect was observed in cells treated with BDNF or GDNF (Figure 3.1B and C). After 21 
days of 1mM n-butyric treatment, the number of cells with flattened cell bodies and 
extension of neurites increased significantly (Figure 3.1A) but the cells treated with 
BDNF or GDNF still showed no sign of differentiation (Figure 3.1B and C). Therefore, it 
can be concluded that 1mM n-butyric acid gave the highest efficiency of neuronal 




differentiation in MN9D cells and this method of differentiation was chosen for MN9D 
cells during the construction of the subtractive library.  
3.3.2) n-Butyric Acid Induces Differentiation of MN9D Cells 
 
 To further characterize the effect of n-butyric acid on MN9D cells, a more 
thorough study was carried out. From the first experiment, it was shown that, upon 
treatment with 1mM n-butyric acid, MN9D cells exhibit a mature neuronal morphology, 
characterized by a flattened cell body and the extension of neurites (Figure 3.2A). We 
went on to show that the treated cells express a mature neuronal marker, growth-
associated protein 43 (GAP43) which was undetectable in the untreated MN9D cells 
(Figure 3.2B). There was a decrease in the doubling time of the treated cells (data not 
shown), indicating they are exiting the cell cycle. This was confirmed by propidium  
iodide staining and FACS analysis which showed an arrest of treated cells in the G0 and 
G1 phase (Figure 3.2C).  
3.3.3) cDNA Subtractive Library Identifies Different Classes of Genes Up-regulated 
 During MN9D Differentiation 
 
 A cDNA subtractive library was constructed using mRNAs from untreated MN9D 
cells as the control and mRNAs from 6-days post-treated MN9D cells as the driver. A 
total of 1500 clones were screened by colony PCR (Figure 3.3). Clones with a single 
insert were selected for the isolation of plasmid for subsequent sequencing. Sequencing 
results were then sent for BLAST analysis and a total of 380 unique clones were 
identified. These 380 clones belong to different classes of genes, as shown in Table 3.1. 
Genes coding for ribosomal proteins made up the largest part of the library, accounting 
for about 23% of the population, followed by uncharacterized and hypothetical proteins, 




which made up 20.82%. In addition, genes coding for signaling molecules account for 
about 7.28% of the clones. 
 Some of the isolated genes that are known to be involved during neuronal 
differentiation are given in Table 3.2.  
3.3.4) Microarray Results Confirmed the Up-regulation of Genes From Subtractive 
 Library 
 
 Since the efficiency of a subtractive library is rarely 100%, microarray 
experiments were carried out to analyze the changes in the expression level of the genes 
during differentiation, at a large-scale level. A total of 316 cDNAs lacking the poly A tail 
from the unique clones were selected for spotting on glass slides. These cDNAs serve as 
the probe. Each cDNA was spotted 4 times on a single glass slide, over 4 different panels.  
Each panel consists of the 316 cDNAs from the library, a β-actin cDNA (for 
normalization) and 5 bacterial genes (serve as negative controls). 
 cDNAs from untreated and treated MN9D cells were labeled with either Cy3 or 
Cy5 dyes and used for hybridization to the glass slides. A total of 3 slides were used for 
hybridization and the results are averaged and presented. Figure 3.4A shows a picture of 
a registered scanned image of array slide with both Cy3 and Cy5 intensities images 
merged together. As shown in the figure, there is no hybridization of the labeled targets 
to the bacterial genes and therefore, the spots for these negative controls appear dark. The 
scatter plot (Figure 3.4B) showed that more than 90% of the cDNAs are up-regulated in 
6-days post-treated MN9D cells, confirming the validity of results from the subtractive 
library. 




3.3.5) Casein kinase 2β, SOD1, Hsc70, Syndecan I, Prion protein and PARP 
 Expression Levels During MN9D Differentiation 
 
 To further determine if the increase at the transcript level was paralleled by an 
increase at the protein level, Western blot for six different proteins identified from the 
library were performed over the course of MN9D differentiation. 
 Casein kinase 2β showed an increase in level as early as after the first split 
(Figure 3.5A). Subsequent to that, the level remained relatively constant. Both 
Superoxide dismutase 1 (Figure 3.5B) and Hsc70 (Figure 3.5C) showed a similar protein 
profile change during the course of MN9D differentiation. In both cases, the protein level 
reached a peak at around 3rd split post induction, followed by a slight decrease on 4th split 
post-induction. Syndecan I expression level increased after the second split and remained 
at a high level throughout the whole course of differentiation (Figure 3.5D). As seen in 
Figure 3.5E, the Western blot for Prion protein gave three different bands, which 
corresponded to different isoforms of the protein. However, there was no significant 
difference in the level of Prion protein in the cell after differentiation. It was observed 
that only cleaved forms of PARP were present in the untreated and 1st split MN9D cells. 
However, uncleaved PARP appeared after the second split and remained at a high level 
throughout the whole course of differentiation, whereas the cleaved forms decreased 













Figure 3.1 Efficiency of different differentiating agents on MN9D differentiation. 
MN9D cells were treated with either, 1 mM n-butyric acid, 50 ng/ml BDNF or 10ng/ml 
GDNF for 5 and 10 days. Photographs were then taken to determine the degree of 
morphological differentiation induced by the different treatment. Tratment with 1mM n-
butyric acid resulted in extension of neurites and a flattening of cell bodies after 5 days. 
Howver, no morphological differentiation was observed for treatment with 50 ng/ml 
BDNF or 10 ng/ml GDNF. The cells were also treated with PBS to serve as a mock 
control. The white bar represent 20µm. 
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Figure 3.2 N-butyrate induces differentiation of MN9D cells. (A) MN9D cells were 
treated with 1mM n-butyrate. Morphological changes can be observed 6 days after 
treatment. Untreated MN9D cells were round and only occasionally extended short 
neurites whereas n-butyrate treated cells had flattened cell bodies and extension of longer 
neurites. N-butyrate treated cells expressed the neuronal marker, GAP43. 
Immunostaining showed that n-butyrate treated MN9D cells expressed GAP43, which 
was not expressed in the control cells (B). MN9D cells were arrested in G0 and G1/G2 
phases upon treatment with n-butyrate. Cells were stained with propidium iodide and 












                       
 
Figure 3.3 Colony PCR results for white colonies from the subtractive library 
screen. For colonies containing a single insert (single band), plasmids were isolated from 
the colonies and subsequently sent for sequencing. In those colonies that contain more 
than one insert (multiple bands), no sequencing was carried out. 
 
 




































































Figure 3.4 The subtractive library has an efficiency of more than 90%. cDNAs from 
the subtractive library were spotted on a glass slide and subjected to microarray analysis. 
cDNAs from n-butyrate treated MN9D cells (labeled with Cy5 dye) and control cDNAs 
(labeled with Cy3 dye) were hybridized to the cDNA spots, washed and analyzed using 
QuantArray Microarray Analysis Software version 3.0. A) Scanned image of a panel of 
the cDNA microarray. The bacterial cDNAs (dashed boxed), positive control β-actin 
cDNA (circled) and blank spots (solid boxed) are as shown.  B) A scattered plot of Cy5 
intensity against Cy3 intensity was plotted for each of the cDNA spot. More than 90% of 
the spots showed a Cy5/Cy3 ratio of more than 1, which indicated an increased 
expression of the respective cDNAs upon n-butyrate treatment. 
 
  
                              
 




                         
 
Figure 3.5 Changes in expression of CKIIβ, SOD1, Hsc70, Syndecan I, Prion protein 
and PARP1 during MN9D differentiation. MN9D cells were induced with n-butyrate 
and split after 3 days over a course of 12 days, resulting in a total of 4 splits, labeled 1st, 
2nd, 3rd and 4th in the figure (please refer to Materials and Methods on page. Proteins were 
extracted from the treated cells after each split and Western blots were carried out CKIIβ 
(A), SOD1 (B), Hsc70 (C), Syndecan I (D), Prion protein (E) and PARP1 (F). CKIIβ 
level peaked at the 1st split and returned to control level subsequently. SOD1, Hsc70 and 
Syndecan I levels started to increase only after the 2nd split and remained highly 
expressed. Prion protein expressed three different isoforms and each isoform showed a 
different expression profile during the course of MN9D differentiation. Only PARP 
cleaved forms were present before the first split. Subsequently, full length PARP band 
was observed. β-actin (G) was used as a loading control. Each blot is representative of 3 












Table 3.1 Distribution of the genes identified from suppressive subtractive library. 
The 1500 genes screened were classified under major classes of proteins as indicated. 




Class of genes Percentage (%) 
Cell adhesion  1.2 
Cytoskeleton 3.2 
Growth factors 0.1 
Heat shock proteins 5.0 
Histones 2.2 
Hypothetical or uncharacterized 20.8 
Melanoma antigen 2.6 
Mitochondrial 10.2 
Others 11.6 
Protein metabolism 8.1 
Ribosomal 23.1 
Signal transduction 7.3 
Splicing factors 2.3 
Synapse formation 1.7 
 
 




Table 3.2 List of genes identified from the subtractive library that have been 
reported to be involved in different aspects of neuronal differentiation. 
 
Genes involved in 
neuritogenesis or neuronal 
migration 
Accession no.   Remarks 
ADP-ribosyltransferase 
(NAD+, poly (ADP-ribose) 
polymerase) 1  
BC012041 Overexpression of PARP disrupts organization 
of cytoskeletal F-actin and Tissue polarity in 
Drosophila (Uchida et al., 2002) 
Bone morphogenetic 
protein-4   
S65032 Addition of BMP4 robustly increased the 
neuritogenic effect of NGF (Althini et al., 2003) 
Casein kinase II beta 
subunit 
NM_031021 An increase in casein kinase 2β activity 
accompanying neurite outgrowth (Diaz-Nido et 
al., 1992) 
Laminin receptor 1  BC003829 Laminin receptor binds laminin, which is 
known to induce process outgrowth (Choi et al., 
1994) 
NCK-associated protein 1 BC003962 Drosphila homolog of NAP1 controls axonal 
pathfinding and cytoskeletal organization 
(Hummel et al., 2000) 
Nucleoside diphosphate 
kinase B 
NM_008705 Over-expression of NDK leads to neurite 
extensions in PC12 cells (Ishijima et al., 1999) 
Superoxide dismutase 1 BC002066 Neuroblastoma expressing a mutant SOD1 
showed a defect in neurite outgrowth and 
decreased viability upon differentiation (Lee et 
al., 2002) 
Prion protein NM_011170 Cellular prion protein binds laminin and 
promotes neuritogenesis (Graner et al., 2000) 
Agrin BC028992 Agrin potentiates the ability of FGF-2 to 
stimulate neurite outgrowth (Kim et al., 2003) 
Tyrosine 3-monooxygenase 
activation protein, epsilon 
polypeptide  
 
NM_009536 14-3-3epsilon binds to NUDEL and this 
interaction is required for neuronal migration 




Genes involved in 
neurotransmitter 
synthesis/release 
Accession no Remarks 
Chromogranin B 
 
NM_007694 Chromogranin B (CgB) is a major member of 
the chromogranin/secretogranin family of 
catecholamine storage vesicle secretory 




NM_013680 Synapsin I is a novel Rab3 interactor on 
synaptic vesicles and it is suggested that the 
synapsin-Rab3 interaction may participate in 
the regulation of synaptic vesicle trafficking 
within nerve terminals (Giovedi et al., 2004) 













There is increased expression of calcyclin in 
retinoic acid treated neuroblastoma cells, and 
seems to play a role in inhibiting cell 




NM_031165 Developmental expression of Hsc70 in human 
brain correlates with the time course of overall 
neuronal maturation, suggesting an increasing 
role of Hsc70 during neuronal differentiation 
(Kato et al., 1995). Hsc70 binds to the 
unphosphorylated form of retinoblastoma 
protein, pRb, suggesting that it may function as 
a molecular stabilizer of unphosphorylated pRb 




NM_008143 RACK1 over-expression induces a partial G(1) 


































3.4.1) Choice of Cell Line 
MN9D cells serve as a good system for this type of study since it is a fusion 
between embryonic primary cells from mouse ventral midbrain with cells from the mouse 
neuroblastoma cell line N18TG2, which are dopaminergic in nature (Choi et al., 1999). 
Several properties of these cells suggest that they are similar to embryonic DA cells. 
These include the formation of cell aggregates when cultured in non-adherent conditions, 
which suggest that the cell line inherited embryonic properties from the primary 
dopaminergic neurons (Choi et al., 1999). In addition, these cells express RALDH1, a 
highly specific marker for immature embryonic DA precursor cells (Wallen et al., 1999). 
MN9D cells has also been used in a number of other studies for neuronal differentiation 
(Oh et al., 1996; Heller et al., 1996; Castro et al., 2001; Choi et al., 2001).  
3.4.2) Increased Translational Activity During Neuronal Differentiation 
It is observed that about 23% of the clones identified from the subtractive library 
comprises of proteins that are involved in protein synthesis, namely the ribosomal 
proteins. It is highly plausible that there is increased translational activity upon neural 
differentiation. Indeed, previous 2D-gel studies (Ray et al., 1996) and subtractive library 
analysis on RA-treated ES cell neural differentiation (Bain et al., 2000) have shown an 
overall increase in protein synthesis at the protein and transcript level respectively. Our 
results further reinforce the notion that neuronal differentiation is accompanied by a 
corresponding increase in translational activities. 




3.4.3) Casin kinase 2β, SOD1, Prion protein, PARP and Neuritogenesis  
Casein kinase 2β plays an important role in neuritogenesis by phosphorylating the 
microtubule-associated proteins, leading to microtubule assembly (Diaz-Nido et al.,  
1988). It has previously been reported that there is an increase in casein kinase 2β activity 
accompanying neurite outgrowth. The role of casein kinase 2β during neuronal 
differentiation is further augmented by the work of Ulloa et al. which demonstrated that 
depletion of casein kinase II by antisense oligonucleotide prevents neuritogenesis in 
neuroblastoma cells (Ulloa et al., 1993). The identification of casein kinase 2β as one of 
the up-regulated genes during and the corresponding increase in protein level (Figure 
3.5A) during MN9D differentiation is consistent with its role in neuritogenesis. 
 SOD1 is a ubiquitous protein that functions to scavenge free radicals and thereby 
protecting cells from oxidative stress. It is well established that mutations in SOD1 gene 
leads to amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative 
disease that attacks motor neurons in the brain (upper motor neurons) and 
spinal cord (lower motor neurons). No known function has been attributed to SOD1 
with regards to neuronal differentiation until recently when it was shown that 
neuroblastoma expressing a mutant SOD1 showed a defect in neurite outgrowth and 
decreased viability upon differentiation (Lee et al., 2002). This indicates that SOD1 may 
have a new role in promoting neurite outgrowth and neuronal survival, which account for 
the gradual increase in SOD1 protein level from 2nd to 3rd split after induction. 
Prion protein is known to be ubiquitously expressed in the central nervous system 
but its physiological role has yet to be fully understood. However, it has been shown that 
the transcript level of prion protein increased upon neuronal differentiation in human 




NTERA2 tetracarcinoma-derived stem cells (Ackerman et al., 1994) and rat PC12 cells 
(Lazarini et al., 1994). Future studies revealed that the increase in transcript level is 
correlated with an increase in the protein level during neuronal differentiation (Kuwahara  
et al., 2000). More recently, Prion protein was shown to play a role in neurite outgrowth 
and neuronal survival (Chen et al., 2003). In fact, there are three different isoforms of 
prion protein expressed in the nervous system. In our case, we detected 3 different bands 
in the Western blot as well. The relative importance of each of these isoforms during 
neuronal differentiation remains to be elucidated. Although there is no significant change 
in the level of Prion protein after differentiation, it may be possible that there is a 
translocation of Prion protein to the plasma membrane to exert its effect on 
differentiation. It is worthwhile to note that prion transcript level may not be correspond 
to the protein level. In fact, it has been reported that neurons that were immunonegative 
for Prion protein expressed high levels of message for prion protein (Ford et al., 2002). 
PARP1 is known to play important roles in nuclear events such as cell cycle, cell 
proliferation, and maintenance of chromosomal stability. However, a recent study 
showed that co-expression of PARP indirectly suppressed the effect of RhoA GTPase in 
Drosophila (Uchida et al., 2002). In this study, over-expression of PARP was found to 
disrupt the organization of cytoskeletal F-actin in embryos and tissue polarity in adult 
flies. Since such phenotypes resembled those flies with mutation in tissue polarity gene, 
genetic interaction of PARP with known tissue polarity genes was examined, one of 
which was RhoA. It was found that co-expression of PARP actually suppressed the effect 
of RhoA GTPase. The identification of PARP1 from our library and its increase in 




protein level suggests that it may play a role in inhibiting the activity of Rho and 
promoting neuritogenesis.  
3.4.4) Hsc70 and Cell Cycle Arrest in Neuronal Cells 
Of the many heat-shock proteins, only hsc70 is highly up-regulated upon 
differentiation. At the protein level, the expression peaked at around the 3rd split post- 
induction. In a review paper by (Calabrese et al., 2002), it is reported that Hsc70 is more 
highly expressed in neuronal cells that are stained for βIII tubulin, as compared to Hsp70 
which is expressed mainly on GFAP-immunoreactive cells, suggesting a specific role of 
HSC70 in neurons. Moreover, the time course of developmental expression of Hsc70 in 
human brain correlates with the time course of overall neuronal maturation, suggesting an 
increasing role of Hsc70 during neuronal differentiation (Kato et al., 1995). Hsc70 may 
be involved in terminal cell cycle arrest during neuronal differentiation, as evident by its 
binding to the unphosphorylated form of retinoblastoma protein, pRb, suggesting that it 
may function as a molecular stabilizer of unphosphorylated pRb (Inoue et al., 1995). 
3.4.5) Syndecan I and Shaping of Morphogen Gradient 
Syndecan I belongs to a family of heparan sulfate proteoglycans (HSPGs) that are 
localized to cell surfaces or within the extracellular matrix of tissues where they bind 
fibroblast growth factors (FGFs) and many other HS binding growth factors (Bernfield et 
al., 1999; Ornitz, 2000). There is increasing evidence to suggest that HSPGs play an 
important role in shaping extracellular morphogen gradients in tissues (Christian, 2002; 
Strigini and Cohen, 2000; Giraldez et al., 2002). Genetic studies have provided strong 
evidence that HSPGs are essential for normal development (Lander and Selleck, 2000). 
Differential expressions of Syndecans 1 – 4 have been found in mouse embryos and 




syndecan-1 is the most abundantly expressed and localizes exclusively to neuroepithelial 
cells in the ventricular zone (Ford-Perriss et al., 2003). This is in close agreement with 
our results because MN9D cell line is obtained from the ventral mesencephalon, which 
originates from the neuroepithelial cells in the ventricular zone. Recently, Wnt signaling 
has been found to play a role in the differentiation of dopaminergic neurons (Castelo- 
Branco et al., 2003). It may be possible that Syndecan 1 actually regulate such Wnt 
signaling pathways to effect neuronal differentiation. 
3.5) Conclusion 
  A great amount of information on the transcriptional control of dopaminergic 
neuron differentiation has been acquired during recent years. However, our understanding 
of general patterning and morphogenetic events leading to the generation of 
dopaminergic neuron is still limited. Using suppressive subtractive hybridization as a first 
step, we have identified an array of genes up-regulated during MN9D cell differentiation. 
Although the genes that we have studied in-depth here are not known to act in a common 
pathway, the fact that each of them has been reported to play a role during neuritogenesis, 
or even in neuron cell cycle arrest and shaping of morphogen gradient, strongly suggest 
the validity of using the library to further identify novel genes that may be involved in 
dopaminergic neuron differentiation. 
 As we are interested in identifying novel transcription factor(s) that may play a 
role during dopaminergic neuron differentiation, we went on to further study neuronal 
PAS domain protein 1 (NPAS1), which was identified from the subtractive library screen, 
in greater detail.  
 









 Transcription factors play an important role in different developmental processes, 
and their spatial and temporal expression often coincide with their functions. One family 
of transcription factors, the bHLH-PAS proteins have generated much interest in recent 
years due to their involvement in different physiological functions. Previously, we have 
identified one bHLH-PAS protein, NPAS1 as a gene up-regulated upon differentiation of 
a dopaminergic MN9D cell line. In this study, we went on to further characterize the 
expression of NPAS1 during the course of MN9D differentiation. As we are interested in 
its physiological role during development, we also set out to determine the expression 
pattern of NPAS1 during embryonic development in the mouse. In this study, NPAS1 
was found to be expressed widely during prenatal stages but its expression is restricted to 
the central nervous system, spinal cord and liver in the adult stage. In the ventral 
midbrain, NPAS1 expression starts at E11.5 and increases throughout development. From 
these results, we postulate that NPAS1 may play an important role during development of 
the ventral midbrain. 
 






 The birth, differentiation and maturation of dopaminergic neurons is a long 
process which is intricately controlled by numerous transcription factors regulating 
different aspects of neuronal differentiation and maturation (Burbach et al., 2003; Wallen 
and Perlmann, 2003; Simon et al., 2003). The time of expression of such transcription 
factors often coincide with their role during the different stages of dopaminergic neuronal 
development. Some of the transcription factors important for dopaminergic neuron 
development include Nurr1 (Zetterstrom et al., 1996), Lmx1b (Smidt et al., 2000), Pitx3 
(Smidt et al., 1997; Smidt et al., 2000; Smidt et al., 2004), Engrailed 1 and 2 (see review 
by Simon et al., 2004) and Ebf3 (Thuret et al., 2004). 
 One of the most well studied transcription factor Nurr1, which is expressed from 
E10.5 onwards in mouse ventral midbrain coincides very well with the time when TH is 
expressed (Zetterstrom et al., 1996; Zetterstrom et al., 1997). Further studies found that 
Nurr1 is required for specifying the neurotransmitter phenotype of dopaminergic neuron 
(Castello et al., 1998; Saucedo-Cardenas et al., 1998; Zetterstrom et al., 1997). On the 
other hand, Lmx1b which is expressed from E7.5 onwards is required for survival of 
these dopaminergic neurons during development but has no effect on the neurotransmitter 
phenotype (Smidt et al., 2000). Another transcription factor, Ebf3, which is expressed 
around E11 in mouse ventral midbrain, has been postulated to play a role in axonal 
growth of dopaminergic neuron since its expression coincide with the period of axonal 
outgrowth of these neurons (Thuret et al., 2004). From these data, it is observed that the 
onset of expression of these transcription factors coincides very well to their roles in 
various aspect of dopaminergic neuronal differentiation.  




 In addition to the above, some members of the bHLH-PAS protein family are also 
known to play important role during development of the central nervous system. They 
include neuronal PAS domain protein 2, NPAS2 which is known to play a crucial role in 
regulation of the circadian rhythm in the mammalian system (Reick et al., 2001; Dudley 
et al., 2003), SIM2 which has been implicated in Down’s syndrome (Muenke et al., 1995; 
Chrast et al., 2000; Rachidi et al., 2005) and NXF which is a competitor for SIM2 (Ooe et 
al., 2004). 
 As we are interested in the role of NPAS1 (also a bHLH-PAS protein) during 
dopaminergic neuron differentiation, we decided to determine the expression of NPAS1 
during MN9D differentiation as well as its expression in the ventral midbrain during 
mouse embryonic development. In this study, we employed real-time PCR to trace the 
expression of NPAS1 during MN9D cell differentiation. NPAS1 is found to be up-
regulated upon treatment of MN9D cells with 1 mM n-butyrate, and Western blot results 
also showed a similar increase. Western blot for NPAS1 showed that the protein is 
expressed in all regions of the mouse embryo tested, which include the forebrain, 
midbrain, hindbrain, spinal cord, tail, limb and liver. However, in the adult stage, NPAS1 
expression is limited to the central nervous system and liver. Upon further analysis, 
NPAS1 transcript level is found to be expressed in the ventral midbrain as early as E12.5 
and the expression increases up till E18.5. On the other hand, NPAS1 shows a single 
peak at E15.5 in the dorsal midbrain and could not be detected at other stages; Western 
blot analysis yielded similar results. From its expression pattern in the ventral midbrain, 
we postulate that NPAS1 may play a role during dopaminergic neuron differentiation in 
the embryonic ventral midbrain. 





4.2) Materials and Methods 
 
4.2.1) Isolation of RNA from Different Stages of Differentiated MN9D Cells  
 
MN9D cells were differentiated as described in Section 3.2. The total RNA was 
extracted using kit from QIAGEN (USA). 
4.2.2) Dissection of Mouse Embryos 
 Pregnant Swiss Albino mice obtained from the Animal Holding Unit, NUS, were 
sacrificed by cervical dislocation and the embryos dissected out in ice-cold PBS. The 
midbrains of the embryos were then dissected out under the microscope and subsequently 
separated into the dorsal and ventral halves (Figure 4.1). The dissected tissues were 
collected in RLT buffer and stored at -80°C until ready for RNA isolation. 
4.2.3) Construction of cDNAs for Real-time PCR 
 
 To remove any contamination of genomic DNA, 1 μl of DNase (1 unit/μl) was 
added to 1 μg of RNA and topped up with deionized water to a final volume of 10.5 μl. 
The mixture was then incubated at 37ºC for 40 min. Next, 1 μl of 0.02M EDTA was 
added followed by an incubation at 65ºC for 10 min. Random priming was carried out by 
adding 0.5 μl of random primers and incubating at 65ºC for 10 min and then placed on 
ice. For reverse transcription, the random-primed RNA was split into 2 tubes – RT+ and 
RT- (6 μl each) and 6 μl of deionized water, 4 μl of 5 X first strand buffer, 2 μl of 0.1M 
DTT and 1 μl dNTPs were added into each tube. The tubes were then incubated at 25ºC 
for 10 min followed by 42ºC for 2 min after which 1 μl of reverse transcriptase was 
added to the RT+ tube. The tubes were then incubated at 42ºC for 50 min, 70ºC for 10 
min and stored at -20ºC. The cDNA was diluted 6 times before use for real-time PCR. 




4.2.4) Real-time PCR 
 
 The SYBR® Green PCR Master Mix (Applied Biosystems, USA) was used. 
Standards used were undiluted cDNAs synthesized from total RNA of untreated MN9D 
cells. The PCR started with 50°C for 2 min, 95°C for 10 min and then continued with 40 
cycles of 15 s at 95°C and 1 min at 60°C on the ABI Prism detection system (Applied 
Biosystems, USA). A melting curve was obtained for each PCR product after each run to 
confirm that the signal corresponded to a unique amplicon of the predicted size. The 
specificity of the PCR product was verified by sequencing. Expression levels were 
obtained by subtracting the value for each sample in the absence of reverse transcriptase 
from the corresponding value in the presence of reverse transcriptase and then 
normalizing to the housekeeping gene encoding HPRT, obtained for every sample in 
parallel assays in two to four independent experiments. The primers used for NPAS1 gene 
were 5’- ACCTAGGTGGACACATCCTACAGT-3’ and 5’- 











                                               
 
Figure 4.1 Schematic diagram to show DM and VM dissected out from mouse 
embryo. The central nervous system of an E14.5 mouse embryo is outlined as shown. 
The midbrain is dissected out by two cuts made at positions indicated by the two straight 
solid lines. The dissected midbrain is then cut along the dotted line to obtain the dorsal 




4.2.5) Extraction of Nuclear and Cytosolic Protein Fractions 
 
Nuclear and cytosolic protein fractions from MN9D cell line was extracted using 
NE-PER® Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology, USA) 




4.3.1) Characterization of mNPAS1 Antiserum 
  
 Since there is no commercial NPAS1 antibody available, we decided to generate 
our own mNPAS1 antibody. A hydrophilic region within the C-terminus of NPAS1 
(Figure 4.2A) was chosen for peptide synthesis and subsequently this peptide was used to 
generate NPAS1 antibody. The specificity of the antibody was tested by a Western blot 
analysis of HEK293 cells expressing FLAG-tagged mouse NPAS1. A single band of 
about 62kDa, the expected size of the recombinant NPAS1 protein was observed (Figure 
4.2B). On the other hand, no band was observed in cell lysate of HEK293 cells 




expressing FLAG-tagged ARNT, confirming the specificity of the antibody for NPAS1 
epitope. 
 Since we have shown that the NPAS1 antibody recognizes NPAS1 in Western 
blot, we went on to determine if the antibody is able to recognize native NPAS1. For this 
purpose, immunocytochemistry was carried out in HEK293 cells over-expressing FLAG-
tagged NPAS1. As shown in Figure 4.2C, there is a positive signal in the cytoplasm but 
not in the nucleus, indicating that FLAG-tagged NPAS1 is excluded from the nucleus. On 
the other hand, there is no staining observed in cells over-expressing FLAG-tagged 
ARNT, indicating that the antibody is specific to NPAS1 protein. As a positive control, 
the cells were also stained with FLAG antibody to ensure that the FLAG_NPAS1 and 
FLAG_ARNT fusion proteins were properly expressed. As shown in the second panel, 
when stained with FLAG antibody, a positive signal was observed in the cytoplasm but 
not in the nucleus (consistent with the staining pattern with NPAS1 antibody) in cells 
over-expressing FLAG_NPAS1. In the case of cells over-expressing FLAG_ARNT, a 
positive signal was observed in the nucleus, indicating that FLAG_ARNT is localized to 
the nucleus. From these results, it is confirmed that the NPAS1 anti-serum can recognize 
native NPAS1. 
4.3.2) NPAS1 Transcript and Protein Level Increased During Early MN9D  
          Differentiation 
 
 In order to determine the relevance of NPAS1 during various stages of 
dopaminergic neuronal differentiation, real-time PCR was carried out to trace the 
expression profile of NPAS1 during the early stages of MN9D differentiation. As shown 
in Figure 4.3A, the transcript level of NPAS1 increased to at least two folds as early as 1 
hour post induction. The transcript level continued to increase steadily up till 1 day post 




treatment, when it reached 15 fold. This large increase in NPAS1 transcript level 
indicates that it may be playing a crucial role during dopaminergic neuronal 
differentiation. 
To determine if the increase in transcript level of NPAS1 is correlated to an 
increase in the protein level, Western blot was carried out for NPAS1 during different 
stages of MN9D differentiation. As shown in Figure 4.3B, the level of NPAS1 protein 
increases up till 25h post treatment with 1 mM n-butyric acid, which is consistent with its 
increase at the transcript level. 
4.3.3) NPAS1 Protein Level does not Change At Later Stages of MN9D  
          Differentiation 
 
 We went on to determine the expression of NPAS1 over the whole course of 
MN9D differentiation. Western blot for NPAS1 was carried out on protein lysates 
isolated from MN9D cells after 0, 3, 6, 9 and 12 days of treatment with 1 mM n-butyric 
acid. As shown in Figure 4.4, there is no change in NPAS1 protein level throughout the 
12 days. On the other hand, ARNT protein level increased steadily throughout the whole 
course of MN9D differentiation. Although there is no change in NPAS1 protein level 
from day 0 to day 3, we previously found that there is an increase on NPAS1 protein 
level from day 0 to day 1 after n-butyrate treatment (see Figure 4.3B). We therefore 
postulate that there is a dynamic change in NPAS1 protein level over the course of 
MN9D differentiation. It is possible that the turnover rate of NPAS1 at later stages of 
MN9D differentiation is higher, which account for no change in its protein level from 1 
day after induction. 
 
 




4.3.4) NPAS1 is widely Expressed in the Mouse Embryo 
 As we are interested in the role of NPAS1 during development, we decided to 
determine the expression profile of NPAS1 in the mouse embryo. With the NPAS1 
antibody in hand, Western blot was carried out with protein lysates from different regions 
of E12.5, E14.5, E16.5 and E18.5 embryos. As shown in Figure 4.5, during embryonic 
development NPAS1 was found to be expressed in all the tissues tested, which include 
the forebrain, midbrain, hindbrain, spinal cord, tail, liver and limb. However, in the adult 
stage, NPAS1 expression is restricted to the central nervous system, spinal cord and liver. 
This expression profile of NPAS1 suggests that it may be playing a wider role during 
embryonic development in many organs. 
4.3.5) Expression of NPAS1 Transcript and Protein in the DM and VM 
 
 Since MN9D cell line is a fusion between a dopaminergic precursor cell and a 
neuroblastoma, it may be possible that the increase of NPAS1 is due to an effect of n-
butyric acid on the neuroblastoma and not the neuronal precursor cell. In order to rule out 
this possibility and to determine if NPAS1 plays a physiological role during the 
development of dopaminergic neuron in the ventral midbrain, real-time PCR was carried 
out using cDNAs from both the dorsal and ventral midbrain respectively, of mouse 
embryos at different developmental stages (Figure 4.6A). NPAS1 transcript level showed 
a single peak at E15.5 in the dorsal midbrain. In contrast, in the ventral midbrain, NPAS1 
expression began as early as E11.5 and increased steadily thereafter, up till E18.5. 
 Western blot for NPAS1 was also carried out with protein lysates from the DM 
and VM at different prenatal stages (E12.5, 14.5, 16.5 and 18.5). As shown in Figure 
4.6B, NPAS1 was detected in the DM only at E18.5. On the other hand, NPAS1 was 




detected in the VM as early as E14.5. Such expression pattern suggests that NPAS1 may 
play an important role during development of the ventral midbrain.
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Figure 4.2 The NPAS1 antibody recognizes both denatured and native NPAS1.  
(A) Hydrophilic region of NPAS1 used as epitope for peptide synthesis and subsequent 
antibody production. (B) Protein lysates from HEK293 cells transfected with plasmids 
over-expressing either FLAG_ARNT (lane 1) or FLAG_NPAS1 (lane 2) were used for 
Western blot with the anti-NPAS1 antibody. A single band of about 60 kDa was observed 
in protein lysate over-expressing FLAG_NPAS1 but not in lysate over-expressing 
FLAG_ARNT. (C) HEK293 cells were transfected with plasmids expressing either 
FLAG-tagged NPAS1 or FLAG-tagged ARNT. The cells were then stained with either 
FLAG or NPAS1 primary antibodies and detected with rhodamine-conjugated secondary 
antibody. As a negative control, no primary antibody was used. Positive staining in 
cytoplasm of cells over-expressing FLAG_NPAS1 was observed with either NPAS1 or 
FLAG antibodies. In cells over-expressing FLAG_ARNT, no staining was observed with 
NPAS1 antibody but the nuclei were stained positive with FLAG antibody. All cells were 
stained with Hoechst for nuclei. 
 
100µm 































                    
 
Figure 4.3 Changes in NPAS1 transcript and protein level during early stages of 
MN9D differentiation. (A) Real-time PCR for NPAS1 was carried out on cDNAs from 
untreated MN9D cells and cells treated with n-butyric acid after 1, 3, 7, 12 and 25 hours. 
There was an increase in NPAS1 transcript over the first 25 hours of MN9D 
differentiation. HPRT was used for normalization. The mean value and SEM are 
calculated from three separate experiments carried out in triplicates. (B) Western blot was 
carried out with protein lysates collected from untreated MN9D cells and cells treated 
with n-butyric acid after 1, 3, 7, 12 and 25 hours. There was an increase in NPAS1 level 




























Figure 4.4 Changes in NPAS1 and ARNT protein levels over the course of MN9D 
differentiation. Protein lysates were collected from MN9D cells treated with 1mM n-
butyrate after 0, 3, 6, 9 and 12 days. Western blot was carried out to detect NPAS1 and 
ARNT respectively. NPAS1 did not show any change from 0 to 12 days. There was a 
gradual increase of ARNT over the 12 days of MN9D differentiation. β-actin was used as 











































































             
 
Figure 4.5 NPAS1 is expressed in many regions of the mouse embryo but has 
restricted expression in the adult stage. Proteins were isolated from different regions - 
forebrain, midbrain, hindbrain, spinal cord, tail, limb and liver- at different embryonic 
(E12.5, E14.5, E16.5 and E18.5) as well as adult stage. Western blot was then carried out 
with the anti-NPAS1 antibody. NPAS1 was found to be expressed in the all the regions 
tested at all developmental stages. β-actin was used as a loading control. 






































Figure 4.6 Expression of NPAS1 transcript and protein in the DM and VM at 
different embryonic stages. (A) Real-time PCR was carried out for NPAS1 with cDNAs 
isolated from the DM and VM at different embryonic stages (E9.5, 10.5, 11.5, 12.5, 15.5 
and 18.5). In the VM, NPAS1 was first detected at E11.5 and increased steadily 
throughout. NPAS1 transcript level showed a single peak at E15.5. HPRT was used for 
normalization. The results are from one representative experiment (n = 3) and presented 
as mean and SEM (n = 3). (B) Western blot was carried out for NPAS1 with protein 
lysates isolated from the DM and VM at different embryonic stages (E12.5, 14.5, 16.5 
and 18.5). NPAS1 was observed only at E18.5 in the DM. There was a steady increase in 











4.4.1) Dynamic Changes in NPAS1 Expression 
 
 It has been reported previously that NPAS1 is only expressed in the brain and 
spinal cord in the adult mouse tissues using Northern blot analysis (Zhou et al., 1997). As 
a result, subsequent studies on NPAS1 have been focused on the central nervous system. 
Using antibody generated against NPAS1, other groups have found that the protein is 
expressed in inter-neurons in the forebrain (Erbel-Sieler et al., 2004) in the adult and in 
cortical neurons in E16.5 embryos (Ohsawa et al., 2005). Thus far, there is no study done 
on the expression of NPAS1 in different regions of the mouse embryo. As we are 
interested in the role of NPAS1 during embryonic development, we did a profile of the 
expression of NPAS1 in different tissues of different mouse embryonic stages. As shown 
in Figure 4.7, NPAS1 is detected in all the tissues tested at all the stages, indicating that 
NPAS1 is expressed widely during prenatal stages. Contrary to the claims by Zhou et al, 
we found that NPAS1 is also expressed in the adult liver. This discrepancy may arise due 
to NPAS1 transcript being less stable compared to the protein and therefore could not be 
detected by Northern blot but detectable in Western blot. From these expression patterns, 
we postulate that NPAS1 may play a broader role during prenatal development and have 
more specific role in the brain during post-natal development. 
4.4.2) NPAS1 Begins Expression during Middle Embryonic Stage 
 
 It is worthwhile to note that NPAS1 was reported to start expression only at E18.5 
in the mouse (Zhou et al., 1997). However, using Western blot, we showed that NPAS1 is 
expressed in embryo as early as E12.5. This discrepancy may be due to the fact that 
above-mentioned fact that NPAS1 transcript is highly unstable; moreover, the samples 




that we used is from a small region of the embryo compared to whole embryo which was 
used in the paper (Zhou et al., 1997), thereby enhancing the amount of NPAS1 in the 
protein lysate. Previously, because of the late expression of NPAS1 transcript, it has been 
suggested that NPAS1 may play a regulatory role in the development of the brain. 
However, with the detection of NPAS1 in earlier stages of development, we postulate 
that NPAS1 may also play a role in the earlier process of neuronal development, such as 
differentiation, than actually proposed.  
4.4.3) NPAS1 May Play a Role during Ventral Midbrain Development 
 Although NPAS1 was identified as a gene up-regulated during dopaminergic 
MN9D differentiation, it is important to establish its physiological role. Since MN9D is a 
cell line derived from fusion between a primary cell from the mouse mesencephalon and 
a neuroblastoma, a first step will be to determine if it is expressed in the midbrain. As 
shown in Figure 4.6, there is an increasing expression of NPAS1 from E12.5 to E18.5 in 
the ventral midbrain, a period during which dopaminergic neurons are born, differentiate 
and mature. Therefore, the identification of NPAS1 from differentiating MN9D cells 
reflects its role during dopaminergic neuron development in the ventral midbrain; albeit 
NPAS1 may also be playing an important role in other regions of the developing embryo 
as evident from its widespread expression. 
 To study the function of any protein, it is important to have some background 
information of the domains present in the protein. However, relatively little has been 
done to characterize NPAS1. Therefore, we set out to first characterize the different 
functional domains of NPAS1 in the next chapter before going further to study the role of 
NPAS1 during dopaminergic neuron differentiation. 










Neuronal PAS domain protein 1 (NPAS1), a basic helix-loop-helix (bHLH)-PAS 
transcription factor expressed in the central nervous system has been suggested to be 
involved in neuronal differentiation. Many members of the bHLH-PAS family form 
heterodimer with ARNT to regulate transcription either in a positive or negative manner. 
As we are interested in the molecular mechanism underlying the role of NPAS1 during 
central nervous system development, we set out to characterize the functional domains 
within NPAS1. In this study, we showed that a nuclear export signal within the N-
terminus of NPAS1 excludes it from the nucleus, and nuclear localization of NPAS1 is 
dependent on the presence of ARNT. Furthermore, we showed that NPAS1 and ARNT 
interact via their N-terminus. With the methods used here, we did not identify any 
transactivation domain within NPAS1; instead we mapped out at least two repression 
domains within NPAS1, suggesting that NPAS1 acts as a repressor. We further showed 
that NPAS1 has differential trans-repression effect on ARNT and ARNT2 in different 










 Each member of the bHLH-PAS protein family consists of an N-terminal basic 
region that binds DNA, the HLH and PAS domains for dimerization and specificity of 
interacting partner and a highly divergent C-terminal region (Reisz-Porszasz, 1994; Jiang 
et al, 1996). Many of these proteins form heterodimer with another bHLH-PAS domain 
protein, the AhR nuclear translocator (ARNT) (Hoffman et al, 1991), which is 
ubiquitously expressed. The basic region of each subunit then contacts a half-site of the 
asymmetric E-box (Mason et al, 1994; Fukunaga and Hankinson, 1996) to regulate 
transcription (Salceda et al, 1996; Swanson, 2002). Besides ARNT, another protein 
ARNT2, which is highly similar to ARNT, is shown to be able to interact with the 
partners of ARNT (Ema et al, 1996). However, Arnt2 expression is more restricted to the 
brain and kidneys which differs from that of Arnt, suggesting that ARNT2 may play 
different roles from ARNT (Hirose et al, 1996). 
 ARNT contains a transactivation domain in its C-terminal domain that is able to 
recruit co-activators to activate transcription (Whitelaw et al, 1994; Kobayashi et al, 
1997). However, depending on the interacting partner, certain heterodimers of ARNT 
may actually function as transcriptional repressors. Under hypoxic condition, HIF-1α and 
HLF are two transcription factors that are activated (Ema et al, 1997). They form 
heterodimers with ARNT and binds to HRE (hypoxia response element) to up-regulate 
genes, such as those for erythropoietin (EPO), vascular endothelial growth factor (VEGF) 
(Forsythe et al, 1996) and glycolytic enzymes. When exposed to carcinogenic and toxic 
environmental chemicals, AhR interacts with ARNT and bind to regulatory DNA 
sequence XRE (xenobiotic response element) to activate genes to neutralize the 




deleterious effect (Denison et al, 1988; Pohjanvirta and Tuomisto, 1994). In these cases, 
the heterodimers function as positive regulators of transcription. On the other hand, 
mSIM 1 and SIM 2 regulate transcription in a negative manner (Ema et al, 1996). 
Another bHLH-PAS domain protein, inhibitory PAS domain protein, has also been 
reported to demonstrate dominant negative regulation of HIF-mediated control of gene 
expression during hypoxia (Makino et al, 2001). 
 Being transcription factors, the bHLH-PAS domain proteins need to be localized 
to the nucleus in order to carry out their role as transcriptional regulators. To date, many 
different mechanisms for nuclear localization of the different bHLH-PAS domain 
proteins have been reported. For example, both mammalian ARNT and SIM2 are 
constitutively localized to the nucleus.  A bipartite nuclear localization signal within 
ARNT is found to be responsible for this nuclear localization (Eguchi et al, 1997). On the 
other hand, both NLS and NES (Ikuta et al, 1998) were identified in AhR. In this case, 
AhR is able to shuttle between the cytoplasm and nucleus but requires the binding of its 
ligand, TCDD in order to be retained in the nucleus (Burbach et al, 1992; Kallio et al, 
1998). In addition, Drosophila Trachealess (Trh) and SIM2 require the presence of 
Tango, the ARNT homolog to be localized in the nucleus (Ward et al, 1998). 
  Neuronal PAS domain protein 1 (NPAS1/MOP5) is a bHLH-PAS domain protein 
that is found to be expressed only in certain regions of the brain (Zhou et al, 1997). 
NPAS1 mRNA expression is first detected at embryonic day 15 of mouse development, 
shortly after organogenesis of the brain. NPAS1 is found to be highly homologous to 
NPAS3, whose expression is also exclusively in the brain (Brunskill et al, 1999). Recent 
studies reveal that laboratory mice lacking NPAS1 and NPAS3 exhibit a spectrum of 




behavioral and neurochemical abnormalities. NPAS1 and NPAS3 are found to be 
expressed in inhibitory interneurons and the viability and anatomical distribution of such 
neurons are unaffected in the absence of either transcription factor, suggesting a 
functional redundancy of NPAS1 and NPAS3. In addition, adult brain tissues from 
NPAS3- and NPAS1/NPAS3-deficient mice showed a distinct reduction in reelin (Erbel-
Sieler, 2004). These results suggest that NPAS1 may play a role during neuronal 
differentiation. 
 Although NPAS1 knockout mice showed behavioural abnormalities that may be 
related to schizophrenia, relatively little is known about the mechanism of action by 
NPAS1, except that it forms a heterodimer with ARNT and negatively regulates the 
expression of erythropoietin (EPO), a factor that promotes production of neuronal 
progenitors in the CNS (Studer et al, 2000; Shingo et al, 2001). In order to better 
understand the role of NPAS1, we set out to characterize the different domains of 
NPAS1. In this study, we report that NPAS1 requires the presence of either ARNT or 
ARNT2 for translocation into the nucleus, and a NES within the N-terminus prevents 
nuclear localization in the absence of ARNT or ARNT2. Similar to other bHLH-PAS 
domain proteins, NPAS1 interacts with the N-terminus of ARNT via its N-terminal 
domain. Using the methods employed in this paper, we were unable to identify any 
transactivation domain in NPAS1. Instead, we identified at least two non-overlapping 
repression domains in NPAS1. We also found that NPAS1 is able to suppress the 
transactivation function of ARNT and ARNT2, further supporting previous findings that 
NPAS1 play a negative transcriptional regulatory role. 




5.2) Materials and Methods 
5.2.1) Construction of Plasmids 
Expression plasmid encoding a GFP epitope-tagged version of the mouse NPAS1 
protein (pcDNA3.1(-)_fl NPAS1_GFP) was constructed as follows. The 
pGEMTEasy_mNPAS1 described above was used as a template with the following set of 
primers 5’-TCTAGAACCATGGCGACCCCCTATCCC-3’ and 5’-
CTCGAGGTCTCCCTTCCGCTGCA-3’. The amplified DNA product was TA cloned 
into pGEMTEasy vector, digested with the restriction enzymes XbaI and XhoI and ligated 
into the pcDNA3.1(-)_GFP vector. The encoded mNPAS1 has the GFP-epitope linked to 
the C-terminus. To generate the N-terminus (aa 1-354) and C-terminus (aa 348-594) 
deletion mutants of NPAS1 [pcDNA3.1(-)_NPAS1(N)_GFP and pcDNA3.1(-
)_NPAS1(C)_GFP], cDNAs encoding the N-terminus or C-terminus region of NPAS1 




CCCGGGCTCGAGGTCTCCCTTCCGCTGCA-3’ respectively. Expression plasmids 
encoding a FLAG epitope-tagged version of full length NPAS1, NPAS1 N-terminus and 
NPAS1 C-terminus were constructed as follows. For the full length plasmid, 
pcDNA_GFP_fl NPAS1 was used as a template with the primers 5’-
GGATCCAAGCTTATGGCGACCCCCTATCCC-3’ and 5’-
GTCGACCTCGAGTCAGTCTCCCTTCCGCTGCACCCT-3’. For NPAS1(N) plasmid,  
pcDNA_GFP_fl NPAS1 was used as a template with the primers 5’-





GTCGACCTCGAGGCTTTGGCGGATCCTGGTTGC-3’. For NPAS1(C) plasmid, 
pcDNA_GFP_fl NPAS1 was used as a template with the primers 5’-
CGTCGAAAGCTTGCAACCAGGATCCGCCAA-3’ and 5’-
GTCGACCTCGAGTCAGTCTCCCTTCCGCTGCACCCT-3’. The amplified DNA 
products were digested with the restriction enzymes HindIII and XhoI and ligated into 
pXJ_FLAG vector. 
 pcDNA3.1(+) plasmids containing either full length Arnt or Arnt2 cDNAs were 
kind gifts from Dr. Jacques Michaud (Research Center, Hôpital Sainte-Justine, Canada) 
and Dr. Chen-ming Fan (Department of Embryology, Carnegie Institution of 
Washington, USA) respectively. Expression plasmid encoding a FLAG or HA epitope-
tagged version of the mouse full length ARNT, ARNT(N) or ARNT(C) were constructed 
as follows. In all three constructs, the pcDNA3.1(+) plasmid described above was used as 
template. For full length ARNT, the primers used were 5’-
TACGCAGGATCCATGGCGGCGACTACAGCT-3’ and 5’-
GGTCGACTCGAGCTATTCGGAAAAGGGGGG-3’. For ARNT(N), the primers used 
were 5’- TACGCAGGATCCATGGCGGCGACTACAGCT-3’ and 5’-
CCTGAACTCGAGTGCCGGCCGGGGGTTAGG-3’. For ARNT(C), the primers used 
were 5’-TAACCCGGATCCGCAGAGAATTTCAGGAAT-3’. The amplified DNA 
products were digested with the restriction enzymes BamHI and XhoI and ligated into 
pXJ40_FLAG or pXJ40_HA vector. Expression plasmid encoding a FLAG epitope-
tagged version of the mouse ARNT2 protein (pXJ40_FLAG_ARNT2) was constructed as 
follows. The pcDNA3.1(+) plasmid described above was used as template with the 




primers 5’-GGATCCAAGCTTATGGCAACCCCGGCCGCC-3’ and 5’-
GAATTCCCCGGGCTACTCAGAAAATGGAGG-3’. The amplified DNA product was 
digested with the restriction enzymes HindIII and SmaI and ligated into pXJ40_FLAG 
vector. To generate ARNTΔb, two rounds of PCR was carried out with the following sets 




GGTCGACTCGAGCTATTCGGAAAAGGGGGG-3’. The two PCR products were then 
used as template for a second round of PCR with the primers 5’-
TACGCAGGATCCATGGCGGCGACTACAGCT-3’ and 5’-
GGTCGACTCGAGCTATTCGGAAAAGGGGGG-3’ to generate the cDNA coding for 
ARNTΔb. The PCR product was then digested with restriction enzymes BamHI and XhoI 
and ligated into pXJ40_FALG vector. The encoded mARNT and deletion mutants, 
ARNT2 or ARNTΔb have the FLAG or HA-epitope linked to the N-terminus. 
For yeast hybrid work, expression plasmids encoding a LexA DBD epitope-
tagged version of full length NPAS1, NPAS1 N-terminus and NPAS1 C-terminus were 
constructed as follows. The pcDNA3.1(-)_fl NPAS1_GFP plasmid was used as template 
with the following sets of primers 5’-CGTCGACCATGGATGGCGACCCCCTATCCC-








GTCGACCTCGAGTCAGTCTCCCTTCCGCTGCACCCT-3’ to generate the fl NPAS1, 
NPAS1(N) or NPAS1(C) inserts respectively. The amplified DNA products were 
digested with the restriction enzymes NcoI and XhoI and ligated into pLexA vector 
(Clontech, USA). Expression plasmids encoding a LexA DBD epitope-tagged version of 
full length (pLexA_fl ARNT), N-terminus (aa 1-579) [pLexA_ARNT(N)] or C-terminus 
(aa 578-771) [pLexA_ARNT(C)] of ARNT protein were constructed as follows. The 
pcDNA3.1(+)_fl ARNT plasmid was used as a template with the following sets of 
primers 5’-TGGCTGGAATTCGCAGAGAATTTCAGGAAT-3’ and 5’-
GGTCGACTCGAGCTATTCGGAAAAGGGGGG-3’ or 5’- 
TGGCTGGAATTCGCAGAGAATTTCAGGAAT-3’ and 5’-
CCTGAACTCGAGTGCCGGCCGGGGGTTAGG-3’ or 5’-
TGGCTGGAATTCGCAGAGAATTTCAGGAAT-3’ and 5’- 
GGTCGACTCGAGCTATTCGGAAAAGGGGGG-3’ to generate the fl ARNT, 
ARNT(N) and ARNT(C) inserts respectively. The amplified DNA products were 
digested with the restriction enzymes EcoRI and XhoI and ligated into pLexA vector. 
Expression plasmid encoding a LexA DBD epitope-tagged version of ARNT(C) lacking 
the stop codon [pLexA_ARNT(C)-stop] was constructed as follows. The 
pLexA_ARNT(C) plasmid as described above was used as a template with the following 
primer 5’-TGGCTGGAATTCGCAGAGAATTCCAGGAAT -3’ and 5’-
TCGACGGATCCCTTCGGAAAAGGGGGGAAACA-3’. The amplified DNA product 
was digested with restriction enzymes EcoRI and BamHI and ligated into pLexA vector. 
Expression plasmids encoding a LexA DBD and ARNT(C) epitope-tagged version of full 
length [pLexA_ARNT(C)_fl NPAS1], N-terminus [pLexA_ARNT(C)_NPAS1(N)] or C-




terminus [pLexA_ARNT(C)_NPAS1(C)] of NPAS1 protein were constructed as follows. 
Plasmids pLexA_fl NPAS1, pLexA_NPAS1(N) and pLexA_NPAS1(C) were digested 
with restriction enzyme SalI and the inserts were purified and subcloned into 
pLexA_ARNT(C)-stop vector. Expression plasmid encoding a LexA DBD and ARNT(C) 
epitope-tagged version of ARNT (N) was generated as followed. The pLexA_ARNT(N) 
plasmid was used as a template with primers 5’-
GAATTCGGATCCGTATGGCGGCGACTACAGCT-3’ and 5’-
CCTGAACTCGAGTGCCGGCCGGGGGTTAGG-3’. The amplified DNA product was 
digested with restriction enzymes BamHI and XhoI and ligated into pLexA_ARNT(C)-
stop vector. 
For mammalian hybrid work, expression plasmids encoding a GAL4 DBD 
epitope-tagged version of full length NPAS1, NPAS1 N-terminus and NPAS1 C-
terminus were constructed as follows. The pcDNA3.1(-)_fl NPAS1_GFP plasmid was 
used as template with the following sets of primers 5’-
CGTCGACCCGGGCATGGCGACCCCCTATCCC-3’ and 5’-
GTCGACAAGCTTTCAGTCTCCCTTCCGCTG-3’ or 5’- 
CGTCGACCCGGGCATGGCGACCCCCTATCCC-3’ and 5’-
GTCGACAAGCTTGCTTTGGCGGATCCTGGT-3’ or 5’-
CGTCGACCCGGGGGCAACCAGGATCCGCCAA-3’ and 5’- 
GTCGACAAGCTTTCAGTCTCCCTTCCGCTG-3 to generate the fl ARNT, ARNT(N) 
and ARNT(C) inserts respectively. The amplified DNA products were digested with the 
restriction enzymes SmaI and HindIII and ligated into pM vector (Clontech, USA). 
Expression plasmids encoding a GAL4 DBD epitope-tagged version of full length (pM_fl 




ARNT), N-terminus [pM_ARNT(N)] or C-terminus [pM_ARNT(C)] of ARNT protein 
were constructed as follows. pLexA_fl ARNT, pLexA_ARNT(N) and pLexA_ARNT(C) 
were digested with restriction enzymes EcoRI and SalI and the inserts were subcloned 
into pM vector. Expression plasmid encoding a GAL4 DBD epitope-tagged version of 
ARNT(C) lacking the stop codon [pM_ARNT(C)-stop) was constructed as follows. 
Plasmid pLexA_ARNT(C)-stop was digested with restriction enzymes EcoRI and BamHI 
and the insert subcloned into pM vector. Expression plasmids encoding a GAL4 DBD 
and ARNT(C) epitope-tagged version of full length [pM_ARNT(C)_fl NPAS1], N-
terminus [pM_ARNT(C)_NPAS1(N)] or C-terminus [pM_ARNT(C)_NPAS1(C)] of 
NPAS1 protein were constructed as follows. pLexA_fl NPAS1, pLexA_NPAS1(N) and 
pLexA_NPAS1(C) were digested with restriction enzyme SalI and the inserts were 
purified and subcloned into pM_ARNT(C)-stop vector. Expression plasmid encoding a 
GAL4 DBD and ARNT(C) epitope-tagged version of ARNT (N) was generated as 
followed. The pLexA_ARNT(N) plasmid was digested with restriction enzymes BamHI 
and XhoI and the insert subcloned into pM_ARNT(C)-stop vector. Expression plasmids 
encoding a GAL4 DBD epitope-tagged version of full length ARNT2 protein (pM_fl 
ARNT2) was constructed as follows. The pcDNA3.1(+)_fl ARNT2 plasmid as described 
above was used as a template with primers 5’-
TCTCCCCCCGGGGATGGCAACCCCGGCCGCC-3’ and 5’-
GAATTCAAGCTTCTACTCAGAAAATGGAGG-3. The amplified DNA product was 
digested with restriction enzymes SmaI and HindIII and ligated into pM vector. 





Cells were fixed in ice-cold 3% paraformaldehyde in PBS for 30 minutes 
followed by permeabilization with 2% Triton X-100 in PBS. The cells were then blocked 
in 5% goat serum in PBS for 1 hour followed by incubation with the rabbit FLAG 
antibodies (Sigma, USA) in dilution buffer (2% goat serum in PBS) for 1 hour at room 
temperature. After this, three washes were carried out before incubating the cells with 
rhodamine-coupled goat anti-rabbit IgG (Santa Cruz Technologies, USA) in dilution 
buffer for 1 hour at room temperature. Following this, the cells were washed thrice and 
stained with Hoescht stain (Pierce, USA) for 5 minutes before the images were acquired. 
5.2.3) Immunoprecipitation 
 Cells transfected with expression plasmids were lysed in 1 ml of lysis buffer as 
described above. Lysates were directly analyzed, either as whole-cell lysates (15 µl) or 
used in affinity precipitation with M2 anti-FLAG agarose beads (Sigma-Aldrich) or anti-
GFP agarose beads (BST Scientific). Briefly, the lysate and beads were incubated 
overnight at 4°C with gentle rotation. The beads were then washed 5 times with 2% 
Triton X-100 in PBS. Samples were run in SDS-PAGE gels followed by Western 
blotting. 
5.2.4) Culture and Transformation of Yeast Cells 
 All yeast cultures were grown in the appropriate synthetic dropout media 
(BIO101) at 30°C with shaking at 280 rpm. For transformation, 1 ml of overnight culture 
of strain EGY48 yeast cells was harvested by centrifugation at 5000 rpm for 1 min. The 
supernatant was discarded and the yeast pellet was resuspended in 95 μl of ONE-STEP 
buffer (0.2N LiCl, 40% PEG 3550, pH 5.0 and 100 mM DTT) by vortexing. The 




suspension was then transferred into a microfuge tube containing ~300 ng of plasmid 
DNA and 50 μg of Herring sperm DNA, which has been pre-mixed by vortexing. The 
whole mixture was then vortex again and incubated at 45°C for 30 min. The yeast 
suspension was then plated out on the appropriate synthetic dropout agar plates. 
5.2.5) Beta-galactosidase Assay in Yeast 
 Five independent yeast clones were selected for each set of transformation and 
grown overnight in selective medium. The yeast cultures were then used for beta-
galactosidase assay with Yeast β-galactosidase assay kit (Pierce, USA) according to the 
microplate assay protocol (stopped) in the instruction manual. 
5.2.6) Chloramphenicol Acetyltransferase (CAT) and β-gal Assay from Mammalian   
          Cells 
 
 Cells were transfected with the respective pM and/or pcDNA3.1(-)_GFP effector 
plasmids, together with a  reporter plasmid, pG5CAT (Clontech, USA) and an internal 
control plasmid pSV40_β-gal (Promega, USA). After 48 hours, the cells were processed 
and tested for CAT and β-gal activities using CAT ELISA and β-gal ELISA kit 
respectively (Roche, Germany). 
 






5.3.1) Cloning of Full Length NPAS1 
 
 The full length mouse NPAS1 cDNA is about 1.8 kb [Accession no. 
NM_008718]. Initially, two primers were designed to PCR the full length cDNA of 
NPAS1 but the attempt was unsuccessful. We then decided to PCR two overlapping 
fragments of the cDNA spanning a unique NdeI restriction site (Figure 5.1) using two 
pairs of primers, NPAS1(start)f and NPAS1(976)r and NPAS1(961)f and NPAS1(stop)r 
(Table 5.1). The template used for PCR was cDNAs from 6 days differentiated MN9D 
cells. Two fragments with the expected size were obtained and they were digested with 
NdeI, purified and then ligated together. Next, the ligated product of full length NPAS1 
cDNA was inserted into pGEMT-Easy vector and sequenced to ensure that the correct 
cDNA was obtained. Alignment of our sequencing results with the published NPAS1 
cDNA revealed two differences at positions respectively (Figure 5.2). The first difference 
occurred at position 60 involving a change of T to C residue at the third position of a 
codon and therefore is a silent mutation that still code for the same amino acid. The 
second difference was a change of T to C residue at position 1217 and resulted in a 
proline residue replacing a lysine residue. Since both amino acids are hydrophobic and 
non-polar, we considered it to be a conserved mutation which should not affect the 
overall function of the protein. This full length NPAS1 cDNA that was constructed was 
be used as a template for construction of all NPAS1-related plasmids. 
5.3.2) Co-expression ARNT or ARNT2 with NPAS1 Causes NPAS1 Nuclear 
 Translocation  
 
 Since NPAS1 belongs to the bHLH-PAS domain protein family of transcription 
factors, we decided to determine if NPAS1 is constitutively localized to the nucleus. 




When NPAS1 was tagged to GFP at the N-terminus (NPAS1_GFP) and expressed in a 
neuronal cell line, MN9D, the fusion protein was found to be excluded from the nucleus 
(Figure 5.4A). To rule out the possibility that GFP tag at the N-terminus may interfere 
with proper localization of the fusion protein, NPAS1 was tagged to GFP at the C-
terminus, GFP_NPAS1. This fusion protein was also found to be excluded from the 
nucleus (figure 5.5A), suggesting that NPAS1 is indeed excluded from the nucleus 
regardless of the position of the GFP tag. 
A phylogenetic analysis reported previously revealed that NPAS1 is an ortholog 
of Drosophila Trachealess (Figure 5.3) (Hogenesch et al, 2000), and nuclear localization 
of Trachealess is known to require its interacting partner, Tango (the ortholog of 
mammalian Arnt) (Ward et al., 1998). We postulate that NPAS1 may use a similar 
mechanism for entering the nucleus. Indeed, when NPAS1_GFP was co-expressed with 
FLAG-tagged ARNT or ARNT2 (FLAG_ARNT or FLAG_ARNT2), NPAS1_GFP was 
found to be localized to the nucleus (Figure 5.4B and C). In contrast, the native GFP 
protein was evenly distributed between the cytoplasm and nucleus when co-expressed 
with FLAG_ARNT or FLAG_ARNT2 (Figure 5.6), indicating that the nuclear 
translocation is specific to NPAS1 and not the GFP tag. The same results were observed 
when Hela, HEK293T and SHSY5Y cells were used (Figure 5.7, 5.9 and 5.11 for 
NPAS1_GFP and Figure 5.8, 5.10 and 5.12 for GFP in the respective cell lines), 








5.3.3) N-terminus of NPAS1 is Excluded from the Nucleus 
 We went on to map out the region within NPAS1 that is important for this nuclear 
localization. The N-terminal (aa 1-354) and C-terminal (aa 348-594) domains of NPAS1 
(Figure 5.13A) were individually fused upstream of GFP to generate NPAS1(N)_GFP 
and NPAS1(C)_GFP fusion protein respectively, and the subcellular localization of these 
fusion proteins were determined. In MN9D cell, when co-expressed with FLAG, 
NPAS1(N)_GFP was found to be excluded from the nucleus. On the other hand, 
NPAS1(C)_GFP was found in both the cytoplasm and nucleus (Figure 5.13B). The same 
phenomenon was observed in HEK293 (Figure 5.14). These results suggest that the N-
terminus of NPAS1 excludes it from the nucleus in the absence of ARNT over-
expression. In addition, as seen in Figure 5.15, upon co-expression with FLAG_ARNT or 
FLAG_ARNT2, NPAS1(N)_GFP localized to the nucleus. 
5.3.4) Leptomycin B Has No Effect on Subcellular Localization of NPAS1 
 To determine if NPAS1 is constitutively localized to the cytoplasm or if there is a 
shuttling of NPAS1 between the cytoplasm and nucleus, MN9D cells over-expressing 
NPAS1_GFP fusion proteins were treated with leptomycin B. It is a chemical that is 
commonly used in blocking the nuclear export machinery involving CRM1 but it did not 
affect the subcellular localization of NPAS1_GFP. As shown in Figure 5.16, 
NPAS1_GFP was still excluded from the nucleus when the cells were treated with 
50ng/ml Leptomycin B for 1 and 8 hours respectively. The result is consistent with the 









5.3.5) Mutation of NES within NPAS1 Localizes it to the Nucleus  
 
The N-terminus of NPAS1 is predicted to contain a nuclear export signal (NES) at 
aa 310-3317. To determine if this NES signal is responsible for nuclear exclusion of 
NPAS1, all four leucine and a single isoleucine residue were mutated to alanine residues. 
As shown in Figure 5.17, the mutant NPAS1_GFP fusion protein was found 
predominantly in the nucleus of MN9D and HEK293 cells, suggesting that this NES is 
responsible for excluding NPAS1 from the nucleus in the absence of ARNT.  
5.3.6) NPAS1 and ARNT Interact with Each Other Via Their N-termini 
 
It has been reported that NPAS1 and ARNT are able to interact with each other 
both in vitro and in vivo [Ohsawa et al, 2005]. However, the exact domains where they 
interact have not been mapped out. As it is known that bHLH-PAS domain proteins 
interact via their N-termini, we decided to test out if NPAS1 also interact with ARNT via 
its N-terminus. Plasmids encoding FLAG-tagged NPAS1, ARNT or ARNT2 fusion 
proteins were transfected into MN9D, SHSY5Y and HEK293 cells and the presence of 
the fusion proteins were determined. As shown in Figure 5.18A, FLAG-tagged ARNT 
and ARNT2 fusion proteins were properly expressed in all three cell lines. In contrast, 
FLAG-tagged NPAS1 fusion proteins were expressed at a very low level in HEK293 
cells and could not be detected in both MN9D and SHSY5Y cells. Therefore, we decided 
to over-express FLAG_fl NPAS1, FLAG_NPAS1(N) and FLAF_NPAS1(C) individually 
with HA_fl ARNT in HEK293 cells and use agarose conjugated to FLAG Ab for pull 
down assay. As shown in Figure 5.18B, only fl NPAS1 and NPAS1(N), but not 
NPAS1(C) were able to pull down fl ARNT. This result suggests that NPAS1 interacts 
with ARNT via the N-terminus. 




 To determine the domain where ARNT interacts with NPAS1, FLAG_fl ARNT, 
FLAG_ARNT(N) and FLAG_ARNT(C) were individually over-expressed in MN9D 
cells and agarose conjugated to FLAG Ab was used for pull down assay to detect 
endogenous NPAS1. As shown in Figure 5.18C, only fl ARNT and ARNT(N), but not 
ARNT(C) were able to pull down NPAS1. This shows that ARNT interact with NPAS1 
via its N-terminus. 
5.3.7) Transcriptional Activity of ARNT Is Not Required for Nuclear Localization    
          of NPAS1 
 
 To further delineate the role of ARNT in the nuclear translocation on NPAS1, an 
internal deletion mutant of ARNT lacking the basic region was generated (Figure 5.19A). 
This mutant, ARNTΔb was tagged to the C-terminus of a FLAG eptiope. To ensure that 
this mutant does not possess any transcriptional activity, HEK293 cells were transfected 
with plasmids expressing FLAG_ARNTΔb to determine its effect on the TH promoter 
(which has been shown to be positively regulated by ARNT). As seen in Figure 5.19B, 
ARNTΔb did not have and transcriptional activity on the TH promoter. We also found 
that ARNTΔb is still able to interact with NPAS1 (Figure 5.19C), indicating that the basic 
region is not required for this interaction.  
 We went on to over-express FLAG_ARNTΔb with NPAS1_GFP in MN9D cells 
and then determine the sub-cellular localization of NPAS1_GFP fusion protein. As 
shown in Figure 5.19D, NPAS1_GFP is found to be localized to the nucleus. This 
suggests that any transcriptional activity of ARNT is not required to facilitate the nuclear 
translocation of NPAS1. 
 
 




5.3.8) NPAS1 Does Not Contain Any Transactivation Domain 
 Most of the members of the bHLH-PAS domain protein family are known to 
contain at least one activation domain which is responsible to transcriptional activation. 
We decided to investigate if NPAS1 contain an activation domain as well by using yeast 
one-hybrid system. Full length NPAS1 cDNA was fused downstream of the LexA DNA 
binding domain (DBD) of the pLexA plasmid to generate the LexA_NPAS1 fusion 
protein and the construct was transformed into EGY48 yeast cells, which have previously 
been transformed with the lac Z reporter gene under the control of LexA operators. As 
shown in Figure 5.20, there is no activation of lac Z by LexA_NPAS1 or LexA fused to 
different domains of NPAS1. In contrast, the LexA_ARNT and LexA_ARNT(C) fusion 
proteins are able to activate the lac Z reporter gene, confirming the presence of an 
activation domain in the C-terminus of ARNT, which has already been reported 
previously. 
 It is known that the yeast cell does not contain all the post-translational 
modifications found in mammalian cell. To rule out that the lack of reporter activation by 
NPAS1 is due to certain post-translational modifications missing in the yeast system and 
rendering NPAS1 to be non-functional, a similar experiment was carried out in MN9D 
cells. This time round, full-length or different deletion mutants of NPAS1 were fused 
downstream to the GAL4 DNA binding domain. As seen in Figure 5.22, there is no 
activation of reporter CAT activity by GAL4_NPAS1 or GAL4 fused to different 
domains of NPAS1. In contrast, the GAL4_ARNT and GAL4_ARNT(C) fusion proteins 
are able to activate the reporter gene. Similar profiles of reporter gene activation (Figure 




5.21) were observed in HEK293 cell line, further supporting the lack of an activation 
domain in NPAS1. 
5.3.9) NPAS1 Harbors at Least Two Distinct, Non-overlapping Repression  
          Domains 
 
 Since we could not detect any activation domain in NPAS1, we decided to test if 
NPAS1 contains any repression domain instead. To carry out this test, cDNAs of full 
length or different deletion mutants of NPAS1 were fused downstream to the construct 
containing the ARNT C-terminus fused downstream of the LexA DNA binding domain. 
This parent construct, pLexA_Arnt(C) has been showed to induce a high level of reporter 
gene activation (Figure 5.20). The rationale of the experiment is that if a repression 
domain is present in any of cDNAs fused downstream of ARNT(C), there will be a 
significant decrease in the basal level of the reporter gene activation. 
 As shown in Figure 5.22B, full-length, as well as the N-terminus and C-terminus 
domains of NPAS1, when individually fused downstream of Arnt(C), caused a significant 
decrease of reporter gene activation when compared to the parent plasmid. In contrast, 
when the N-terminus of ARNT was fused downstream of Arnt(C), the lac Z activity was 
about the same as that caused by the parent plasmid, indicating that the decrease in 
reporter gene activity is specific to the different NPAS1 cDNAs. To eliminate the 
possibility that the decrease in reporter gene level was due to the different fusion proteins 
being not properly expressed, Western blot was carried out as above (Figure 5.22C). All 
the fusion proteins are shown to be expressed, indicates that the suppression of reporter 
gene activity is to due to the presence of repression domains within NPAS1. 
 To ensure that the repression domains are physiologically functional, similar 
experiments were carried out in HEK293 and MN9D cells. The results obtained from the 




mammalian system (Figure 5.23) were almost identical to that obtained from the yeast 
system, confirming the presence of repression domains within NPAS1. To eliminate the 
possibility that repression by NPAS1 is specific to ARNT(C), another system was used to 
test for repressive effect of NPAS1. In this system, a luciferase reporter plasmid with 
GAL4 binding sites coupled to a strong TK promoter was used. This reporter plasmid 
gave a high level of luciferase activity when transfected into HEK293 cells. Upon co-
transfection with plasmids expressing GAL4 fusion proteins of either full length NPAS1, 
NPAS1(N) or NPAS1(C), the reporter activities decreased in all cases (Figure 5.24). This 
result further supports the notion that NPAS1 contains at least two autonomous 
repression domains, one in the N-terminus and another in the C-terminus.  
5.3.10) Dominant Repression by NPAS1 on ARNT and ARNT2 Transactivation      
            Function 
 
Since it has previously been reported that SIM2 (which contains two repression 
domains) was able to suppress the transactivation function of ARNT when they interact, 
we decided to test if NPAS1 behave the same way with ARNT or ARNT2. As a foirst 
step to determine the ratio of plasmids to be used, increasing amount of plasmid over-
expressing GFP tagged NPAS1 was used with a fixed amount of plasmids expressing 
either GAL4_fl ARNT or GAL4_ARNT2. As shown in Figure 5.25A, the lowest level 
that the reporter CAT activity was reduced to was about 50% when 1.5 µg of plasmid 
expressing NPAS1_GFP was used, and this suppressive effect did not increase with 
increasing amount of NPAS1_GFP plasmid transfected. Therefore, 1.5 µg of plasmid 
expressing NPAS1_GFP was used in subsequent experiments. 
GAL4_fl ARNT, GAL4_fl ARNT2 or GAL4_ARNT(C) was individually co-
expressed with full length NPAS1 (tagged with GFP) in HEK293T cells and the level of 




CAT activity determined (Figure 5.25B). When fl NPAS1_GFP was co-expressed with 
GAL4_fl ARNT or GAL4_fl ARNT2, the reporter CAT activity was reduced to about 
50%. In contrast, when NPAS1_GFP was co-transfected with GAL4_Arnt(C), the 
transactivation function of ARNT(C) was enhanced. This result suggests that the N-
terminus of ARNT is important for the suppressive effect by NPAS1. The same 
experiment was carried out in MN9D cells. As shown in Figure 5.25C, similar results 
were observed with GAL4_ARNT and GAL4_ARNT2. However, NPAS1_GFP was 
found to be able to suppress the transactivation function of GAL4_ARNT(C) as well. 





1      ATGGCGACCC CCTATCCCAG AAGCGGTGGC CGAGGTGAAG TCAAGTGCGG GGGCGGCCGT 
 
61     GGAGCCGGCG TCCCCTGGGA TTTCCTGCCT GGGCTGATGG TCAAGGCCCC GCCCGGACCC 
 
121    TGCCTGCAGG CGCAGCGCAA AGAGAAGTCC CGCAACGCTG CGCGCTGGCG ACGCGGGAAG 
 
181    GAAAATCTGG AGTTCTTCGA GCTAGCCAAG CTGCTCCCTC TGCCCGGTGC CATCTCCAGC 
 
241    CAGCTGGACA AGGCGTCCAT CGTGCGTCTT AGCGTCACCT ACCTCCGCCT GCGTCGTTTT 
 
301    GCCGCGCTGG GGGCGCCGCC CTGGGGGTTG CGGGCCGTCG GGCCTCCGGC TGGCCTCGCC 
 
361    CCAGGCCGCC GAGGCCCTGT GGCTCTGGTC TCTGAAGTCT TCGAGCAACA CCTAGGTGGA 
 
421    CACATCCTAC AGTCCTTGGA TGGCTTCGTG TTCGCTTTGA ACCAGGAAGG GAAATTTCTC 
 
481    TACATCTCAG AGACAGTGTC CATCTACCTG GGTCTCTCAC AGGTGGAGCT GACGGGCAGC 
 
541    AGCGTCTTCG ACTACATCCA TCCTGGGGAC CACTCGGAGG TCCTAGAGCA ACTTGGATTG 
 
601    CGGGCTGCAA GCATCGGTCC CCCTACACCA CCTTCCGTGT CCTCCTCTTC CTCATCGTCT 
 
661    TCCTCCTCGC TGGTGGACAC CCCTGAGATT GAAGCCAGCC CCACCGAGGC ATCGCCTGCC 
 
721    TTCCGAGCCC AAGAGCGGTC CTTCTTTGTC CGCATGAAGT CCACCCTCAC CAAGAGGGGC 
 
781    CTGAATGTCA AAGCCTCGGG GTACAAGGTC ATTCATGTGA CAGGGCGCCT GAGGGCCCGA 
 
841    GCCCTGGGTC TTGTAGCCCT TGGACACACG CTGCCCCCAG CCCCACTGGC TGAGCTGCCT 
 
901    TTGCACGGAC ACATGATTGT CTTCCGCCTC AGCCTGGGCC TCACCATCCT TGCTTGTGAG 
 
961    AGCAGAGTTA GCGACCATAT GGACATGGGG CCCTCAGAGC TTGTGGGACG CAGCTGCTAC 
 
1021   CAGTTTGTTC ATGGACAGGA TGCAACCAGG ATCCGCCAAA GCCATCTGGA CCTGCTGGAC 
 
1081   AAAGGGCAGG TGGTGACTGG TTACTACCGT TGGCTGCAGC GTGCGGGGGG CTTCGTGTGG 
 
1141   CTGCAGTCTG TAGCCACTGT GGCCGGGAAC GGGAAGAGCA CTGGGGAGCA TCACGTGCTG 
 
1201   TGGGTCAGTC ACGTGCTCAG CAATGCTGAA GGTAGTCAAA CACCCCTGGA TGCCTTCCAG 
 
1261   CTTCCAGCTA TTGTGTCTCA GGAGGAGCCA TCCAGGCCAG GCCCAGAGCC CACAGAGGAA 
 
1321   GAGCCTCCAG TTGACGGGAA GCAGGCTGTG CCTGCGGACC AGGACAAGGA CAAGGACCCT 
 
1381   CAGGCCCGAG GCAAACGCAT CAAAGTGGAG GCCAGCCCGA AGGAAGCTAG AGGCTCAGAG 
 
1441   GACAGTGGAG AAGAGGAGCT CTCGGATCCA CCGGCTCCAC CTCGGCCAGA ATTCACTTCT 
 
1501   GTCATCCGGG CGGGAGCCCT GAAGCATGAT CCAGTGCTGC CGTGGGGCTT GACAACTCCC 
 
1561   GGAGACCCCT CACCCGCCCT CCTTCATGCA GGCTTCCTGC CACCCGTTGT GCGGGGCCTG 
 
1621   TGCACCCCAG GCACCATCCG CTATGGCCCT GCGGAGTTGA GCCTGATGTA TCCACATCTG 
 
1681   CACAGGCTGG GCGCAGGCCC CTCGCTTCCA GAGGCCTTTT ACCCTACGCT GGGCTTGCCC 
 
1741   TATCCGGGGC CCACAGGTAC TAGGGTGCAG CGGAAGGGAG ACTGA 
 
 
Figure 5.1. Sequence of NPAS1 cDNA (Accession no. NM_008718). The full length 








Table 5.1. Primers used to PCR out two fragments of NPAS1 overlapping at the 






















tca gtc tcc ctt ccg ctg cac cct ag 
 
 





1     ATGGCGACCCCCTATCCCAGAAGCGGTGGCCGAGGTGAAGTCAAGTGCGGGGGCGGCCGC 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||* 
1     ATGGCGACCCCCTATCCCAGAAGCGGTGGCCGAGGTGAAGTCAAGTGCGGGGGCGGCCGT 
 
61    GGAGCCGGCGTCCCCTGGGATTTCCTGCCTGGGCTGATGGTCAAGGCCCCGCCCGGACCC 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
61    GGAGCCGGCGTCCCCTGGGATTTCCTGCCTGGGCTGATGGTCAAGGCCCCGCCCGGACCC 
 
121   TGCCTGCAGGCGCAGCGCAAAGAGAAGTCCCGCAACGCTGCGCGCTGGCGACGCGGGAAG 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
121   TGCCTGCAGGCGCAGCGCAAAGAGAAGTCCCGCAACGCTGCGCGCTGGCGACGCGGGAAG 
 
181   GAAAATCTGGAGTTCTTCGAGCTAGCCAAGCTGCTCCCTCTGCCCGGTGCCATCTCCAGC 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
181   GAAAATCTGGAGTTCTTCGAGCTAGCCAAGCTGCTCCCTCTGCCCGGTGCCATCTCCAGC 
 
241   CAGCTGGACAAGGCGTCCATCGTGCGTCTTAGCGTCACCTACCTCCGCCTGCGTCGTTTT 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
241   CAGCTGGACAAGGCGTCCATCGTGCGTCTTAGCGTCACCTACCTCCGCCTGCGTCGTTTT 
 
301   GCCGCGCTGGGGGCGCCGCCCTGGGGGTTGCGGGCCGTCGGGCCTCCGGCTGGCCTCGCC 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
301   GCCGCGCTGGGGGCGCCGCCCTGGGGGTTGCGGGCCGTCGGGCCTCCGGCTGGCCTCGCC 
 
361   CCAGGCCGCCGAGGCCCTGTGGCTCTGGTCTCTGAAGTCTTCGAGCAACACCTAGGTGGA 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
361   CCAGGCCGCCGAGGCCCTGTGGCTCTGGTCTCTGAAGTCTTCGAGCAACACCTAGGTGGA 
 
421   CACATCCTACAGTCCTTGGATGGCTTCGTGTTCGCTTTGAACCAGGAAGGGAAATTTCTC 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
421   CACATCCTACAGTCCTTGGATGGCTTCGTGTTCGCTTTGAACCAGGAAGGGAAATTTCTC 
 
481   TACATCTCAGAGACAGTGTCCATCTACCTGGGTCTCTCACAGGTGGAGCTGACGGGCAGC 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
481   TACATCTCAGAGACAGTGTCCATCTACCTGGGTCTCTCACAGGTGGAGCTGACGGGCAGC 
 
541   AGCGTCTTCGACTACATCCATCCTGGGGACCACTCGGAGGTCCTAGAGCAACTTGGATTG 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
541   AGCGTCTTCGACTACATCCATCCTGGGGACCACTCGGAGGTCCTAGAGCAACTTGGATTG 
 
601   CGGGCTGCAAGCATCGGTCCCCCTACACCACCTTCCGTGTCCTCCTCTTCCTCATCGTCT 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
601   CGGGCTGCAAGCATCGGTCCCCCTACACCACCTTCCGTGTCCTCCTCTTCCTCATCGTCT 
 
661   TCCTCCTCGCTGGTGGACACCCCTGAGATTGAAGCCAGCCCCACCGAGGCATCGCCTGCC 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
661   TCCTCCTCGCTGGTGGACACCCCTGAGATTGAAGCCAGCCCCACCGAGGCATCGCCTGCC 
 
721   TTCCGAGCCCAAGAGCGGTCCTTCTTTGTCCGCATGAAGTCCACCCTCACCAAGAGGGGC 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
721   TTCCGAGCCCAAGAGCGGTCCTTCTTTGTCCGCATGAAGTCCACCCTCACCAAGAGGGGC 
 
781   CTGAATGTCAAAGCCTCGGGGTACAAGGTCATTCATGTGACAGGGCGCCTGAGGGCCCGA 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
781   CTGAATGTCAAAGCCTCGGGGTACAAGGTCATTCATGTGACAGGGCGCCTGAGGGCCCGA 





841   GCCCTGGGTCTTGTAGCCCTTGGACACACGCTGCCCCCAGCCCCACTGGCTGAGCTGCCT 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
841   GCCCTGGGTCTTGTAGCCCTTGGACACACGCTGCCCCCAGCCCCACTGGCTGAGCTGCCT 
 
901   TTGCACGGACACATGATTGTCTTCCGCCTCAGCCTGGGCCTCACCATCCTTGCTTGTGAG 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
901   TTGCACGGACACATGATTGTCTTCCGCCTCAGCCTGGGCCTCACCATCCTTGCTTGTGAG 
 
961   AGCAGAGTTAGCGACCATATGGACATGGGGCCCTCAGAGCTTGTGGGACGCAGCTGCTAC 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
961   AGCAGAGTTAGCGACCATATGGACATGGGGCCCTCAGAGCTTGTGGGACGCAGCTGCTAC 
 
1021  CAGTTTGTTCATGGACAGGATGCAACCAGGATCCGCCAAAGCCATCTGGACCTGCTGGAC 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1021  CAGTTTGTTCATGGACAGGATGCAACCAGGATCCGCCAAAGCCATCTGGACCTGCTGGAC 
 
1081  AAAGGGCAGGTGGTGACTGGTTACTACCGTTGGCTGCAGCGTGCGGGGGGCTTCGTGTGG 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1081  AAAGGGCAGGTGGTGACTGGTTACTACCGTTGGCTGCAGCGTGCGGGGGGCTTCGTGTGG 
 
1141  CTGCAGTCTGTAGCCACTGTGGCCGGGAACGGGAAGAGCACTGGGGAGCATCACGTGCTG 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1141  CTGCAGTCTGTAGCCACTGTGGCCGGGAACGGGAAGAGCACTGGGGAGCATCACGTGCTG 
 
1201 TGGGTCAGTCACGTGCCCAGCAATGCTGAAGGTAGTCAAACACCCCTGGATGCCTTCCAG 
      ||||||||||||||||*||||||||||||||||||||||||||||||||||||||||||| 
1201  TGGGTCAGTCACGTGCTCAGCAATGCTGAAGGTAGTCAAACACCCCTGGATGCCTTCCAG 
 
1261  CTTCCAGCTATTGTGTCTCAGGAGGAGCCATCCAGGCCAGGCCCAGAGCCCACAGAGGAA 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1261  CTTCCAGCTATTGTGTCTCAGGAGGAGCCATCCAGGCCAGGCCCAGAGCCCACAGAGGAA 
 
1321  GAGCCTCCAGTTGACGGGAAGCAGGCTGTGCCTGCGGACCAGGACAAGGACAAGGACCCT 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1321  GAGCCTCCAGTTGACGGGAAGCAGGCTGTGCCTGCGGACCAGGACAAGGACAAGGACCCT 
 
1381  CAGGCCCGAGGCAAACGCATCAAAGTGGAGGCCAGCCCGAAGGAAGCTAGAGGCTCAGAG 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1381  CAGGCCCGAGGCAAACGCATCAAAGTGGAGGCCAGCCCGAAGGAAGCTAGAGGCTCAGAG 
 
1441  GACAGTGGAGAAGAGGAGCTCTCGGATCCACCGGCTCCACCTCGGCCAGAATTCACTTCT 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1441  GACAGTGGAGAAGAGGAGCTCTCGGATCCACCGGCTCCACCTCGGCCAGAATTCACTTCT 
 
1501  GTCATCCGGGCGGGAGCCCTGAAGCATGATCCAGTGCTGCCGTGGGGCTTGACAACTCCC 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1501  GTCATCCGGGCGGGAGCCCTGAAGCATGATCCAGTGCTGCCGTGGGGCTTGACAACTCCC 
 
1561  GGAGACCCCTCACCCGCCCTCCTTCATGCAGGCTTCCTGCCACCCGTTGTGCGGGGCCTG 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1561  GGAGACCCCTCACCCGCCCTCCTTCATGCAGGCTTCCTGCCACCCGTTGTGCGGGGCCTG 
 
1621  TGCACCCCAGGCACCATCCGCTATGGCCCTGCGGAGTTGAGCCTGATGTATCCACATCTG 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1621  TGCACCCCAGGCACCATCCGCTATGGCCCTGCGGAGTTGAGCCTGATGTATCCACATCTG 
 




1681  CACAGGCTGGGCGCAGGCCCCTCGCTTCCAGAGGCCTTTTACCCTACGCTGGGCTTGCCC 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1681  CACAGGCTGGGCGCAGGCCCCTCGCTTCCAGAGGCCTTTTACCCTACGCTGGGCTTGCCC 
 
1741  TATCCGGGGCCCACAGGTACTAGGGTGCAGCGGAAGGGAGACTGA 
      ||||||||||||||||||||||||||||||||||||||||||||| 
1741  TATCCGGGGCCCACAGGTACTAGGGTGCAGCGGAAGGGAGACTGA 
 
Figure 5.2. Comparison of NPAS1 sequence from NCBI database with clone from 
MN9D cell. Alignment of NPAS1 cDNA (upper line) from NCBI database and NPAS1 
cDNA cloned from MN9D cells (lower line). Nucleotides which are conserved are 
indicated by a vertical line, while those that are different are indicated by an asterisk (*). 








Figure 5.3 Phylogenetic tree of bHLH-PAS domain proteins. Human NPAS1 is 
shown to be an ortholog to Drosophila Trachealess. (Adapted from Hogenesch et al, 
2000). 
 
                   
 
Figure 5.4 Effect of ARNT and ARNT2 on cellular localization of NPAS1_GFP in 
MN9D cells. MN9D cells were co-transfected with expression plasmids coding for GFP-
tagged NPAS1 and FLAG (i), FLAG-tagged ARNT (ii) or FLAG-tagged ARNT2 (iii). 
Cells were stained with Hoechst stain (blue) to show the position of the nuclei. 
GFP_NPAS1 fusion protein (green) was found to be localized in the cytoplasm when it 
was co-expressed with the empty FLAG plasmid (i). When co-expressed with FLAG-
tagged ARNT (ii) or FLAG-tagged ARNT2 (iii), NPAS1 was localized in the nucleus. 
The cells were stained with FLAG Ab and detected with Rhodamine-conjugated 
secondary Ab to show expression of FLAG-tagged proteins. Images on the far left were 
taken under phase-contrast to show the outline of the cells. The results are representative 
of three independent experiments.
20µm 
    Characterization of NPAS1 
 113
 
                 
 
 
Figure 5.5 Effect of ARNT and ARNT2 on cellular localization of GFP_NPAS1 in MN9D cells. MN9D cells were co-transfected 
with expression plasmids coding for GFP-tagged NPAS1 and FLAG (A), FLAG-tagged ARNT (B) or FLAG-tagged ARNT2 (C). 
Cells were stained with Hoechst stain (blue) to show the position of the nuclei. GFP_NPAS1 fusion protein (green) was found to be 
localized in the cytoplasm when it was co-expressed with the empty FLAG plasmid (A). When co-expressed with FLAG-tagged 
ARNT (B) or FLAG-tagged ARNT2 (C), NPAS1 was localized in the nucleus. The cells were stained with FLAG Ab and detected 
with Rhodamine-conjugated secondary Ab to show expression of FLAG-tagged proteins. Images on the far left were taken under 
phase-contrast to show the outline of the cells. The results are representative of three independent experiments. 
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Figure 5.6 Effect of ARNT and ARNT2 on cellular localization of GFP in MN9D cells. MN9D cells were co-transfected with 
expression plasmids coding for GFP and FLAG (A), FLAG-tagged ARNT (B) or FLAG-tagged ARNT2 (C). Cells were stained with 
Hoechst stain (blue) to show the position of the nuclei. GFP (green) was found to be localized in both the cytoplasm and nuclei in all 
three cases. The cells were stained with FLAG Ab and detected with Rhodamine-conjugated secondary Ab to show expression of 
FLAG-tagged proteins.Images on the far left were taken under phase-contrast to show the outline of the cells. The results are 
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Figure 5.7 Effect of ARNT and ARNT2 on cellular localization of NPAS1_GFP in HeLa cells. HeLa cells were co-transfected 
with expression plasmids coding for GFP-tagged NPAS1 and FLAG (A), FLAG-tagged ARNT (B) or FLAG-tagged ARNT2 (C). 
Cells were stained with Hoechst stain (blue) to show the position of the nuclei. NPAS1_GFP fusion protein (green) was found to be 
localized predominantly in the cytoplasm when it was co-expressed with the empty FLAG plasmid (A). When co-expressed with 
FLAG-tagged ARNT (B) or FLAG-tagged ARNT2 (C), NPAS1 was localized predominantly in the nucleus. The cells were stained 
with FLAG Ab and detected with Rhodamine-conjugated secondary Ab to show expression of FLAG-tagged proteins. Images on the 
far left were taken under phase-contrast to show the outline of the cells. The results are representative of three independent 
experiments. 
20µm 




                              
  
 
Figure 5.8 Effect of ARNT and ARNT2 on cellular localization of GFP in HeLa cells. HeLa cells were co-transfected with 
expression plasmids coding for GFP and FLAG (A), FLAG-tagged ARNT (B) or FLAG-tagged ARNT2 (C). Cells were stained with 
Hoechst stain (blue) to show the position of the nuclei. GFP (green) was found to be localized in both the cytoplasm and nuclei in all 
three cases. Images on the far left were taken under phase-contrast to show the outline of the cells. The cells were stained with FLAG 
Ab and detected with Rhodamine-conjugated secondary Ab to show expression of FLAG-tagged proteins. The results are 
representative of three independent experiments. 
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Figure 5.9 Effect of ARNT and ARNT2 on cellular localization of NPAS1_GFP in HEK293T cells. HEK293T cells were co-
transfected with expression plasmids coding for GFP-tagged NPAS1 and FLAG (A), FLAG-tagged ARNT (B) or FLAG-tagged 
ARNT2 (C). Cells were stained with Hoechst stain (blue) to show the position of the nuclei. NPAS1_GFP fusion protein (green) was 
found to be localized predominantly in the cytoplasm when it was co-expressed with the empty FLAG plasmid (A). When co-
expressed with FLAG-tagged ARNT (B) or FLAG-tagged ARNT2 (C), NPAS1 was localized in the nucleus. The cells were stained 
with FLAG Ab and detected with Rhodamine-conjugated secondary Ab to show expression of FLAG-tagged proteins. Images on the 
far left were taken under phase-contrast to show the outline of the cells. The results are representative of three independent 
experiments. 
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Figure 5.10 Effect of ARNT and ARNT2 on cellular localization of GFP in HEK293 cells. HEK293 cells were co-transfected with 
expression plasmids coding for GFP and FLAG (A), FLAG-tagged ARNT (B) or FLAG-tagged ARNT2 (C). Cells were stained with 
Hoechst stain (blue) to show the position of the nuclei. GFP (green) was found to be localized in both the cytoplasm and nuclei in all 
three cases. The cells were stained with FLAG Ab and detected with Rhodamine-conjugated secondary Ab to show expression of 
FLAG-tagged proteins. Images on the far left were taken under phase-contrast to show the outline of the cells. The results are 
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Figure 5.11 Effect of ARNT and ARNT2 on cellular localization of NPAS1_GFP in SHSY5Y cells. SHSY5Y cells were co-
transfected with expression plasmids coding for GFP-tagged NPAS1 and FLAG (A), FLAG-tagged ARNT (B) or FLAG-tagged 
ARNT2 (C). Cells were stained with Hoechst stain (blue) to show the position of the nuclei. NPAS1_GFP fusion protein (green) was 
found to be localized predominantly in the cytoplasm when it was co-expressed with the empty FLAG plasmid (A). When co-
expressed with FLAG-tagged ARNT (B) or FLAG-tagged ARNT2 (C), NPAS1 was localized in the nucleus. The cells were stained 
with FLAG Ab and detected with Rhodamine-conjugated secondary Ab to show expression of FLAG-tagged proteins. Images on the 
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Figure 5.12 Effect of ARNT and ARNT2 on cellular localization of GFP in SHSY5Y cells. SHSY5Y cells were co-transfected 
with expression plasmids coding for GFP and FLAG (A), FLAG-tagged ARNT (B) or FLAG-tagged ARNT2 (C). Cells were stained 
with Hoechst stain (blue) to show the position of the nuclei. GFP (green) was found to be localized in both the cytoplasm and nuclei in 
all three cases. Images on the far left were taken under phase-contrast to show the outline of the cells. The cells were stained with 
FLAG Ab and detected with Rhodamine-conjugated secondary Ab to show expression of FLAG-tagged proteins. The results are 
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Figure 5.13 N-terminus of NPAS1 Prevents Nuclear Localization in MN9D Cells. 
Deletion mutants of NPAS1 were constructed as shown in (A). MN9D cells were either 
co-transfected with expression plasmids coding for either GFP-tagged NPAS1(N) GFP-
tagged NPAS1(C). Cells were stained with Hoechst stain (blue) to show the position of 
the nuclei. NPAS1(N)_GFP fusion protein was found to be excluded from the nucleus 
whereas NPAS1(C)-GFP fusion protein was evenly distributed throughout the whole cell. 
Images on the far left were taken under phase-contrast to show the outline of the cells. 
The results are representative of three independent experiments.     
 
                            
 
Figure 5.14 N-terminus of NPAS1 Prevents Nuclear Localization in HEK293 Cells. 
HEK293 cells were either co-transfected with expression plasmids coding for either GFP-
tagged NPAS1(N) GFP-tagged NPAS1(C). Cells were stained with Hoechst stain (blue) 
to show the position of the nuclei. NPAS1(N)_GFP fusion protein was found to be 
excluded from the nucleus whereas NPAS1(C)-GFP fusion protein was evenly distributed 
throughout the whole cell. Images on the far left were taken under phase-contrast to show 
the outline of the cells. The results are representative of three independent experiments
20µm
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Figure 5.15 Effect of ARNT and ARNT2 on cellular localization of NPAS1(N)_GFP in MN9D cells. MN9D cells were co-
transfected with expression plasmids coding for GFP-tagged NPAS1(N) and FLAG (A), FLAG-tagged ARNT (B) or FLAG-tagged 
ARNT2 (C). Cells were stained with Hoechst stain (blue) to show the position of the nuclei. NPAS1(N)_GFP fusion protein (green) 
was found to be localized in the cytoplasm when it was co-expressed with the empty FLAG plasmid (A). When co-expressed with 
FLAG-tagged ARNT (B) or FLAG-tagged ARNT2 (C), NPAS1(N) was localized in both the cytoplasm and nucleus. The cells were 
stained with FLAG Ab and detected with Rhodamine-conjugated secondary Ab to show expression of FLAG-tagged proteins. Images 
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Figure 5.16 Leptomycin B has no effect on the subcellular localization of NPAS1_GFP. MN9D cells were transfected with 
expression plasmids coding for NPAS1_GFP. After one day, the transfected cells were treated with 50 ng/ml Leptomycin B and the 
cells were fixed at 0, 1 and 8 h respectively. NPAS1_GFP (FITC) was found to be excluded from the nucleus in all cases. Cells were 
stained with Hoechst stain (blue) to show the position of the nuclei. Images on the far left were taken under phase-contrast to show the 
outline of the cells. The results are representative of three independent experiments. 
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Figure 5.17 Effect of mutation of NES on cellular localization of NPAS1_GFP in MN9D cells. (A) A nuclear export signal is 
predicted in the N-terminus of NPAS1, from aa 310-317. All the leucine and isoleucine residues were mutated to alanine residues to 
generate NPAS1mNES mutant, as indicated. (B) MN9D and HEK293 cells were transfected with plasmids over-expressing 
NPAS1mNES_GFP. Cells were stained with Hoechst stain (blue) to show the position of nuclei. NPAS1mNES_GFP was localized to 
the nucleus. Images on the far left were taken under phase-contrast to show the outline of the cells. The results are representative of 
three independent experiments.
20µm 
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Figure 5.18 Interaction between N_termini of NPAS1 and ARNT. (A) Protein 
lysates from HEK293, SHSY5Y or MN9D cells over-expressing FLAG_fl NPAS1, 
FLAG_fl ARNT or FLAG_fl ARNT2 were collected. Western blot was carried with 
FLAG Ab to detect the fusion proteins. FLAG_ARNT and FLAG_ARNT2 were 
highly expressed in all the cell lines. FLAG_NPAS1 can be detected at low level in 
HEK293 cells but undetectable in SHSY5Y and MN9D cells. (B) Protein lysates from 
HEK293 cells over-expressing either fl NPAS1_GFP, NPAS1(N)_GFP or 
NPAS1(C)_GFP with FLAG_fl ARNT was used for immunoprecipitation with GFP 
Ab conjugated agarose as described in Materials and Methods. Bound proteins were 
detected with FLAG antibody. Only fl NPAS1_GFP and NPAS1(N)_GFP were able 
to pull-down FLAG_fl ARNT. Western blot on whole cell lysates were carried out 
with FLAG and GFP to show proper expression of the fusion proteins. (C) Protein 
lysates from MN9D cells over-expressing either FLAG_fl ARNT, FLAG_ARNT(N) 
or FLAG_ARNT(C) was used for immunoprecipitation with FLAG antibody 
conjugated agarose as described in Materials and Methods. Bound proteins were 
detected with NPAS1 antibody. Only FLAG_fl ARNT and FLAG_ARNT(N) were 
able to pull down NPAS1. Western blot on whole cell lysates were carried out with 
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Figure 5.19 Transcriptional activity of ARNT is Not Required for Nuclear 
Localization of NPAS1. (A) Internal deletion mutant of ARNT lacking the basic 
region (aa 59-85) but with its NLS intact. (B) HEK293 cells were transfected with 
plasmids over-expressing FLAG_fl ARNT, FLAG_ARNT(N), FLAG_ARNT(C) or  
FLAG_ARNTΔb, together with pTH_Luc and pSV40_RL. After two days, lysates 
from the transfected cells were collected for Dual-luciferase assay. Both FLAG_fl 
ARNT and FLAG_ARNT(N) activated the reporter gene level. FLAG_ARNT(C) and 
FLAG_ARNTΔb had no effect on reporter gene level. (C) Protein lysates from 
MN9D cells over-expressing either FLAG_ARNTΔb or FLAG_ARNT(C) were used 
for immunoprecipitation with FLAG antibody conjugated agarose as described in 
Materials and Methods. Bound proteins were detected with NPAS1 antibody. Western 
blot on whole cell lysates were carried out with FLAG and NPAS1 to show proper 
expression of the fusion proteins and endogenous NPAS1 respectively. 
FLAG_ARNTΔb, but not FLAG_ARNT(C) was able to pull down NPAS1. (D) 
MN9D or HEK293 cells were co-transfected with plasmid over-expressing 
NPAS1_GFP and FLAG_ARNTΔb. After two days, cells were fixed and stained with 
Hoechst stain (blue) to show position of the nuclei. NPAS1_GFP was localized to the 
nucleus. The cells were stained with FLAG Ab and detected with Rhodamine-
conjugated secondary Ab to show expression of FLAG_ARNT. Images on the far left 
were taken under phase-contrast to show the outline of the cells. The white bar 
represent 20µm. The results are representative of three independent experiments. 
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Figure 5.20 Absence of transactivation domain in NPAS1 using the yeast system. 
(A) Schematic representations of the different constructs used for transformation into 
EGY48 yeast strain to test for transactivation domain within NPAS1. The boundary 
defined by deleted amino acids is indicated by parentheses as subscripts to the name 
of each construct. Dotted boxes represent the LexA DNA-binding domain. Solid 
boxes represent the bHLH region and hatched areas represent the PAS A and PAS B 
regions. (B) EGY48 yeast strains were transformed with the respective constructs 
shown in Figure A and plated out on synthetic dropout plate lacking uracil and 
histidine, with X-gal added. All three constructs of NPAS1- (ii, iii and iv) and 
ARNT(N)- (vi) LexA fusion proteins did not activate the reporter gene. Both full 
length ARNT- (v) and ARNT(C)- (vii) LexA fusion proteins activate the lac z 
reporter gene, as indicated by the blue colour. (C) Graph showing the quantitative 
differences in the B-gal activity by the different constructs. The results are from one 
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Figure 5.21 Absence of transactivation domain in NPAS1 in the mammalian 
system. (A) Schematic diagram of the different plasmids used for mammalian cells 
transfection in this study. The boundary defined by deleted amino acids is indicated 
by parentheses as subscripts to the name of each construct. Dotted boxes represent the 
GAL4 DNA-binding domain. Solid boxes represent the bHLH region and hatched 
areas represent the PAS A and PAS B regions. (B) HEK293T cells were co-
transfected with a CAT reporter plasmid together with the respective plasmids shown 
in Figure C and assayed for CAT activity as described in Materials and Methods. All 
three constructs of NPAS1- [GAL4_fl NPAS1, GAL4_NPAS1(N) and 
GAL4_NPAS1(C)] and GAL4_ARNT(N) did not activate the reporter gene. Both full 
length ARNT- (v) and ARNT(C)- (vii) GAL4 fusion proteins activate the CAT 
reporter gene. The results are from one representative experiment (n = 3) and 
presented as mean and SEM (n = 3). (C) Analysis of GAL4 fusion proteins. Equal 
amount of transfected cell lysates from HEK293T cells were run on SDS-PAGE gel 
and Western blot was carried out with GAL4 antibodies. All the fusion proteins are 
expressed properly with their expected molecular weight.  
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Figure 5.22. Identification of repression domains in NPAS1 when fused to a 
strong activator in a yeast system. (A) Schematic representations of the different 
constructs used for transformation into EGY48 yeast strain to test for repression 
domains within NPAS1. The boundary defined by deleted amino acids is indicated by 
parentheses as subscripts to the name of each construct. Dotted boxes represent the 
LexA DNA-binding domain and waved boxes represent C-terminal domain of ARNT. 
Solid boxes represent the bHLH region and hatched areas represent the PAS A and 
PAS B regions. (B) The parent plasmid (i) showed a high level of reporter gene 
activation. All three constructs of NPAS1- (ii, iii and iv) LexA fusion proteins abolish 
the reporter gene activation. A negative control, ARNT(N) (v) had no effect on the 
reporter gene activation of the parent plasmid. (C) Graph showing the quantitative 
differences in the B-gal activity by the different constructs. The results are from one 
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Figure 5.23 Identification of repression domains in NPAS1 using the mammalian 
system. (A) Schematic diagram of the different plasmids used for mammalian cells 
transfection in this study. The boundary defined by deleted amino acids is indicated 
by parentheses as subscripts to the name of each construct. Dotted boxes represent the 
GAL4 DNA-binding domain. Solid boxes represent the bHLH region and hatched 
areas represent the PAS A and PAS B regions. (B) HEK293T cells were co-
transfected with a CAT reporter plasmid and a β-gal internal control plasmid together 
with the respective plasmids shown in Figure C and assayed for CAT and β-gal 
activities as described in Materials and Methods. All three constructs of NPAS1- 
[GAL4_fl NPAS1, GAL4_NPAS1(N) and GAL4_NPAS1(C)] decreased the 
transactivation function of the parent plasmid. The negative control, ARNT(N) had a 
slight effect on the transactivation function of the parent plasmid. The results are from 
one representative experiment (n = 3) and presented as mean and SEM (n = 3). 
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Figure 5.24 Identification of repression domains in NPAS1 using a strong 
promoter in mammalian system. HEK293 cells were transfected with plasmids 
expressing GAL4DBD (pM), GAL4DBD_fl NPAS1, GAL4DBD_NPAS1(N) or 
GAL4DBD_NPAS1(C), together with reporter plasmid pGAL4_TK_Luc and internal 
control plasmid pSV40_RL. Protein lysates were collected from these transfected 
cells for Dual-Luciferase assay as described in Materials and Methods. All 
GAL4DBD_fl NPAS1, GAL4DBD_NPAS1(N) and GAL4DBD_NPAS1(C) 
repressed the level of reporter gene. A positive control, which expressed the 
GAL4DBD_MeCP2, where MeCP2 (methyl-CpG binding protein 2) is a strong 
repressor, was used as a control. The results are from one representative experiment 
(n = 3) and presented as mean and SEM (n = 3). 
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Figure 5.25 Partial trans-repression of NPAS1 on ARNT and ARNT2 
transactivation functions.  (A) There is only partial repression by NPAS1 on ARNT 
and ARNT2 transactivation functions. HEK293 cells were transfected with increasing 
amount of plasmid over-expressing NPAS1_GFP, together with reporter plasmid 
pGSCAT and internal control plasmid pSV40_β-gal, with either plasmid over-
expressing GAL4_ARNT or GAL4_ARNT2. CAT and β-gal activities were 
determined according to that described in Materials and Methods. Maximum 
repression was observed to be about 50% at 1.5 µg of plasmid over-expressing 
NPAS1_GFP. (B) NPAS1 represses the transactivation of ARNT and ARNT2 but not 
ARNT(C) in HEK293 cells. HEK293 cells were transfected with plasmid over-
expressing NPAS1_GFP, together with reporter plasmid pGSCAT and internal 
control plasmid pSV40_β-gal, with either plasmid over-expressing GAL4_ARNT, 
GAL4_ARNT2 or GAL4_ARNT(C). CAT and β-gal activities were determined 
according to that described in Materials and Methods. Repression by NPAS1 was 
observed for ARNT and ARNT2 but not ARNT(C). (C) NPAS1 represses the 
transactivation of ARNT, ARNT2 and ARNT(C) in MN9D cells. MN9D cells were 
transfected with plasmid over-expressing NPAS1_GFP, together with reporter 
plasmid pGSCAT and internal control plasmid pSV40_β-gal, with either plasmid 
over-expressing GAL4_ARNT, GAL4_ARNT2 or GAL4_ARNT(C). CAT and β-gal 
activities were determined according to that described in Materials and Methods. 
Repression by NPAS1 was observed for ARNT and ARNT2 and ARNT(C). All 
results are from one representative experiment (n = 3) and presented as mean and 
SEM (n = 3). 
 
 




5.4.1) Mechanism for Nuclear Localization of NPAS1 
 
 NPAS1 is reported to express exclusively in the central nervous system. 
Immunohistochemical studies have shown that NPAS1 is localized to the nucleus in 
inter-neurons (Erbel-Sieler et al, 2004) and cortical neurons (Ohsawa et al, 2005). 
However, it is not known whether NPAS1 is constitutively localized in the nucleus on 
its own or it requires other proteins for its nuclear localization. Using a NLS 
prediction software (http://cubic.bioc.columbia.edu/predictNLS/), no NLS was 
identified in NPAS1. In our studies, we showed that NPAS1 was excluded from the 
nucleus when it was expressed alone but translocated into the nucleus upon co-
expression with ARNT or ARNT2 (Figure 5.4, 5.5, 5.7, 5.9 and 5.11). We also found 
that NPAS1 was still excluded from the nucleus upon treatment with leptomycin B 
(Figure 5.16), suggesting that NPAS1 does not shuttle between the cytoplasm and 
nucleus. This is consistent with the fact that no NLS was predicted to exist within 
NPAS1. Using deletion studies, we discovered that the N-terminus is responsible this 
nuclear exclusion (Figure 5.13 and 5.14), and the mutation of a predicted NES within 
this region successfully localized NPAS1 to the nucleus (Figure 5.17). In this case, we 
made use of the ability of the GFP tag to be localized to both the cytoplasmic and 
nuclear fractions to show that the NES with NPAS1 is functional. This is why 
leptomycin B has no effect on NPAS1_GFP (Figure 5.16) since NPAS1_GFP is 
constitutively excluded from the nucleus. In addition, we found that deletion of the 
basic region of ARNT (which abolishes its transcriptional property) has no effect on 
its ability to localize NPAS1 to the nucleus (Figure 5.19). 
 Some of the bHLH-PAS domain proteins are activated by the binding of a 
ligand to the C-terminus. One example is that of AhR, where upon binding to 
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xenobiotics, it translocates into the nucleus and heterodimerize with ARNT to 
activation transcription (Burbach et al, 1992; Kallio et al, 1998; Ritcher et al., 2001). 
However, it is unlikely that NPAS1 requires a ligand because by simply co-expressing 
with ARNT or ARNT2, NPAS1 is able to enter the nucleus (Figure 5.4, 5.5). This is 
in contrast to that of AhR, where the presence of ARNT did not result in AhR 
entering the nucleus. Moreover, when NPAS1 and ARNT or ARNT2 were co-
expressed in other non-neuronal cell lines (Figure 5.7, 5.9 and 5.11), the same 
phenomenon was observed, further supporting the notion that NPAS1 nuclear 
translocation is not cell type specific. This further reinforces the notion that NPAS1 
may not require a ligand for nuclear translocation. Moreover, this mechanism of 
nuclear translocation was also evident in Drosophila, where Trachealess was shown 
to require the presence of Tango in order to enter the nucleus (Ward et al, 1998), 
suggesting that this mechanism may be conserved throughout the animal kingdom. 
 Many of the bHLH-PAS domain proteins are known to bind ARNT as a 
common heterodimeric partner (Probst et al, 1999), and that such interaction is 
necessary for binding DNA and regulating transcription. A previous study showed 
that NPAS1 is able to interact with ARNT both in vivo and in vitro, and that this 
interaction is important for NPAS1 binding to EPO enhancer (Ohsawa et al, 2005). In 
our study, we showed that NPAS1 and ARNT interact via their N-terminus 
respectively. We therefore propose a mechanism for the nuclear localization of 
NPAS1. In this proposed mechanism, NPAS1 is initially localized in the cytoplasm. 
However, the interaction of ARNT with NPAS1 guides NPAS1 into the nucleus, 
probably via the NLS of ARNT. We postulate that upon heterodimerization with 
ARNT, the NES within the N-terminus of NPAS1 is masked, thereby sequestering 
NPAS1 in the nucleus (Figure 5.26).  
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Figure 5.26 Proposed mechanism for nuclear localization of NPAS1. In the 
absence of ARNT, NPAS1 is localized to the cytoplasm. Upon the presence of 
ARNT, NPAS1 interacts with ARNT is brought into the nucleus via the nuclear 
localization signal of ARNT. Since interaction between NPAS1 and ARNT occurs via 
their N-termini, the nuclear export signal within the N-terminus is masked, thereby 
preventing it from being exported out of the nucleus. 
 
5.4.2) Partial trans-repression by NPAS1 
 Many of the bHLH-PAS proteins harbor at least one transactivation domain 
(TAD) and upon dimerization with ARNT, bind to the respective response element 
and activate gene transcription (Jiang et al., 1997; Ooe et al., 2004; Sonnenfeld et al., 
2005). However, we could not identify any TAD in NPAS1 (Figure 5.20 and 5.21), 
suggesting that NPAS1 may not play a positive transcriptional role. A number of 
bHLH-PAS domain proteins are known to negatively regulate transcription, which 
include IPAS (Makino et al, 2001) and SIM2 (Moffett et al, 1997). In the case of 
SIM2, such negative regulation is due to the presence of two repression domains 
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within the carboxy terminus of mSIM2. Upon heterodimerization with ARNT, the 
effect of these repression domains overrides the ARNT activation domain. 
 Although it has been reported that NPAS1 suppressed the expression of 
erythropoietin (Ohsawa et al., 2005), there is no published data supporting the 
presence of repression domains within NPAS1. Using yeast one-hybrid, we have 
identified at least three non-overlapping repression domains within NPAS1 (Figure 
5.22, 5.23 and 5.24). Using a heterologous system, when full length NPAS1 was co-
expressed with ARNT or ARNT2, the transcriptional activation functions of ARNT 
and ARNT2 were reduced (Figure 5.25B and C), suggesting that NPAS1 negatively 
regulate the activity of ARNT and ARNT2. However, unlike SIM2 which totally 
abolishes the transactivation function of ARNT (Moffett et al, 1997), NPAS1 only 
partially suppresses ARNT and ARNT2 (Figure 5.25A). This partial repressive effect 
with ARNT(2) is confirmed when increasing amount of over-expression of NPAS1 
did not further decrease the repressive effect (Figure 5.25A). We postulate that some 
other factors may cooperate synergistically with NPAS1 to totally abolish the 
transactivation of ARNT and ARNT2, and such factors may be limiting in our system. 
The transactivation function of ARNT(C) was enhanced by full length NPAS1 
in HEK293T cells (Figure 5.25B). This suggests that the N-terminus of ARNT is 
required for the suppressive effect of NPAS1. The mechanism of repression by 
NPAS1 on ARNT may be similar to that of SIM2, which occurs by interaction with 
ARNT via the N-termini (Moffett et al, 1997). On the contrary, full length NPAS1 
was also able to suppress the transactivation function of ARNT(C) in MN9D cells 
(Figure 5.25C), indicating that a different mechanism of suppression by NPAS1 on 
ARNT is involved in MN9D cell line. Since NPAS1 does not interact with ARNT(C), 
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we propose that NPAS1 suppresses the transactivation function of ARNT(C) by 
sequestering some other factors required for ARNT function in MN9D cells. 
From the previous chapter, NPAS1 was found to be upregulated during DA 
neuron differentiation. The repressor function of NPAS1 (identified in this chapter) 
may play a role in down-regulating genes that maybe involved in DA synthesis.  We 
shall explore this function in the next chapter. 
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CHAPTER SIX 




 Catecholamines (dopamine, norepinephrine and epinephrine) are all 
synthesized from a common pathway in which tyrosine hydroxylase (TH) is the rate-
limiting enzyme. Dopamine is the main neurotransmitter present in dopaminergic 
neurons of the substantia nigra pars compacta where degeneration of these neurons, 
and subsequent decrease in dopamine content gave rise to Parkinson’s disease. 
Therefore, much research has been focused on increasing the TH level in neurons for 
cell transplantation treatment. Some of the transcription factors that directly bind and 
activate transcription of the TH gene include cyclic AMP response element binding 
protein (CREB), AP1, Engrailed 1, Nurr1, Pitx3 and hypoxia inducible factor 1 
(HIF1). In our screen for genes that are up-regulated upon dopaminergic MN9D cell 
differentiation, NPAS1 was identified. Using over-expression and siRNA studies, we 
found that NPAS1 negatively regulates the expression of TH. We further showed that 
this negative regulation is mediated by a direct effect of NPAS1 on the TH promoter. 
Since NPAS1 is shown to be expressed in the ventral midbrain, we propose that 
NPAS1 may play a role in regulating TH level of dopaminergic neurons in the ventral 
midbrain during development. 




 Dopaminergic neurons, as the name implies are neurons that synthesize and 
release dopamine as a neurotransmitter. The synthesis of dopamine from tyrosine 
involves several enzymes (Figure 6.1), of which tyrosine hydroxylase (TH) is the rate-
limiting enzyme (Levitt et al., 1965). Besides dopamine, two other catecholamines, 
norepinephrine and epinephrine are also synthesized via the TH enzyme. In recent 
years, many have used TH as a marker for dopaminergic neuron to identify 
dopaminergic neurons that are known to be present in certain regions of the brain. 
 Since oxidation of catecholamines can form reactive quinones and oxygen 
radicals that can damage proteins and DNA (Hastings and Zigmond, 1994; Stokes et 
al, 1996), these catecholamines are actually quite toxic to cells. Due to this reason, the 
TH enzyme is tightly regulated. Two different categories of regulation are observed 
for TH – short-term direct regulation of enzyme activity and medium- to long-term 
regulation of gene expression. Short-term regulation includes feedback inhibition 
(Okuno and Fujisawa, 1991; Andersson et al; 1992; Haavik et al., 1991; Almås et al., 
1992; Daubner et al., 1992; Ribeiro et al., 1992), allosteric regulation (Kuczenski and 
Mandell, 1972; Lloyd and Kaufman, 1974; Katz et al., 1976; Nelson and Kaufman, 
1987; Gahn and Roskoski, 1993) and enzyme phosphorylation. In fact, TH has been 
shown to be phosphorylated in vitro by at least eight different protein kinase systems. 
These include phosphorylation by PKA (Joh et al., 1978; Yamauchi and Fujisawa, 
1979; Vulliet et al., 1980; Edelman et al., 1981), CaM-PKII (Yamauchi et al., 1981; 
Vulliet et al., 1984), PKC (Albert et al., 1984; Vulliet et al., 1985), PKG (Roskoski et 
al., 1987), cdc2/cyclin A (Hall et al., 1992), ERK1 and ERK2 (Haycock et al., 1992; 
Sutherland et al., 1993), MAPKAP kinases (Sutherland et al., 1993) as well as stress-
activated protein kinase 1, MSK1 (Toska et al., 2002). There is growing evidence that 
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the various second messenger systems are capable of ‘cross talk’ (Chaube and Joy, 
2005). 
On the other hand, medium- to long-term regulations of gene expression 
encompass transcriptional regulation (Lewis et al., 1987; Coker et al., 1988; Cambi et 
al., 1989; Fader and Lewis, 1990; Gizang-Ginsberg and Ziff, 1990; Carroll et al., 
1991; Icard-Liepkalns et al., 1992; Yoon and Chikaraishi, 1994; Kim et al., 1994; Goc 
and Stachowiak, 1994; Wong et al., 1994; Best et al., 1995; Craviso et al., 1995), 
alternative RNA splicing (Grima et al., 1987; Kaneda et al., 1987; O’Malley et al., 
1987; Kobayashi et al, 1998a, 1998b; Haycock, 1993; Ichinose et al., 1993; Lewis et 
al., 1993), RNA stability (Vysa et al., 1990; Craviso et al., 1992; Fossom et al., 1992; 
Czyzyk-Krzeska et al., 1992, 1994a, 1994b), translational regulation (Tank et al., 
1986; Baruchin et al., 1990; Kaneda et al., 1991; Leviel et al., 1991) and enzymatic 
stability (Lazar et al., 1981; Vrana et al., 1981; Vrana and Roskoski, 1983; Wilgus 
and Roskoski, 1988; Roskoski et al., 1990, 1993; Okuno and Fujisawa, 1991). 
 Some of the transcription factors known to regulate TH expression include 
CREB (Ghee et al., 1998; Piech-Dumas and Tank, 1999; Lim et al., 2000), Nurr1 
(Sakurada et al., 1999; Iwawaki et al., 2000; Kim et al., 2003), Pitx3 (Lebel et al., 
2001; Maxwell et al., 2005), Egr1 and AP1 (Guo et al., 1998; Papanikolaou et al., 
2000; Nakashima et al., 2003; Maharjan et al., 2005), AP2 (Kim et al., 2001), Sry 
(Milsted et al., 2004), Sp1 (Papanikolaou and Sabban, 1999) and HIF1 (Schnell et al., 
2003). Many of these transcription factors play a crucial role in specifying the 
dopamine transmitter phenotype of neurons in the ventral midbrain. 
 Previously we have shown that neuronal PAS domain protein 1 (NPAS1) is a 
repressor that is upregulated during differentiation of MN9D cells. In this Chapter, we 
went on to determine the role of NPAS1 during dopaminergic neuronal 
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differentiation. We found that TH level decreases over the course of MN9D 
differentiation. Using over-expression and RNA interference experiments, we showed 
that NPAS1 negatively regulates the expression of TH and this is due to a direct effect 
of NPAS1 of the TH promoter. Moreover, TH level was found to decrease in the 
ventral midbrain during the late prenatal stages. Coupled with the results from 
Chapter 4 where NPAS1 expression is found to increase in the ventral midbrain 
during prenatal stages, we suggest that NPAS1 may play a role in modulating TH 
level in ventral midbrain dopaminergic neuron during development. 
   
 
                                     
 
 
Figure 6.1. The dopamine synthesis pathway. Tyrosine is converted to L-dopa by 
the enzyme tyrosine hydroxylase (TH), a reaction that also requires the TH cofactor 6-
tetrahydrobiopterin (BH4). Guanosine triphosphate cyclohydrolase I (GTPCHI) is the 
first and rate-limiting enzyme involved in BH4 synthesis. Conversion of L-dopa to 
dopamine requires the enzyme aromatic amino acid decarboxylase (AADC). 
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pTH_Luc plasmid was a kind gift from Professor Gerald Thiel (Department of 
Medical Biochemistry and Molecular Biology, University of Saarland Medical 
Center, Homburg, Germany). The siRNAs were ordered from QIAGEN (USA). The 
primers used in real-time PCR for TH gene were 5’-
AGTACTTTGTGCGCTTCGAGGTG-3’ and 5’-CTTGGGAACCAGGGAACCTTG-
3’. 
6.2.2) Construction of Plasmids 
 All the plasmids used were previously described in Section 5.2.2. 
6.2.3) Transfection of siRNAs 
 
 The siRNAs were transfected into cells according to instructions given by the 
manufacturer. Essentially, MN9D cells in 12-wells plate were transfected as followed. 
For each well, 0.6 µg of siRNA was used. The ratio of amount of siRNA used to 
RNAiFect transfection reagent is 1 : 9. First, the siRNA stock was diluted with Buffer 
EC-R and mixed by vortexing. Next, RNAiFect transfection reagent was added and 
mixed by pipetting up and down five times. The mix was then incubated for 10 to 15 
mins at room temperature to allow for complex formation before adding to the cells. 
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6.2.4) Chromatin Immunoprecipitation 
Chromatin immunoprecipitation was carried using the EZ ChIP chromatin 
immunoprecipitation kit (Upstate, USA) according to manufacturer’s protocol. 
Chromatin from 6 days differentiated MN9D cells was used. One microlitre of pre-
immune serum or anti-NPAS1 antibody was used as a negative control and the 
experiment respectively. The primers sequences used were for mouse TH promoter 
(5’- ctggtttgattagagagctctaga- 3’ and 5’- - 3’) and mouse Nkx2.2 (5’- 
atgtcgctgaccaacacaaa- 3’ and 5’- gggagtattggaggccctcg- 3’). 
 
 




6.3.1) Over-expression of NPAS1 Promotes G0 Cell Cycle Arrest in MN9D Cells 
 
 NPAS1 is known to bind to the erythropoietin gene promoter and down 
regulates its expression (Ohsawa et al., 2005), thereby inhibiting cell proliferation. As 
a first step to elucidate the role of NPAS1 during MN9D maturation, we decided to 
determine the effect of over-expression of NPAS1 on cell cycle arrest in MN9D cells. 
As shown in Figure 6.2, there is a significant increase in the percentage of cells in the 
G0 phase upon over-expression of NPAS1_GFP, as compared to cells over-expressing 
GFP.  
 6.3.2) Changes of Tyrosine Hydroxylase Level during MN9D Differentiation 
Using sodium butyrate to induce maturation MN9D cells, we have previously 
shown that there were increased neurite extensions and cell cycle arrest upon 
treatment (Chapter 1). Another important aspect of dopaminergic neuron 
differentiation is the expression of TH. Many studies have shown that butyrate can 
increase the expression of TH (Kim et al., 2003). We decided to examine the effect on 
n-butyrate on TH level in MN9D cells. As shown in Figure 6.3A, there was an initial 
increase in TH level after 3 days post-induction with n-butyrate. However, the level of 
TH then started to drop over the whole course of treatment. Finer mapping revealed 
that the level of TH in MN9D cells actually increased over the first three days of n-
butyrate treatment (Figure 6.3B). This dynamic change in TH level during MN9D 
differentiation is puzzling because it has always been thought that differentiation of 
dopaminergic neuron should be accompanied with an increase in TH level. However, 
it is worthwhile to note that work done by Hermanson et al. (2003) showed that 
treatment of MN9D cells with another inducer, retinoic acid, causes cell cycle arrest 
and neurite extensions but also results in a decrease in dopamine content (Hermanson 
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et al., 2003). On the other hand, it was found that dibutryl-cAMP was able to induce 
increased TH expression in another dopaminergic cell line, MES23.5, a fusion 
between rat E15 ventral mesencephalon cell and the mouse N18TG2 neuroblastoma 
(Crawford et al, 1992). However, it should be noted that the MES23.5 cell line 
represents a more mature dopaminergic cell line compared to MN9D. This suggests 
the decrease in TH level observed in MN9D cells upon differentiation may be 
inherent to cell line of immature dopaminergic characteristics.  
6.3.3) Tyrosine Hydroxylase Level Decreased During Late Prenatal Stages in the       
          Ventral Midbrain 
        We went on to determine if the changes in TH level during MN9D 
differentiation mirrors the actual situation during dopaminergic neuron differentiation 
in the ventral midbrain. Real-time PCR for TH was carried out on cDNAs from the 
dorsal and ventral midbrain at different developmental stages of the mouse embryos. 
As shown in Figure 6.4, TH transcript level was detected at E10.5 in the ventral 
midbrain and continued to increase until E12.5. The TH level then decreased at E15.5 
and continued to decrease until E18.5. This result indicates that during late prenatal 
stages, the TH level in the ventral midbrain actually decreases. Therefore, changes in 
TH level during MN9D differentiation correlates very well with the changes in TH 
level during development of the ventral midbrain. On the other hand, there is very low 
or almost undetectable TH transcript in the dorsal midbrain, which is consistent with 
the fact that very low number of dopaminergic neuron is found in that region. 
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6.3.4) Effect of Over-expression of NPAS1 on TH Level 
Since NPAS1 and HIF1 have been separately reported to regulate the same 
gene, EPO (Varma and Cohen, 1997; Grimm et al., 2002; Ohsawa et al., 2005), and 
HIF1 is also known to up-regulate TH expression (Schnell et al., 2003), we postulate 
that NPAS1 may also play a role in regulating TH expression during MN9D 
differentiation. We decided to test the effect of over-expression of NPAS1 on TH 
level in MN9D cells. As shown in Figure 6.5A, over-expression of NPAS1 with 
FLAG decreased TH transcript and protein levels compared to control in which cells 
are transfected with GFP and FLAG (compare lane 1 and 3). Upon co-transfection of 
NPAS1 with ARNT, the TH level also decreased (compare lane 2 with 3). This effect 
was not due to ARNT since when ARNT was co-expressed with FLAG (lane 4), the 
TH level remained the same as the control.  
6.3.5) Effect of NPAS1 Silencing on TH Level 
 We confirmed the repressive effect of NPAS1 on TH expression by silencing 
NPAS1 expression in MN9D cells. Two small interfering RNAs targeting different 
regions of NPAS1 mRNA was designed according to standard protocol, and 
subsequently synthesized (Figure 6.6A). A control siRNA which encodes a random 
sequence not targeting any mammalian sequence was used as a negative control. As 
shown in Figure 6.6B, upon transfection of each of the two test siRNA into MN9D 
cells, the level of NPAS1 decreased slightly compared to cells transfected with the 
control siRNA, indicating that the two test siRNAs are working. Western blotting 
with TH showed that upon knockout of NPAS1, the level of TH increased as to the 
negative control, reinforcing the notion that NPAS1 negatively regulate the level of 
TH. 
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6.3.6) NPAS1 Has a Repressive Effect on TH Promoter 
 NPAS1 can down-regulate TH level by either increasing the turnover rate of 
TH or having a repressive effect on TH promoter. We determined if NPAS1 has a 
direct effect on TH promoter by using a reporter plasmid that has a luciferase reporter 
gene fused downstream of the mouse TH promoter. As shown in Figure 6.7, over-
expression of ARNT increased the luciferase level, indicating that ARNT has a 
positive regulatory role on TH promoter. However, upon co-expression with NPAS1 
(lane 4) or NPAS1(N) (lane 6), the luciferase level decreased drastically, suggesting 
that NPAS1 has a repressive effect on TH promoter. On the other hand, over-
expression of NPAS1(C) with ARNT (lane 8) did not affect the luciferase level, 
indicating that the N-terminus of NPAS1 is crucial for mediating the repressive effect. 
It is interesting to note that NPAS1(C ) is able to activate the TH promoter as well, 
although no plausible explanation can account for this result at this stage. 
There are two plausible mechanisms in which NPAS1 can down-regulate TH 
expression (Figure 6.8). The first one involves NPAS1 competing with another 
bHLH-PAS domain protein (most likely a positive regulator of TH expression) for 
ARNT and thereby inhibiting TH transcription by this protein. Alternatively, NPAS1 
may bind directly to the TH promoter and repressing it.  
6.3.7) NPAS1 Binds to TH Promoter In-vivo 
 Hypoxia-inducible factor 1 (HIF), which also belongs to the bHLH-PAS 
domain protein family, has been shown to bind TH promoter and up-regulates TH 
expression during hypoxia. The rat TH promoter consists of 3 hypoxia response 
elements (HREs) (Figure 6.9A), of which HRE1 is found to be important for TH 
regulation by HIF2α (Schnell et al, 2003). Since the DNA sequence to which bHLH-
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PAS domain proteins bind to is highly conserved, we postulate that NPAS1 should be 
able to bind to DNA sequences within the TH promoter and regulate its expression. 
As we are working with mouse NPAS1, we decided to analyze the mouse TH 
promoter for HRE as well. We found that the mouse TH promoter contains two HREs 
that are highly similar to HRE1 and HRE3 of the rat TH promoter respectively 
(Figure 6.9B).  
To determine if NPAS1 is able to bind to the TH promoter, chromatin 
immuno-precipitation was carried out on protein lysate from 6 days differentiated 
MN9D cells. Chromatin was immunoprecipitated by anti-NPAS1 antibody and the 
precipitated chromatin was tested for the presence of TH promoter region. Figure 6.10 
shows that the TH promoter region was detected by anti-NPAS1 antibody but not by 
the pre-immune serum. The region of an unrelated Nkx2.2 gene exon, which was 
shown not to be bound by NPAS1 (Ohsawa et al., 2005) was not detected by this 
ChIP analysis. These findings indicate that NPAS1 binds to the TH promoter region in 
6 days differentiated MN9D cells. NPAS1 is thus likely to repress TH expression 
through direct binding to the TH promoter region. 
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Figure 6.2. Effect of NPAS1 on cell cycle in MN9D cells. MN9D cells were 
transfected with either GFP or NPAS1_GFP expressing plasmids. After 48 hours, 
cells were harvested and subjected to flow cytometry. There is a significant increase 
in the percentage of cells in the G0 phase upon over-expression of NPAS1 in MN9D 
cells. The mean and SEM are average from three separate experiments. 
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Figure 6.3. Changes in expression of tyrosine hydroxylase during MN9D 
differentiation. Western blot was carried on protein lysates from MN9D cells (A) 
over the whole course of differentiation (0, 3, 6, 9 and 12 days after induction with 1 
mM n-butyric acid), as well as (B) during the early stages of differentiation (0, 1, 2, 
and 3 days after induction with 1 mM n-butyric acid). The TH level decreases over 
the course of MN9D differentiation. However, it was observed that there is an 
increase inTH level during the early stages of MN9D differentiation. β-actin was used 
as a loading control. 
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Figure 6.4 Developmental changes in TH mRNA level in the dorsal and ventral 
midbrain. Real-time PCR was carried out for TH with cDNAs from the DM and VM 
of different embryonic stages. The level of TH transcript was normalized to HPRT 
level. Results shown are the average and SEM of three independent experiments.  
 
                                                               
Figure 6.5 Over-expression of NPAS1 decreased TH level in MN9D cells. MN9D 
cells were co-expressed with either NPAS1_GFP or GFP with FLAG or 
FLAG_ARNT. When the cells were over-expressed with NPAS1 and FLAG (lane 1), 
the TH transcript and protein levels decreased when compared to control cells over-
expressing GFP and FLAG (lane 3). There was also a decrease in TH level in cells 
over-expressing NPAS1 and ARNT (lane 2) compared to cells expressing GFP and 
ARNT (lane 4). 
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 siRNA 1 (from 184 bp): 5' AATCTGGAGTTCTTCGAGCTA 3' 
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Figure 6.6 Silencing of NPAS1 increased TH level in MN9D cells. (A) Region of 
NPAS1 mRNA targeted for siRNAs synthesis and silencing. (B) MN9D cells were 
transfected with NPAS1 siRNA1 (lane 1), NPAS1 siRNA2 (lane 2) or control siRNA 
(lane 3). Upon transfection with NPAS1 siRNAs, TH level increased when compared 
to cells transfected with the control siRNA. The two TH bands represented the 
phosphorylated and non-phosphorylated TH. Western blot with NPAS1 confirmed a 
decrease in NPAS1 in cells transfected with NPAS1 siRNAs. β-actin was used as a 
loading control. The result is representative of three separate experiments. (C) Picture 
showing MN9D cells transfected with the control siRNA, which is labeled with 
fluorescin taken at 12h post-transfection. The picture on the left was taken under the 
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Figure 6.7 NPAS1 has a repressive effect on TH promoter. HEK293 cells were co-
transfected with plasmids expressing FLAG, FLAG_NPAS1, FLAG_NPAS1(N) or 
FLAG_NPAS1(C) with plasmids over-expressing either HA or HA_ARNT in 
different combinations as indicated on the X-axis, together with the pTH_Luc reporter 
plasmid and pSV40_Luc internal control plasmid. Upon over-expression of ARNT, 
the reporter luciferase level increased drastically. When NPAS1 or NPAS1(N) was 
co-expressed with ARNT, the level of reporter luciferase decreased to control level. 
Over-expression of fl NPAS1 or NPAS1(N) with HA has no effect on the reporter 
level. NPAS1(C) has a positive effect on the TH promoter but it did not repress the 
transactivation effect of ARNT. The results are from one representative experiment (n 
= 3) and represented as mean and SEM (n = 3). Western blot was carried out to show 












Figure 6.8 Proposed mechanisms of TH down-regulation by NPAS1. In a normal 
cell, a positive regulator heterodimerizes with ARNT, binds to the TH promoter and 
activate transcription of the TH gene. Upon over-expression of NPAS1, two 
mechanisms of TH repression by NPAS1 are possible. In the first case (A), NPAS1 
competes with the positive regulator for ARNT, resulting in the positive regulator 
unable to heterodimerize with ARNT and therefore, unable to activation TH gene 
transcription. In the second case (B), NPAS1 heterodimerizes with ARNT, binds to 
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-53      GAGGGGCTTT  GACGTCAGCC  TGGCCTTTAA  GAGGCCGCCT  GCCTGGCAAG  GGCATG 
 
Figure 6.9 Structural organization of rat and mouse TH promoter. (A) The rat 
TH promoter consists of three HREs, the sequences of which are shown. HRE1 is 
found to be important required for regulation of TH during hypoxia by HIF2α. (B) 
Analysis of the mouse TH promoter showed that it consists of three HREs within the 
first 250 bp upstream of the translation start site. HRE1 (at -229 bp), HRE2 (at -105 
bp) and HRE3 (at -95 bp) of the mouse TH promoter match exactly to HRE1, HRE2 
and HRE3 of the rat TH promoter respectively. 
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HRE 2 HRE 3
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Figure 6.10 NPAS1 binds to mouse TH promoter in vivo. Chromatin from 6 days 
differentiated MN9D cells was immunoprecipitated with the anti-NPAS1 antibody 
(lane 3) and NPAS1-binding DNA was examined by 39 cycles of PCR. Pre-immune 
serum was used was negative control (lane 1). DNA extracted from 6 days 
differentiated cells was used as positive PCR control (lane 3) to show that the PCR is 
working. All PCR products are around 200 bp. The region of an unrelated Nkx2.2 












6.4.1) Differentiation of DA Neuron is Accompanied by a Decrease in TH level 
 
 Using the dopaminergic cell line MN9D as a starting point to study the 
differentiation of DA neurons revealed that there is a decrease in TH level during the 
differentiation process (Figure 6.3). It was previously mentioned in another paper that 
there is a decrease in dopamine content upon treatment of MN9D cells with another 
differentiating agent, retinoic acid (Hermanson et al., 2003). This suggests that the 
decrease in TH or subsequently dopamine level during DA neuron differentiation may 
be a de novo phenomenon regardless of which inducer being used. In order to 
determine if the change in TH level during MN9D differentiation mirrors what is 
happening in situ, real-time PCR was carried out to probe for the changes in TH level 
in the ventral midbrain during prenatal development. We showed that TH level is not 
continuously increasing throughout development; in fact, there is an increase in TH 
level in the mid-prenatal stages but starts to decrease in the later stages (Figure 6.4). 
One may argue that the number of TH-positive neurons may decrease in the ventral 
midbrain at the later stages due to migration of these neurons (Kawano et al, 1995) or 
the apoptosis of these neurons during development, which account for the decrease in 
overall TH. However, there are different lines of evidence that suggest the dynamic 
change in TH level is bone fide during development in the ventral midbrain.  
 Previous study had shown that there is a decrease in TH level in the rat ventral 
mesencephalon from E15.5 onwards (Solberg et al., 1993). Moreover, using 
transgenic mice which carried GFP gene under the control of a 9-kb rat TH promoter, 
Matsushita et al. (2002) have shown that both the typical expression frequency and 
relative fluorescence intensity of GFP in the ventral midbrain decrease during late 
prenatal stages (at E12.5 and E14.5 respectively) and increase again after postnatal 
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day 7. This result is consistent with our real-time PCR result for TH which shows a 
decrease in the later prenatal stages. Therefore, the decrease in TH level may be 
occurring at the single cell level although factors responsible for such a decrease is 
currently still not known. 
6.4.2) Mechanism for Transcriptional Repression of TH by NPAS1 
In our study, we showed that NPAS1 down-regulates the expression of TH in 
the MN9D dopaminergic cell line (Figures 6.5 and 6.6) and thatNPAS1 has a 
repressive effect on the TH promoter (Figure 6.7). Results from mesencephalic 
culture (Andreeva et al., 2001) and CNS precursors (Studer et al., 2000) suggests that 
TH level is increased during hypoxia. It is well known that one of the critical proteins 
that is responsible for hypoxic response is hypoxia inducible factor 1 (HIF1) that is 
also a bHLH-PAS protein (Wang et al., 1993; O’Rourke et al., 1996). In fact, HIF is 
able to bind to the TH promoter to activate transcription (Snell et al., 2003), 
confirming that the increase in TH level during hypoxia is a direct action of HIF on 
the TH promoter. Both HIF (Jiang et al., 1996) and NPAS1 (Ohsawa et al., 2005) 
require hetero-dimerization with ARNT in order to bind DNA and effect 
transcriptional regulation. HIF has a transactivation domain (Jiang et al., 1996) and 
regulates transcription of a number of genes in a positive manner (see review by 
Wenger, 2000). On the other hand, NPAS1 has been shown to have a repressive effect 
on one of HIF-regulated gene, erythropoietin (Ohsawa et al., 2005). Furthermore, in 
Chapter 5, we have shown that NPAS1 has two repressive domains which are able to 
override the transactivation function of ARNT. Therefore, there are two mechanisms 
that NPAS1 can repress TH expression – directly binding to the TH promoter and 
repressing transcription or competition with HIF for ARNT and thereby decrease 
transcriptional activation of TH by HIF. In this study, we have shown that NPAS1 is 
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able to bind directly to the TH promoter in vivo (Figure 10C). However, we cannot 
rule out the possibility that competition by NPAS1 for ARNT is also responsible for 
the down-regulation of TH. 
Besides hypoxia, HIF has also been implicated in the development of cancer 
by virtue of the genes that it regulates (see review by Vaupel, 2003). Thus far, NPAS1 
has been shown to down-regulate EPO (Ohsawa et al., 2005) and TH genes, both of 
which are also HIF-regulated genes. It will be crucial to identify the whole repertoire 
of genes regulated by NPAS1 to see if they match to those regulated by HIF. If that is 
the case, NPAS1 will serve as a potential candidate gene for cancer treatment. 
6.4.3) NPAS1 Negatively Regulates TH Transcription during Midbrain  
          Development 
 
 To date, most of the studies have been focused in identifying external factors 
(Beck et al., 1996; Sautter et al., 1998; Zawada et al., 1998; Potter et al., 1999; 
Salvatore et al., 2004;) or intrinsic factors (Guo et al., 1998; Sakurada et al., 1999; 
Papanikolaou et al., 2000; Iwawaki et al., 2000; Kim et al., 2003; Nakashima et al, 
2003; Liste et al., 2004; Buytaert-Hoefen et al., 2004; Maxwell et al., 2005; Maharjan 
et al., 2005) that are able to increase the expression of TH. In fact, only Oct2 has been 
reported to down-regulate TH expression (Dawson et al., 1994). However, with the 
notion that there are dynamic changes in TH promoter during midbrain dopaminergic 
neuron development, it becomes increasingly important to identify the full array of 
transcription factors that regulate the TH promoter in order to fully understand the 
developmental process of dopaminergic neurons. 
 Midbrain DA neurons first appeared in the intermediate zone of the 
developing neural tube and then migrate first ventrally and then laterally to form the 
SNc and VTA (Shults et al., 1990; Kawano et al., 1995). In mice, DA neurons appear 
in the ventral midbrain between E11 and E13, and then migrate ventrolaterally and 
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rostrally during subsequent embryonic development (Kawano et al., 1995). The onset 
of expression of NPAS1 in the ventral midbrain (from E12.5 onwards) coincides very 
well with the time when TH starts to decrease (after E12.5), providing very strong 
evidence that NPAS1 regulates the expression of TH in vivo during development of 
dopaminergic neurons in the ventral midbrain. This time window correlates with the 
stage during which midbrain DA neurons undergo migration. From the results 
presented here, we postulate that NPAS1 negatively regulates TH level during 
dopaminergic neuron development in the midbrain during the late prenatal stages – a 
time of active neuronal migration in the ventral midbrain. This is a novel finding for 
the role of NPAS1 and also for the development of the dopaminergic neurons.  
  Beside NPAS1, NPAS3 has also been identified as an ortholog to Trachealess. 
It was previously reported that in NPAS3-knockout mice, there is an increase in 
Reelin in inter-neurons of the forebrain (Erbel-Sieler et al, 2004), a protein which is 
involved in neuronal migration (see review by Ohshima and Mikoshiba, 2002). This 
provides a very strong link between NPAS3 and neuronal migration in the forebrain. 
In addition, NPAS3-knockout mice also showed dysfunctional glutamate, dopamine 
and serotonin neurotransmitter signaling (Brunskill et al., 2005), raising the 
possibility that NPAS3 has a broader effect on brain development than previously 
thought. More recently, Reelin has also been implicated to be required for the proper 
positioning of nigral DA neurons (Nishikawa et al., 2003). Although no similar 
increase of Reelin in the forebrain was observed in NPAS1-knockout mice (Erbel-
Sieler et al., 2004), it is plausible that a similar phenomenon may be observed in the 
midbrain of these knockout mice, which was not verified in that work. Besides 
determining the effect of NPAS1 on Reelin in the midbrain, it will also be interesting 
to determine the level of TH in the ventral midbrain of NPAS1-knockout mice to see 
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if there is any deviation from the normal mice, which will further confirm the role of 
NPAS1 in regulating TH level during development. The next step will then be to 
determine if neuronal migration of dopaminergic neurons in the ventral midbrain is 
affected in NPAS1-konockout mice, since the time of TH decrease and NPAS1 
increase coincide with the period of active neuronal migration. 
 Such dynamic changes of TH level during development of the ventral 
midbrain DA neurons may raise question on the effectiveness of engineering neural 
stem cells expressing high level of TH for the treatment of PD. However, the 
requirement for a low level of TH at late prenatal stages is not known and certainly 
warrants further research in order to fully understand the development of these 
midbrain DA neurons. 
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CHAPTER SEVEN 
FUTURE WORK AND FINAL CONCLUSION 
 
7.1) Summary of Work 
  
 Till far, we have identified NPAS1 as a transcription factor that is up-
regulated during differentiation of a dopaminergic MN9D cell line. Through 
expression profiling, we found that NPAS1 is widely expressed in the mouse prenatal 
stages but its expression becomes more restricted in the adult stage. Interestingly, we 
found that there is an increase of NPAS1 in the ventral midbrain during embryonic 
development, a region from which MN9D cell line was generated. 
Subsequent characterization of NPAS1 led to a mechanism for the nuclear 
localization of NPAS1 and the mapping of at least two repression domains. We also 
showed that NPAS1, like other bHLH-PAS domain proteins, is able to interact with 
ARNT via its N-terminus. Moreover, NPAS1 is able to repress the transactivation 
function of ARNT. 
A functional role of NPAS1 to down-regulate TH level was discovered by 
over-expression and siRNA experiments.  This down-regulation is due to a direct 
binding of NPAS1 to the TH promoter. At the same time, it was found that TH level 
in the ventral midbrain decreases during prenatal stages while the level of NPAS1 
increases. This provides very strong evidence for a novel role of NPAS1 in regulating 
TH expression during dopaminergic neuron development in the midbrain. 
7.2) Future Work 
  
 Despite the amount of work carried out in this study, there are still more 
confirmatory experiments that need to be done. Most of these works require more 
elaborate techniques which is beyond the scope of this thesis. However, all these 
experiments will serve to provide more concrete evidence for the role of NPAS1 as a 
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regulatory molecule of TH level during dopaminergic neuron development in the 
ventral midbrain. 
7.2.1) Competition between NPAS1 and HIF for ARNT  
 
 Previously, we have proposed two mechanisms by which NPAS1 can 
negatively regulate TH promoter. We have provided evidence that NPAS1 is able to 
directly bind to the TH promoter and regulate it in a negative manner. However, we 
cannot rule out the possibility that NPAS1 may also be competing with HIF for 
ARNT and decreasing the positive regulatory effect of HIF/ARNT heterodimer on TH 
promoter. It will be interesting to do a binding competition assay to determine if this 
mechanism is also responsible for down-regulation of TH expression by NPAS1. 
7.2.2) Expression of NPAS1 and TH in Dopaminergic Neurons 
 
 Although there are supporting evidences that NPAS1 may be regulating the 
expression of TH in neurons of the ventral midbrain, we have not shown that the two 
proteins are expressed in the same neuron. Immuno-histochemical staining had been 
carried out on E12.5 and E14.5 central nervous system (Kevin Lam’s thesis) but no 
positive staining for NPAS1 could be observed (in contrast to Western blot result 
which showed that NPAS1 is expressed in the VM at both stages). A plausible reason 
for this may be the low level of NPAS1 protein expressed during these early stages, 
since positive staining could be observed in E18.5 embryo. However, no co-
localization of NPAS1 and TH could be detected at this late stage (Kevin Lam’s 
thesis). This result is expected since at later stages, the expression of NPAS1 is so 
high that it is likely to decrease TH to undetectable level if they are both expressed in 
the same cell.  
 To overcome the low sensitivity of immunohistochemistry, another method 
will be to use the more sensitive Western blot to show co-localization of NPAS1 and 
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TH in the same neuron. To do this, we can utilize the transgenic mice generated by 
Matsushita et al (2003) where GFP has been tagged to a TH promoter. In that paper 
published, it was found that cells expressing GFP in the VM are stained positive for 
TH as well, resulting in a good way to identify dopaminergic neurons. Cell sorting 
can be carried out on embryonic midbrain tissue to separate cells over-expressing 
GFP from those that do not. These sorted cells will be those that are dopaminergic in 
nature and Western blot can then be carried out for detection of NPAS1 to show co-
localization with TH.  
7.2.3) Functional Redundancy between NPAS1 and NPAS3 on TH Expression 
 Previous studies on NPAS1- and NPAS3- knockout mice have suggested that 
the two proteins may be functionally redundant (Erbel-Sieler et al., 2004). In our 
study, we did not look into the effect of NPAS3 on TH down-regulation by NPAS1. It 
will be interesting to determine if NPAS3 is expressed in the ventral midbrain as well 
and the relevance of NPAS3 towards NPAS1 function during development of 
dopaminergic neurons in the ventral midbrain. 
 However, it is worthwhile to note that a recent publication demonstrated that 
npas3-/- mice but not npas1-/- mice are deficient in the expression of hippocampal FGF 
receptor subtype 1 mRNA, most notably in the dentate gyrus (Pieper et al., 2005). 
Since both NPAS1 and NPAS3 are expressed in the dentate gyrus, it is interesting to 
note that there may be a functional difference between them. It is then all the more 
worthwhile to study the role of NPAS3 during MN9D differentiation to determine if 
there is any functional difference between NPAS1 and NPAS3. 
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7.2.4) Regulation of NPAS1 Promoter 
 Thus far, it is not known how NPAS1 promoter is being regulated. All that is 
known is the downstream targets of NPAS1. In order to fully understand the role of 
NPAS1, it is essential to know how the expression of NPAS1 is regulated. With the 
complete sequencing of the mouse genome, it will be easy to identify transcription 
binding sites within the NPAS1 promoter and carry out experiments to determine true 
regulatory elements with it. 
7.2.5) Role of NPAS1 on TH Level during Prenatal Development 
 To confirm the role of any protein during development, the best way is to look 
into knockout mice for any abnormalities. In our case, NPAS1 knockout mice have 
already been generated by another group but their focus have been on behavioral and 
neurochemical abnormalities, with a concentration for inter-neurons in the forebrain 
(Erbel-Sieler et al., 2004). It will be interesting to determine if there is any 
abnormality in the TH level of these knockout animals in the embryonic stages to 
further strengthen the notion of NPAS1 playing a role in the regulation of TH level in 
dopaminergic neurons during ventral midbrain development.  
7.2.6) Mining of Data from the Subtractive Library 
 The subtractive library constructed in this study identified a total of 
approximately 58 unique hypothetical proteins. This pool of proteins serves as a good 
starting point in the search for novel factors involved in VM neuron development. 
After domain prediction, one of the hits turns out to contain a Frizzled-like membrane 
region (Figure 7.1). This is interesting because Frizzled receptors are known to be 
targets of Wnt molecules, which have been suggested to play a role during VM 
neuron development. Therefore, it will be worthwhile to follow up on this protein to 
determine its role during development of VM neurons. Beside this particular hit, some 
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of the hypothetical proteins are predicted to contain DNA binding domain, suggesting 
that they may function as transcription factors. It will also be worthwhile to study 
these proteins, since transcription factor are usually master regulators of gene 
expression which can significant affect the development of a cell. 
 
Figure 7.1 Domain prediction of a hypothetical protein identified from the 
subtractive library. The amino acid sequence predicted from the coding sequence 
was sent for domain analysis at http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi. 
 
7.3) Final Conclusion 
 Early studies on the development of VM DA neurons have led to the 
discovery of the ‘Cartesian grid’ involving FGF8 and Shh for the specification of 
these neurons. Subsequent studies concentrated mainly on the identification of both 
neurotrophic (GDNF) and transcription factors (Nurr1, Pitx3, En1 and En2 and 
Lmx1b) that determine the DA neurotransmitter phenotype. With the knowledge that 
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Parkinson’s disease is due to a decrease in dopamine content of the SNc, research 
have been focused on ways to increase the level of TH in dopaminergic neurons for 
cell replacement therapy for the treatment of PD. However, the efficiency of this 
treatment is not very high and the reason for this is not really known.  
 The discovery of a dynamic change in TH level in the ventral midbrain during 
prenatal development (a decrease during active migration of the neurons) and the 
identification of NPAS1 as a transcription factor possibly involved in this change 
have opened up a new window to study the development of dopaminergic neurons in 
the VM. In addition, another transcription factor is added to the repertoire of 
transcription factors that are known to directly regulate the expression of TH. These 
findings also raises question on the effectiveness of engineering neural stem cells 
expressing high level of TH for the treatment of PD, since the production of such cells 
should be as similar as possible to the in vivo development of VM DA neurons. If 
such a decrease in TH level is essential to the proper development of DA neurons, this 
may help to explain the low efficiency of using such engineered cells in the treatment 
of PD.  However, it is not known if the decrease in TH level at late prenatal stages is 
really crucial to the development of VM DA neurons, and the effect on DA neuron 
development when not allowing such a decrease to occur has not been investigated, 
although it was reported that development of neurons in the VM is not affected in TH 
knockout mice (Zhou and Palmiter, 1995). Taking this finding into consideration, it 
certainly warrants further research to understand the effect of TH level on the 
development of these midbrain DA neurons.  If such a decrease is really essential for 
the proper migration and targeting of these DA neurons, it may be important to take 
this point into consideration when engineering stem cells expressing TH for treatment 
of PD. It will then be crucial to ensure that the TH level can be regulated to allow for 
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proper migration of these stem cells so that they can be incorporated into the SNc 
neuronal circuitry. 
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